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1.1 Nanomedicine 
The medical application of molecular nanotechnology, which is also referred to as 
“nanomedicine”, is believed to lead to progress in human therapeutics in terms of 
improving human health at the molecular scale (1), especially concerning so far 
“undruggable” targets (2) with new and smart medicines equipped with high bioavailability 
and little side effects. Nanomedicines are expected to have a variety of implications in 
treatment (3) and diagnosis (4), which is also expressed in the neologism “theragnostics” (5, 
6). While nanotechnology enables diagnosis at the single-cell and molecular level, 
nanomedical therapeutics are expected to be specifically or even personally tailored. 
Especially concerning advanced drug delivery systems (7), the field of nanomedicine has 
increased and developed strongly in the last decade. In a multidisciplinary approach, drug 
delivery systems (DDS) can be generated that control the pharmacokinetics, toxicity, 
immunogenicity, biorecognition and efficacy of the drug (8). Drug carriers can be soluble 
or insoluble polymers which are formulated as nanoparticles using techniques such as the 
solvent displacement (9) or solvent evaporation/emulsion technique (10), biopolymers (11) 
or dendrimers (12). Other formulations include polymer complexes (13), “dendriplexes” 
(14), liposomes (15), micelles (16), and nanogels (17). Nanoscale particles that deliver 
insoluble small molecule drugs or macromolecules, such as proteins or nucleic acids, to 
their site of action are steadily being optimized while the total market for advanced DDS is 
expected to rise from $64.1 billion in 2005 to $153.5 billion in 2011, according to bcc 
Research (18). Smart and multimodal carriers do not only protect their load from 
degradation in physiologic fluids, but specifically target certain tissue or cell types, are 
decorated with imaging moieties that allow for non-invasive tracking in the body, or have 
controlled-release or stimuli-responsive properties, such as pH- or temperature-sensitivity. 
“Multifunctional” carriers that combine two or more of these favorable attributes are 
increasingly described in the literature (19-22). Targeting strategies can be divided into 
active and passive mechanisms. The best-know passive effect in tumor targeting is the so-
called “enhanced permeability and retention” (EPR) effect, first described by Maeda et al. 
in 1986 (19). Due to the increased microvascular permeability and endothelial fenestration 
in tumor vasculature, compared to most healthy tissues, nanoparticles are passively targeted 
into the tumor where they show enhanced retention. Passive targeting requires long 
circulating nanomedicines that accumulate in the tumor by extravasation through the leaky 
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tumor vasculature over time. Active targeting, on the other hand, is based on ligand-
receptor recognition between cell surface receptors and nanomedicines functionalized with 
the according ligands and facilitates intracellular uptake by receptor-mediated endocytosis.  
In vitro and in vivo as well as real time imaging are other advantages of multifunctional 
nanomedicines. While nanoparticles that per se are most commonly used for molecular 
imaging are gold nanoparticles, quantum dots (QDs) and magnetic nanoparticles (4), some 
of them can as well be used for functionalization of nanomedicines (20). QDs are 
nanoparticles that emit specific wavelengths which can be tuned as a function of particle 
size (21). These inorganic particles are made of semiconductor cores, such as CdSe, CdTe 
or PbSe, which can be capped with a shell of ZnS. Due to their high toxicity they can not be 
used in vivo without modification. Because of their high sensitivity and bright and stable 
fluorescence, they can be applied for in vitro (22) and in vivo (20) fluorescence microscopy 
at cellular resolution. QD-based nanoparticles can both serve for immunofluorescence 
diagnostics (23) and for drug delivery (24). Magnetic nanoparticles are used for cell-
tracking (25) and calcium sensing (26) by Magnetic Resonance Imaging (MRI). While 
clinical MRI is most commonly performed by aligning the nuclear magnetization of 
hydrogen atoms in water in the body, imaging quality and contrast can be enhanced by the 
use of paramagnetic contrast agents based on gadolinium or superparamagnetic iron oxide 
nanoparticles (SPIONs). Other applications for SPIONs than molecular imaging (27) and 
tumor diagnosis (28) are hyperthermia treatment after heating with radio frequency or laser 
light (29), and investigation of movement in an external magnetic field. Due to their 
relatively low intracellular labeling efficiency, new developments have arisen, such as 200 
nm perfluorocarbon nanoparticles (30) that allow for medical imaging with elimination of 
background signals. Other imaging modalities include radioactive isotopes that emit gamma 
rays, such as 111Indium (111In) and 99mTechnetium (99mTc), or positron emitting isotopes like 
64Cupper (64Cu) or 68Gadolinium (68Gd). While 111In and 99mTc can be used for Single 
Photon Emission Computed Tomography (SPECT) imaging, 64Cu, 68Gd, and 18F are 
commonly used for Positron Emission Tomography (PET) imaging. SPECT and PET do 
not provide any morphological data but are routinely used for functional analysis. Both 
techniques can be used for assessment of pharmacokinetics and receptor binding of 
radiolabeled drugs by static and dynamic acquisition. Nuclear imaging can provide clinical 
data at an early stage of drug development and replace endpoint analysis. Non-invasive 
Chapter 1 
 
4 
longitudinal scans in pre-clinical research may even lead to for reduction of lab animals 
needed (31). 
Taken together, multifunctional nanomedicines are favorable due to the many applications 
and detection methods that can be performed in the same experiment, animal or patient. 
 
Figure 1: The design of potential multifunctional vectors for siRNA delivery. While the core 
of poly ethylene imine (PEI) complexes negatively charged nucleic acids and is known for 
its pH-sensitive “proton-sponge-effect” that triggers release of the complexes into the 
cytosol upon acidification (37), the second block in the block-copolymer-based delivery 
systems is poly caprolacton (PCL), a block that adds amphiphilicity. Poly ethylene glycol 
(PEG) is supposed to shield positive charges of siRNA/PEI complexes to reduce interaction 
with blood components and thereby increase circulation time in vivo (32). Addition of 
targeting moieties and inorganic particles for imaging further increases the multitude of 
possible applications.  
1.2 Non-Viral Delivery of Nucleic Acids 
One of the sectors of nanomedicine is delivery of nucleic acids, a sub-sector of drug 
delivery that this dissertation focuses on. In contrast to viral delivery vectors, which are 
highly efficient, non-viral counterparts bear less immunostimulatory, mutagenetic, and 
oncogenic complications, and some can approach viruses concerning their transfection 
efficiencies (33). Therapeutic nucleic acids of interest for nanomedicine can be DNA in 
plasmids (pDNA) (34), antisense oligonucleotides (AONs) (35), ribozymes (36), 
DNAzymes (37), and lately siRNA (38) and shRNA (39). While pDNA is used in gene 
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therapy to deliver missing or to replace dysfunctioning genes (40), all of the other 
therapeutic nucleic acids are utilized to down-regulate gene expression by post-
transcriptional gene silencing (41). This also explains their different target compartments: 
pDNA as well as shRNA expression vectors need to be delivered into the nucleus for 
transcription, whereas the site of action of AONs, ribozymes, DNAzymes, siRNA and 
shRNA is the cytosol. Unfortunately, cells lack an efficient uptake mechanism for nucleic 
acids, although there is evidence for a cell surface DNA-receptor (42) and for a putative 
transmembrane protein SID-1, which seems to be necessary for uptake of naked siRNA 
(43). Since all nucleic acids are labile, negatively charged biomacromolecules, spontaneous 
intracellular translocation that retains bioactivity of the macromolecules is unlikely. A 
sector of drug delivery research therefore focuses on protective formulation of nucleic acids 
into smart nanodevices that have high transfection efficiencies. 
The primary prerequisites of delivery vehicles for nucleic acids that will finally make it 
from bench to bedside are biocompatibility and robust processes of assembly, conjugation 
and purification (7). Pre-formulation studies are commonly followed by the optimization of 
biophysicochemical parameters, and if successful, by scale-up for the manufacturing of 
therapeutic amounts. A broad variety of lipid based vectors, polymers, biopolymers, 
dendrimers, polypeptides, and inorganic nanoparticles have been investigated by groups all 
around the world (44). The most prominent polymeric vector is certainly poly (ethylene 
imine) (PEI), which is commercially available or can be polymerized as low or high 
molecular weight PEI (45). PEI was first introduced as non-viral gene delivery vector by 
Bousif et al. in 1995 (46) who described its outstanding property called the “proton-sponge-
effect”. While liposomes escape the endo-/lysosomal compartment after endocytosis due to 
fusogenic properties, PEI is believed to attract an influx of chloride and subsequently an 
osmotic influx of water into the lysosome as it is protonated. This altogether leads to 
swelling and bursting of the lysosomes which release the polymer and nucleic acid into the 
cytosol. 
Almost all polymeric vectors, unfortunately, have in common that they either form 
positively charged or amphiphilic complexes with nucleic acids that cause toxicity by 
interaction with negatively charged cell membranes (47) or cellular components and 
pathways after successful intracellular entry (48). There seems to be a correlation between 
transfection efficiency and toxicity up to the point where cells no longer survive. Since it 
has been reported that low molecular weight (LMW) PEI is significantly less toxic than 
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high molecular weight counterparts (34), a recent study investigated reversible disulfide-
based cross-linking of LMW PEI (49) to achieve macromolecular vectors. A common 
principle for decreasing the surface charge of polycation-nucleic acids composites and their 
non-specific charge-dependent interactions was adopted from “stealth® liposomes” that are 
surface modified with poly (ethylene glycol) (PEG) or other hydrophilic compounds, such 
as carbohydrates (15). This steric stabilization decreased self-aggreagation and interactions 
with proteins in biological fluids, and increased salt and serum stability (50). Also 
recognition and phagocytotic capture by cells of the reticulo endothelial system (RES) or 
aggregation within pulmonary capillary beds in vivo was prevented, and thereby their 
circulation half-lives were enhanced (51).  Derivatives of PEI with PEG, saccharides and a 
monoclonal antibody (mAb) have been reported to yield stable complexes that partly 
retained their transfection efficiency (52). In a systematic study, different PEG grafting 
degrees and PEG chain lengths were investigated, suggesting that surface charge and 
toxicity decreased as a function of PEGylation. Transfection efficiency, on the other hand, 
decreased as well, at comparable polymer-to-DNA ratios, which could, because of the low 
toxicity, be readressed by increasing the polymer concentration (53). An even smarter 
system has recently been described where PEG chains are connected via a peptide sequence 
which is cleaved in presence of matrix metalloproteinases (MPPs) (54). Thus, the emerging 
multifunctional envelope-type nano devices (MENDs) are PEGylated extracellularly and 
lose the PEG block upon contact with an MPP that cleaves the peptide spacer. As non-
specific endocytosis is triggered by interaction of cationic particles with heparin sulfate 
proteoglycans on the cell surface (55), a certain amount of positive surface charge of non-
viral vectors is favorable. Other noteworthy modifications of PEI that were employed to 
enhance endosomal release, transfection efficiency, pharmacokinetic parameters, and 
biocompatibility, are full deacylation (56) and succinylation (57) of commercially available 
PEIs, crosslinking of branched HMW PEI (58, 59), synthesis of PEI-alginate composites 
(58), synthesis of amphiphilic (59) and cyclodextrin-threaded triblock copolymers (60), of 
25kDa-PEI-cholesterol (61) and alkyl-oligoamine LMW-PEI derivatives (62), conjugation 
of melittin (63), grafting of chitosan (64), and immobilization on poly-L-lactide (PLLA) 
films for layer-by-layer assembly of polyelectrolytes (65) and, of course, conjugation of 
targeting ligands, as described below. 
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1.3 Targeted Gene Delivery Using Cell Specific Ligands 
Targeted delivery systems are expected to selectively interact with internalizing receptors 
on certain cell types in a “lock and key” model that eventually triggers receptor-mediated 
uptake of the delivery system. Therefore, in this approach, non-specific, charge-related 
interactions that can also lead to non-specific toxicity are not necessary for efficient 
delivery. The dilemma that non-toxic, non-viral vectors which display neutral surface 
charge, are often less efficient than their non-shielded counterparts (53), can be overcome 
by attaching targeting ligands. As another advantage, selective delivery systems require 
much lower amounts of siRNA or DNA for the same effect as a result of specific 
transfection. Targeting approaches exploit the fact that certain receptors are overexpressed 
on a variety of tissues and especially malignant abnormal cells, due to their active 
proliferation and their demand for nourishment. Therefore, many targeted delivery systems 
are specific for growth factor receptors and are therefore suitable for tumor therapy (66). 
But one has to clearly differentiate between active and passive targeting. While tumor 
accumulation of nanoparticles is most likely due to the EPR effect (19) and has been 
reported to be not significantly different for targeted and non-targeted vectors, targeted 
intracellular uptake is mediated by cell-type and receptor-specific targeting moieties (67, 
68). A variety of ligands have been used for modification of polymers to increase 
specificity, reduce the dose, and increase transfection efficiency. Conjugates of PEI are 
listed in Table 1.  
Target Receptor Ligand Used Type of Cell or Tumor Ref. 
Asialoglycoprotein receptor Lactose Hepatocytes (71) 
 Galactose 
Hepatocytes/ Airway Epithelial 
Cells 
(69) 
 Mannose Dendritic Cells / Hepatocytes (70) 
Transferrin Receptor Transferrin 
Erythrocytes, Actively 
Proliferating Cells 
(71) 
Lactoferrin Receptor Lactoferrin Bronchial Epithelial Cells (72) 
Epidermal Growth Factor 
Receptor (EGFR) 
Epidermal Growth 
Factor (EGF) 
Variety of Cancer Cells (73) 
Human Epidermal Growth 
Factor Receptor 2 (HER2/neu) 
Trastuzumab Mamma Carcinoma (74) 
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Target Receptor Ligand Used Type of Cell or Tumor Ref. 
Fibroblast Growth Factor 
Receptor 
Fibroblast Growth 
Factor (FGF) 
Fibroblasts (75) 
Nerve Growth Factor 
Receptor (NGFR) 
Recombinant 
Peptide 
Neuronal Cells (76) 
Folate Receptor Folic Acid 
Actively Proliferating Cells, 
Especially Nasopharyngial KB 
Carcinoma Cells 
(77) 
Integrin Receptor (ανβ3) RGD Peptides 
Umbilical Cord Cells, Tumor 
Endothelial Cells 
(78) 
Hyaluronic Acid Receptor Hyaluronic Acid Liver and Kidney Cancer Cells (79) 
Platelet Endothelial Cell 
Adhesion Molecule (PECAM) 
Anti-PECAM 
Antibody 
Airway Endothelial Cells (80) 
Table  1: Conjugates of PEI for specific receptor interaction. 
Even though successful targeting of liposomes was described in the literature almost 29 
years ago (81), until today cell- or tissue-specific delivery has not been clinically exploited.  
There are various further possible ligands such as aptamers (82),  recombinant antibody 
fragments (83), affibodies (84), nanobodies (85) or synthetic peptidomimetics (86) which 
partly have been used to target other delivery systems than PEI. It is therefore obvious that 
a myriad of further multifunctional PEI-based vectors for known and to-be-determined 
targets are conceivable. 
In this sense, Chapter 2 of this thesis describes specificity and activity of differently 
synthesized PEG-PEI-based gene delivery system coupled with a novel peptidomimetic 
small molecule targeting the integrin receptor alpha ν beta 3.  
1.4 Dendrimers in Gene Delivery 
Dendrimers are highly branched monodisperse macromolecules with symmetrical 
architecture which can be synthesized by divergent or convergent routes (87). Their 
solubilizing properties are determined by the core and internal groups while their solubility 
and chemical behavior is mostly determined by their peripheral groups.  
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Because of their well-defined particle size and shape, dendrimers are of particular interest 
for gene transfer, but also for drug delivery and imaging applications (12, 94). Starburst 
polyamidoamine (PAMAM) is the most commonly used dendrimer in gene delivery and is 
commercially available as generation 4 “fractured” PAMAM (88) from Qiagen 
(SuperFect®) or in a variety of generations as cationic or half anionic dendrimers (96) from 
Dendritech. The heat-degraded structures are believed to feature higher chain flexibility 
which is drawn on for the increased transfection efficiency at low generation (88). PAMAM 
is also believed to interact with DNA like non-acetylated histones (89) in a way that 
initiation of transcription in the complexed DNA is inhibited. Due to their high buffer 
capacity, PAMAM dendrimers are thought to owe their transfection efficiency to the 
“proton sponge” effect first described for PEI (46). In an attempt to use poly (L-lysine) 
(PLL) modified PAMAM as transfection reagent, it was shown that PLL selectively 
condensed DNA, whereas PAMAM maintained endosomal release (90). While high 
transfection efficiencies of non-modified PAMAM are achieved only at relatively high 
generations of 5-10 (91), synthetic efforts were made to reduce the toxicity of PAMAM. 
This was successfully achieved by quarternization of the internal amines and by 
neutralizing the surface with a hydroxyl periphery, which on the other hand also reduced 
transfection efficiency (92). A year later, the same group reported another approach where 
they maintained high transfection efficiency in spite of low toxicity by synthesis of a 
PAMAM-PEG-PAMAM triblock copolymer (93). As already described for PEI, several 
modifications of PAMAM were synthetized to improve in vitro and in vivo parameters. 
Besides targeting strategies like the attachment of mannose (94) and galactose (95), further 
modifications include more amphiphilic vectors, such as alkyl chain- or phenylalanine-
modified PAMAMs (96), other amino acid-modified PAMAMs (101), and cyclodextrin 
attachment to the surface (97). 
Other dendrimers that have extensively been investigated and optimized for gene delivery 
are poly (propylenimine) (PPI) (98) and poly (L-lysine) (PLL) (99) based dendrimers. 
While PPI dendrimers exhibit their best transfection efficiencies at low generations of 2 and 
3 (98), generations 5 and 6 of PLL dendrimers are most efficient (100). Several 
modifications of PPI, such as attachment of arginine (101) and quarternization (102) of the 
more acidic internal amines were achieved to improve transfection efficiency and DNA 
binding. Complexes of DNA and linear PLL are known to remain in the endo-/lysosomal 
compartment due to the lack of “protein sponge” effect of PLL (103). In line with the in 
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vitro results by Akinic et al., an in vivo study with PLL-based dendrimers was not 
successful concerning transgene expression although the dendriplexes accumulated in the 
tumor (104). PLL has also been modified in a number of synthetic approaches, for example 
by replacement of terminal lysine with arginine or histidine of which only the arginine 
modification enhanced transfection efficiency (105).   
Additional groups of dendrimers that have been described as nucleic acid delivery systems 
are amino-functionalized dendritic polyglycerols (106), amine-modified 
polyaminophosphine dendrimers that show reduced aggregation behavior (107) and 
carbosilane dendrimers that have recently been employed for siRNA delivery to peripheral 
blood mononuclear cells and lymphocytic T-cells to reduce HIV replication (108).  
In Chapter 3, structure-function relationships of a new class of dendrimers for delivery of 
nucleic acids are described, namely, differently substituted triazine dendrimers. Therefore, 
the impact of hydroxyl-, amine-, guanidinium-, or alkyl-periphery on physicochemical and 
biological parameters is evaluated.  
Chapter 4 reports on the advancement of triazine dendrimers in terms of generation and 
core structure. As a result of further synthetic development, five different dendrimers of 
three different generations and 3 different core flexibilities were investigated concerning 
suitability as gene delivery vectors in a two-dimensional study design. 
 Figure 2: Triazine dendrimers are expected to condense pDNA, which is subsequently 
endocytosed. Efficient triazine dendrimer-mediated gene delivery of luciferase encoding 
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pDNA can be measured as bioluminescence in present of the substrate luciferin plus co-
substrates. (Cover artwork for (109)) 
1.5 Concepts of siRNA Mediated Post-Transcriptional Gene Silencing 
In 2006, Andrew Fire and Greg Mello were awarded the Nobel Prize in Physiology for their 
discovery of gene silencing by introduction of double-stranded RNA (dsRNA) (110). Their 
work  lead to the identification of a catalytic mechanism of a multi-protein complex (111) 
which incorporates short RNAs that on their part are complementary in sequence to mRNA 
which is subsequently degraded (110). This mechanism which is an evolutionary conserved 
defense process for inactivation of foreign, e.g. transposable, viral or bacterial genetic 
information (112, 113), can also be exploited biotechnologically. Long dsRNA molecules 
which naturally or directedly reach the cytoplasm are degraded by “Dicer”, an RNase III-
like enzyme, into small interfering RNAs (siRNAs) of 21 to 25 nucleotides in length (114). 
While long dsRNA can interact with Toll-like receptor 3 (TLR3) (115), synthetic short 
interfering RNA (siRNA) no longer than 19-21 base pairs with 2 nt 3’ overhangs is efficient 
(116, 117) and lacks interferon response (118). After being transferred into the cytosol, 
where it is incorporated into the RNA-induced silencing complex (RISC), double-stranded 
siRNA is cleaved upon activation of RISC, and complementary mRNA can bind to the 
antisense strand. Argonaute (Ago2), an endonuclease in the RISC, subsequently cleaves the 
mRNA leading to down-regulation of target gene expression.   
Since the discovery of an RNA interference (RNAi) mechanism in mammalian cells, RNAi 
is routinely used in functional genomics and drug development (119, 120). RNA based 
therapeutics, on the other hand, are rather sparse. Due to their susceptibility to degradation 
by ubiquitous nucleases and their strongly negative surface charge, siRNA molecules 
require effective formulation and can not easily be compared with small molecule drugs 
(121). Besides interaction with plasma proteins and degradation by serum nucleases (122) 
and fast renal clearance in vivo (121), the bottlenecks in efficient RNAi are both 
translocation of siRNA across the plasma membrane, and its subsequent escape from the 
endosomal/lysosomal compartment. Despite of these drawbacks, successful reports on 
silencing efficacy of naked siRNA can be found in the literature where siRNA is instilled 
into the lung or the vagina (123-125) or delivered to the liver by high pressure tail vein 
injection (126, 127). Also most of the clinical trials involving siRNA based drugs rely on 
local administration to the eyes targeting age related macular degeneration (AMD) and 
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diabetic retinopathy (Acuity Pharmaceuticals, Alnylam Pharmaceuticals, Inc. and Sirna 
Therapeutics, Inc) or direct delivery to the brain or the lung (Alnylam Pharmaceuticals, 
Inc.). While SIRNA-Merck use chemically optimized siRNA in their clinical trial for the  
 
Figure 3: The mechanism of endogenous and induced RNA interference (RNAi). siRNA is 
eventually incorporated into the RISC where complementary mRNA binds before it is 
cleaved. 
treatment of AMD, Alnylam apply cholesterol-attached siRNA targeting the nucleocapsid 
N gene of the respiratory syncytial virus (RSV), which was successful in their Phase II 
GEMINI study. Chemical modification of siRNA is not only a means to improve in vivo 
stability, which has been reported to be a result of modifications of backbone and/or ribose 
(128-130). The additional benefit of methylation of the ribose 2’ hydroxyl group (2’-OMe) 
is the diminishing of immunostimulatory effects (131, 132) which have been described after 
liposomal delivery of siRNA (137). The knockdown kinetics of unmodified and nuclease-
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stabilized siRNA was shown to be essentially the same (133). A promising systemic in vivo 
application of siRNA is gene silencing in the liver which can successfully be achieved with 
so called “SNALP” (stable nucleic acid lipid particles) formulations (134). Naked siRNA 
that is systemically applied is known to be excreted via the kidneys faster than it is 
degraded (135). Other formulations that have been investigated concerning their in vivo 
pharmacokinetics are post-PEGylated protamine-lipoplexes (68), adamantane-PEG-
transferrin-bearing cyclodextrin-containing polyplexes (67), RNA−gold nanoparticle 
conjugates (136), chitosan, liposome and PEI formulated locked nucleic acids (LNAs) 
(137) and PEG-PEI polyplexes (138, 139). While post-PEGylation approaches (140) and 
cholesterol conjugation (135, 137) both extended the circulatory half-life, polyplexes made 
of pre-PEGylated PEI have often been presumed to disassemble in tissue (141) or 
circulation (139).  
Even though RNAi-based knockdown of target mRNA or protein was frequently reported 
in the literature, none of the pharmaceutical companies have robust delivery systems that 
would lead to broad clinical translation into RNAi-based therapeutics. A highly interesting 
case is CALAA-01, the first experimental therapeutic that provides targeted delivery of 
siRNA in humans which has just completed phase I tolerability evaluation of intravenous 
application in adults with solid tumors refractory to standard-of-care therapies by Calando 
Pharmaceuticals (50). CALAA-01 refers to siRNA against the M2 subunit of ribonucleotide 
reductase (RRM2) formulated within the RONDEL™ delivery system, a transferrin-
targeted cyclodextrin-containing polymer RNAi-nanotherapeutic.  
Since the circulatory half-life and biodistribution of siRNA polyplexes has not been 
extensively conducted, in contrast to that of DNA polyplexes, Chapter 5 describes the 
optimization of a method for non-invasive determination of pharmacokinetics and 
biodistribution of siRNA polyplexes. 
Chapter 6 makes use of the optimized method and correlates in vivo pharmacokinetics of 
various (PEG-)PEI/siRNA polyplexes with their in vivo stability, another parameter that is 
crucially important in the development of polymeric siRNA delivery systems. 
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 Figure 4: Intravenously applied complexes of nucleic acids and PEG-PEI have been 
suspected to disassemble either in the circulation or upon liver passage. If amphiphilic 
modifications of nucleic acids are used, binding to albumin is possible as well. (Table of 
Contents Graphic for (142)) 
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1.6 Pulmonary siRNA Delivery 
Delivery of siRNA to the lung has been studied as local administration of naked siRNA in 
2004, already (124, 143, 144). As shown by Bitko et al. (143), knockdown efficiency could 
however be further enhanced  by formulation with a delivery system. Major barriers that 
siRNA has to cross in the lung is the mucus secreted by goblet cells, the epithelium with 
tight junctions and the mucociliary and cellular clearance by macrophages. Despite of these 
hurdles, successful delivery of nucleic acids to the lung has been reported. While linear PEI 
(lPEI) of 22 kDa was described to be more efficient than branched PEI (bPEI) of 25 kDa 
molecular weight (145), coupling of the cell-penetrating-peptide TAT (146), derived from 
the HI virus, of transferrin (147), an RGD peptide (148) and galactose (149) via PEG 
increased transgene expression in the lung in non-viral gene delivery studies. Although 
gene delivery to the lung using PEI has been investigated by many groups, there are only 
little reports on pulmonary PEI-mediated siRNA delivery (56, 150, 151). 
Local delivery of siRNA requires lower amounts, mostly avoids unwanted delivery to non-
target organs and decreases elimination by renal filtration. Well described local applications 
of siRNA are intra-tumoral injections which have been reported to successfully down-
regulate hypoxia inducible factor-1α (HIF-1α) in glioma xenografts (152) and direct 
application to the eye (153), but also intrathecal/intraventricular (154, 155) and intranasal 
(124, 143, 144) administration have been described.  In an attempt to treat or prevent lung 
diseases, intranasal or intratracheal application of siRNA seems reasonable, while systemic 
delivery is not ideal for prevention of local infection. Since liposomal formulations that 
efficiently deliver siRNA (134, 156, 157) may be toxic to the mucosal ephithelia and do not 
allow for controlled or sustained release (158), other effective, safe, non-irritating and 
preferentially smart delivery systems are needed. In a recent report by Robbins et al. that 
investigated off-target effects which had previously been misinterpreted as RNAi, 
activation of TLR7/8 or TLR3 was not observed when PEI complexes of 2’OMe siRNA 
were administered to the lung (151). PEI-mediated RNAi in the lung therefore seems to be 
possible and worthwhile to be further investigated. 
In Chapter 7, pulmonary siRNA delivery with PEI and two PEGylated PEIs is described 
concerning biodistribution and systemic availability after intratracheal instillation as well as 
knockdown efficiency of EGFP in transgene mice. Referring to Robbins et al., in this study 
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2’OMe modified siRNA was used, and immune response was measured in the bronchio-
alveolar lavage fluid (BALF). 
 
Figure 5: Investigation of biodistribution and bioactivity of intratracheally instilled siRNA 
by SPECT imaging and confocal laser scanning microscopy of lung tissue sections. (Table 
of Contents Graphic for (159)) 
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1.7 Nuclear Imaging of siRNA Delivery 
As recently described by Sanhai et al., one of the top priorities in nanomedicine is 
determination of nanoparticle biodistribution. Concerning kinetics of biodistributional 
changes, visualization over time or at certain timepoints in the same animal is crucial, and 
quantification of changes on a mass-balance basis is so far only provided by nuclear 
imaging (160). PET and SPECT are routinely used for diagnosis of cancer, inflammation, 
cardiac disease or neurological disorders (161). While the first small animal PET scans 
were of poor spatial resolution, today’s small animal PET scanners with a resolution of 1 
mm (162) even outrange pinhole-based small animal SPECT imaging. SPECT or gamma 
camera imaging detects gamma photons or X-rays of radionuclides that decay by electron 
capture or isomeric transition (163). A sodium iodide crystal in SPECT scanners detects the 
distribution of γ-ray emission, converts it into an electrical signal and eventually into an 
image. By (pinhole-)collimation between radioactive signal and detector, scattered radiation 
can be decreased. The γ-radiation energy of the radionuclide used needs to be high enough 
(80-250 keV) to penetrate the body in order to reach the detector, while energy can be 
decreased in small-animal imaging. The great advantage of SPECT is that various 
radionuclides with different photon energies can be acquired simultaneously in dual-isotope 
SPECT images. Sensitivity of SPECT is partly decreased due to the absorption of lead 
collimators, allowing only about 0.1 % of the γ-radiation to be detected. Therefore, high 
radiation doses and long acquisition times are needed for SPECT imaging (163).  PET, on 
the other hand, uses radionuclides that emit positrons by β+ decay which annihilate 
ubiquitous electrons, leading to conversion into two gamma photons of 511 keV. The 
detection of photons can either be instrumented with photon sensitive crystals or with 
detectors based on multi-wire gas chambers, where the photons are converted into 
electrons, which are multiplied in the gas and detected at the anode (164). The list of 
suitable positron emitters is not as broad as the one of gamma emitters. Additionally, PET 
imaging is more expensive, especially due to the high energy radionuclides, and can not be 
performed over several days because of their short half-lives.  
Due to the possibility to acquire dynamic images and to non-invasively investigate 
biodistribution, nuclear imaging techniques are ideal methods to preclinically investigate 
pharmacokinetics and pharmacodynamics of new drugs, as has been reported for 18F-
fluoropaclitaxel (165). Nuclear imaging can even be seen as the bridging gap between 
basic, preclinical, clinical research, and clinical application (166). Since pharmacokinetic 
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parameters of siRNA delivery systems crucially affect their success and have to be 
evaluated for new delivery systems, PET and SPECT imaging are most helpful in 
preclinical investigations of delivery, binding and washout processes. Collection of kinetic 
data in small regions of interest (ROIs) even allows for calculation of pharmacokinetic 
parameters such as perfusion and clearance. Disadvantages of radiolabeling are surely 
instability issues and differences in biophysicochemical parameters of labeled and non-
labeled particles. Both concerns have to be tested to obtain reliable results. Since no 
morphological data can be obtained from nuclear imaging, co-registration of MRI or 
computed tomography (CT) images in hybrid systems even enhances the significance of the 
images.  
While tissue gamma counting and autoradiography have widely been performed with 32P-
labeled nucleic acids (139, 167), non-invasive detection of pharmacokinetics and 
biodistribution has only sparsely been reported (67, 130, 168), which can be understood as 
an issue in probe design. 
Stability of self-assembled systems is an important issue under “working” conditions, 
especially if poycations are involved that are known to interact with cells and biological 
fluids, double labeling approaches are helpful in detecting biodistribution and kinetics of 
both the vector and the load (139). 
Chapter 5 therefore challenges the probe design situation by optimizing a labeling and 
purification method for siRNA. In this chapter, pharmacokinetics and biodistribution of free 
siRNA versus PEI-complexed siRNA are described. 
Chapter 6 investigates pharmacokinetics and biodistribution of multifunctional vectors 
made of pH-buffering PEI, sterical shielding PEG and an imaging moiety attached to either 
vector or load. In vivo stability is investigated utilizing fluorescently labeled siRNA for 
fluorescence fluctuation spectroscopy (FFS) and by radioactive double-labeling in order to 
correlate it with pharmacokinetics and biodistribution in a multicomponent approach. 
In continuation of the results found in Chapter 6, Chapter 7 describes the suitability of local 
pulmonary application of siRNA/(PEI-)PEI polyplexes concerning biodistribution, assessed 
by imaging, and eventually in vivo knock down of target gene expression. 
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Figure 6: Amine-modified siRNA can easily be coupled with isothiocyanate derivatives of 
chelators for complexation of hot metal ions. Purification of the small RNA from excesses of 
chelator and metal ions has to be set great importance on to maintain valid data. (Similar 
as previously published (169)) 
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 Figure 7: Polyamines like PEI can easily be radiolabeled and purified due to the large 
difference in molecular weights. 
1.8 Polymer Genomics and Nanotoxicology 
Potential safety issues that are a major concern for in vivo application of nano-sized 
particles can be neglected in certain in vitro diagnostics. As a difference is made between in 
vitro and in vivo applicability, QDs, for example, that are popularly used in cell culture, or 
even in animal models, do not have a good chance in becoming theragnosics for application 
in humans as a result of their material toxicity. Concerning nanotoxicity, the sort of 
material, the size, chemical composition at the surface, degradability, aspect ratio and soft- 
or hardness of matter are important parameters (170) with the main molecular mechanism 
for toxicity of nanomaterials being induction of oxidative stress (171). 
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While we are exposed to increasing concentrations of particulate matter (PM) in our daily 
lives (172), PM with a mean diameter of 2.5 µm (PM2.5) can cause not only lung diseases 
but also cardio-vascular complications upon translocation of inhaled particles into other 
organs (173). The World Health Organization (WHO) has reported that life-expectancy can 
be decreased by up to ten months due to air pollution with PM (174), and the German 
Research Center for Environmental Health has proved that patients suffering from asthma 
exhibit augmented symptoms on days of high appearance of PM (175). Several American 
and European studies have shown a statistical correlation between air pollution and death 
rate, bronchitis, paranasal sinusitis and impairment of lung function (176). As it has been 
reported that environmental ultrafine particles (177) can have adverse effects on the 
respiratory tract, the potential of possible therapeutic nano devices is an important issue. 
If it comes to toxicity of non-virally delivered siRNA, a less organ related level of toxicity 
but rather molecular toxicity can become an issue. Since endogenous small RNAs exist in 
perfect balance with their precursors and targets (178), cellular delivery of synthetic siRNA 
that is not optimally designed can cause saturation of the RNAi machinery and imbalance 
of the small RNA-mediated pathways, which leads to unwanted effects in the cell. Off-
target effects such as activation of Toll-like receptors 3 (115) and 7/8 (179) have been 
reported, resulting in production of proinflammatory cytokines, and can be related to 
sequence-specific motifs in the sense or antisense strand (180). Other off-target effects can 
be caused by imperfect pairing between siRNA and mRNA (181), incorporation of the 
sense instead of the antisense strand into RISC (182), which can be avoided if the 
5’phosphate group of the sense strand is modified (183). Without loss of specificity and 
bioactivity, immunostimulatory effects of siRNA have been reported to be diminished by 
chemical modification of the ribose, such as 2’OMe-, 2’F- or 2’deoxy-ribose (132, 156, 
184, 185), while locked nucleic acids (LNAs) have been reported to cause hepatotoxicity in 
vivo (186). Another recent approach is synthesis of asymmetric shorter-duplex siRNA 
(asiRNA) that exhibit significantly decreased non-specific effects (187).  
But unwanted and toxic effects in delivery of nucleic acids can as well be caused by the 
delivery vehicle or the emerging nanoscale particles. There are a number of reports in the 
literature explaining that drug delivery systems can not be considered as inert. Especially 
cationic polymers that are known to interact with membranes on the cellular level (47), but 
also subcellularly (188), can cause membrane toxicity and apoptosis. Additionally, a 
number of genes can be up- and down-regulated upon contact with polymers which is 
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investigated in “polymer genomics” or “toxicogenomics” (189, 190). Interestingly, 
polymers can have different effects than their polyplexes (189). Arising nanoparticular 
devices therefore have to be well examined for their toxic potential (191), especially if 
applied to the lung, and nanomedicine unfortunately does not come without nanotoxicology 
(192).  
Chapter 8 therefore investigates off-target effects related with nanotoxicity in a number of 
cell culture models and also factors in conditions given in artificial reporter gene expressing 
cell lines. 
1.9 Structure of the Thesis: Aims and Outline 
This thesis focuses on a number of issues in non-viral delivery of nucleic acids concerning 
biophysicochemical parameters and in vivo application. These factors are elucidated in this 
chapter and adopted in the following ones. Part I of the thesis describes new approaches in 
non-viral gene delivery vectors (Chapters 2-4), while Part II concentrates on in vitro and in 
vivo delivery of siRNA (Chapters 5-8).  
In the context of targeted gene delivery, Chapter 2 investigates bioconjugates of PEG-PEI 
and a novel peptidomimetic small molecule for integrin receptor targeting which are 
synthesized in two different routes. Hypothesizing that these conjugates would efficiently 
transfect integrin-overexpressing cells, their specificity, efficiency, biocompatibility and 
suitability are subject of that chapter. Chapter 3 reports on a new class of dendritic non-
viral vectors, namely triazine-based dendrimers. First of all, the impact of the peripheral 
groups of a generation 2 rigid dendrimer is observed by studies of complexation behavior, 
biocompatibility, and finally transfection efficiency. In continuation, Chapter 4 describes 
the synthetic development of generation 1-3 rigid dendrimers, but also generation 2 bow-tie 
and flexible dendrimers, and their suitability as gene delivery vectors depending on 
structural parameters. 
Chapter 5 emerged out of the lack of in vivo studies describing the pharmacokinetic 
parameters of naked or protected siRNA and establishes a method for fast and efficient 
radiolabeling and purfication of siRNA for further non-invasive in vivo real-time imaging. 
This method is also applied in Chapter 6 where pharmacokinetic parameters of siRNA 
complexed with differently PEGylated PEIs are compared. Additionally, that chapter 
accounts for instability issues of self-assembled complexes in a double-labeling approach 
and a specific investigation of stability in presence of serum using a sophisticated 
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fluorescence-based method. The same radiolabeled polyplexes are used for intratracheal 
application in Chapter 7 which non-invasively observes residence times in the lung, but 
also bioavailability, biocompatibility and bioactivity in terms of target gene knock down. 
Chapter 8 describes various reasons of off-target effects in non-viral siRNA delivery which 
can especially be observed in artificial cell lines that express reporter genes. Cytotoxic 
effects, gene regulation by polycations but also the impact of the promoter driving the 
reporter gene are investigated and new screening model cell lines are established. 
All results are summarized in Chapter 9, where an outlook also provides information on 
further possible applications and developments. 
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2.1 Abstract 
This study describes the synthesis and characterization of five conjugates of poly(ethylene 
glycol) modified polyethylenimine (PEG-PEIs) coupled in two different synthesis routes to 
a non-peptidic pentacyclic RDG-mimetic for integrin receptor-targeted gene delivery. 
Synthesis of this panel of different conjugates allowed for systematic analysis of structure-
activity relationships. Conjugates were therefore characterized concerning molecular 
composition, DNA condensation, size and zeta potential of self-assembled polyplexes. In 
vitro characterization included investigation of blood compatibility, binding affinity to 
receptor-positive and receptor-negative cells measured by flow cytometry, cellular uptake 
quantified by scintillation counting, and efficiency and specificity of transfection assayed 
by reporter gene expression. In a first synthetic approach, low molecular weight PEI 
(LMW-PEI) was PEGylated using a heterobifunctional PEG linker and coupling of the 
RGD-mimetic was achieved at the distal end of PEG chains. In a second synthesis route, 
the RGD-mimetic was directly coupled to AB-block-copolymers of PEI (25 kDa) and PEG 
(30 kDa). Interactions of RGD-PEG-LMW-PEI conjugates with DNA were strongly 
impaired, whereas PEG-PEI-RGD conjugates were more promising candidates due to their 
physico-chemical properties and higher receptor specificity. The binding-, uptake- and 
transfection-efficiency in receptor positive cells was strongly increased upon conjugation of 
the RGD-mimetic to AB-block-copolymers of PEG-PEI and depended on the degree of 
peptide substitution. The conjugates of PEG-PEI AB-block-copolymers with low ligand 
density of the RGD-mimetic appear to be promising candidates for in vivo cancer gene 
therapy. 
2.2 Introduction 
The integrin receptor ανß3 is a known marker of angiogenic vascular tissue (1). The so-
called vitronectin receptor represents a highly interesting therapeutic target because of its 
role in a wide range of pathologies which have been reviewed elsewhere, e.g. angiogenesis 
(2). Vitronectin, fibronectin and fibrinogen, contain the tripeptide motif Arg-Gly-Asp, 
abbreviated as RGD, which is recognized by integrin receptors. Extensive 
neovascularization in tumors makes integrin receptor ανß3 a promising target for cancer 
gene therapy. Targeted delivery of pDNA (3-5) and siRNA (6) condensed by poly(ethylene 
imine)-graft-poly(ethylene glycol) (PEG-PEI) copolymers bearing cyclic RGD peptides 
Chapter 2 
 
46 
was reported earlier in the context of cancer gene therapy. In fact, the N-alkylated cyclic 
pentapeptide c(-RGDf[NMe]V-) is currently being tested in phase II clinical trials under the 
name “Cilengitide” as an angiogenesis inhibitor in glioblastoma multiforme (7). Because of 
metabolic instability of peptides and bioavailability reasons, non-peptidic small molecule 
RGD-mimetics were developed, such as ß-amino acid-based azacarba analogues with 
increased lipophilicity (8), hydantoin scaffolds (9), aminobenzoyl and isonipecotyl groups 
as arginine mimetic and C-terminal tryptophan to maintain ionic and hydrophobic 
interaction (10) or attachment of aliphatic carbamate linkers (11). Another class of 
substances which is similar to the one used in our study was described by Ishikawa et al. 
(12), suggesting that a cyclic guanidine at the N-terminus generates suitable adhesion, 
receptor inhibition and water solubility. None of the RGD-mimetics mentioned above have 
so far been used for targeted gene delivery. 
In this study, we used as a targeting ligand thiol and maleimide derivatives of a 
pentaycyclic peptidomimetic substance of a class of 1-α-Z-2,3-diaminopropionic acid 
substituted 4-amino-1H-pyrimidin-2-ones previously reported to exhibit high affinities to 
the vitronectin receptor in the nanomolar range (13). This ligand was coupled to different 
derivatives of PEI using two different synthetic approaches to generate five different 
bioconjugates for targeted gene delivery based on a novel RGD-mimetic. The position and 
ligand density was varied to identify the most suitable synthetic strategy and composition of 
the conjugates.  
2.3 Materials and Methods 
Materials: 
PEI 25 kDa (Polymin ™, 25 kDa) was a gift from BASF (Ludwigshafen, Germany), low 
molecular weight poly(ethylene imine) (LMW-PEI) with a low degree of branching (14) 
and the block copolymer poly(ethylene glycol)-poly(ethylene imine) (PEI25k-PEG30k) 
(15) were synthesized as described earlier.  
RGD-mimetics (RGD-M) were obtained as maleimide derivative (C34H36N8O7, Mw 668.70 
g/mol) or as sulfhydryl derivative (C30H35N7O5S, Mw 605.71 g/mol) from Abbott 
Laboratories (Abbott Park, IL, USA) as shown in Figure 1. Orthopyridyl-disulfide 
poly(ethylene glycol)- succinimidyl propionic acid (NHS-PEG2kDa-OPSS) was purchased 
from Nektar Therapeutics (San Carlos, CA, USA), the luciferase encoding plasmid pCMV-
Luc from The Plasmid Factory (Bielefeld, Germany), Luciferase Assay Reagent (LAR) and 
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Cell Culture Lysis Reagent (CCLR) were bought from Promega (Mannheim, Germany), 
ion exchange columns SP Sepharose HP from Amersham Pharmacia Biotech (Freiburg, 
Germany), and centricon YM-30 from Millipore (Millipore, Schwalbach, Germany). 
Fluorescein-5-isothiocyanate (FITC), Dithiothreitol (DTT), and 2,4,6-
Trinitrobenzenesulfonic Acid (TNBS), were purchased from Sigma-Aldrich 
Laborchemikalien GmbH (Seelze, Germany), dimethylacetamide (DMAc), and all other 
chemicals were used of analytical grade.  
 
Conjugate Synthesis: 
Conjugates were synthesized using two different approaches. Either (i) prePEGylated PEI 
(PEI25k-PEG30k), synthesized as described previously (15), was coupled directly with a 
maleimide-derivative of the RGD-M, or (ii) LMW-PEI (PEI 5 kDa) was PEGylated with a 
2 kDa SPA-PEG2k-OPSS linker which was activated with DTT before coupling to a thiol-
derivative of the RGD-M. For the first synthetic approach (i), shown in Figure 2, 23.3 mg 
PEG-PEI, corresponding to 10 mg PEI (0.4 µmol), was diluted to 500 µl with in either 
double distilled water (conjugate 10-1) or HEPES buffered saline (HBS, 20 mM HEPES, 
150 mM NaCl, pH 7.5) (conjugates 10-2 and 5-2) in a 1.5 ml Eppendorf cup. RGD-M was 
dissolved in dimethylacetamide (DMAc) and amounts of 2.67 mg (4.0 µmol) (conjugates 
10-1 and 10-2) or 1.33 mg (2.0 µmol) (conjugate 5-2) were added to the polymer solution, 
vortexed for 30 sec and incubated under constant shaking on a sample shaker TH 15 
(Edmund Bühler, Hechingen, Germany) at room temperature for 24 h. After incubation, 
purification was accomplished by ultrafiltration using centricon YM-30 spin columns.  
The second synthetic approach (ii), (Figure 3), involved coupling of a PEG linker to LMW-
PEI. For this step, 5 mg LMW-PEI (1 µmol) were dissolved in HEPES buffered saline, pH 
7.5, and reacted for 8 h with either 11.5 mg (5 µmol) (conjugate I) or 23 mg (10 µmol) 
(conjugate II) PEG linker, which had been dissolved in 200 µl absolute ethanol. Purification 
of the conjugates was achieved by modified ion exchange chromatography on an ÄKTA 
FPLC system equipped with 2 SP Sepharose HP cation exchange columns (ÄKTA Prime, 
Amersham Pharmacia Biotech, Freiburg, Germany) as previously described (16, 17). The 
intermediate products, namely the PEGylated PEI precursors which were eluted with a high 
ionic strength buffer (3 M NaCl, 20 mM HEPES) from the ion exchange column, were 
desalted using centricon YM-3 spin columns as recommended by the manufacturer. They 
were characterized concerning their PEI concentration by copper complexation (18, 19) and 
concerning their coupling degree by a pyridon-2-thion release assay (20). For this assay and 
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for activation of the PEG-linker, PEG-PEIs were treated with a 10-fold molar excess of 
DTT for 4 h at room temperature. Pyridon-2-thion release was measured 
spectrophotometrically at 343 nm and the activated PEG-PEIs were purified using centricon 
YM-3 spin columns in presence of 10 mM EDTA to avoid metal catalyzed sulfhydryl 
oxidation (21). The activated, purified and characterized precursors were mixed with a 3-
fold (Conjugate I) or 10-fold (Conjugate II) molar excess of a sulfhydryl derivative of the 
RGD-M dissolved in DMAc and were coupled by formation of disulfide bonds. After 
another ultrafiltration step, coupling degree of all conjugates was determined 
spectrophotometrically at 297 nm, the wavelength that had shown maximal absorption in a 
wavescan of RGD-M. Measured absorption was compensated with the blank value of the 
non-coupled precursor.   
 
Fluorescent Labeling of Polymers and Conjugates: 
Polymers were labeled as previously reported (22). Briefly, 20 mg polymer were dissolved 
in 2 ml 0.1 M sodium bicarbonate buffer, pH 9.0, and mixed with 1 mg FITC in 200 ml 
DMSO, stirred in the dark for 3 h at room temperature and purified by ultrafiltration using 
centricon YM-10 spin columns with a MWCO of 10 kDa. The concentration of the purified 
sample was determined at 405 nm after formation of a picrate with 2,4,6-
Trinitrobenzenesulfonic Acid (TNBS) in an assay previously described (23). The 
absorbance of the fluorescent dye was found not to interfere with the results from the TNBS 
assay. 
FITC-labeled conjugates were obtained by labeling the pre-synthesized conjugates as 
described above. Since the targeting ligand, namely the RGD-M, does not contain primary 
amines, we presumed that post-labeling would not negatively affect the conjugates, whereas 
pre-labeling could interfere with the coupling steps of either RGD-Mal or the PEG-linker. 
 
Radioactive Labeling of Conjugate 5-2: 
Similar to the fluorescent labeling, conjugate 5-2 was dissolved in 1 ml 0.1 M sodium 
bicarbonate buffer, pH 9.0, at a concentration of 10 mg/ml, mixed with p-SCN-Bn-DTPA 
(Macrocyclics, Dallas, TX, USA) in DMSO at a final concentration of 1 mg/ml and reacted 
for one hour at room temperature. The reaction was stopped by addition of 0.1 M citrate 
buffer, pH 5.0, before the reaction mixture was purified by ultrafiltration using centricon 
YM-10 spin columns with a MWCO of 10 kDa. The concentration of the purified sample 
was determined at 405 nm using the TNBS-assay (23).  
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An amount of 100 µg of DTPA coupled polymer or conjugate were diluted in 0.1 M acetate 
buffer, pH 4.5, and mixed with 10 MBq 111InCl3 for 30 min at room temperature, followed 
by size exclusion chromatography using a PD-10 Sephadex G25 prepacked column from 
Amersham Pharmacia Biotech (Freiburg, Germany). 
 
Polyplex formation: 
Polyplexes were formed by mixing equal volumes (25 µl each) of pDNA and polymer or 
conjugate diluted in 150 mM NaCl solution to obtain the desired nitrogen to DNA 
phosphate ratio (N/P ratio). Briefly, the appropriate amount of polymer was added to a 
pDNA dilution (0.04 µg/µl) to yield a final concentration of 0.02 µg DNA per µl, vortexed 
for 10 sec and incubated for equilibration for 10 min.  
 
Dynamic Light Scattering (DLS) and Laser Doppler Anemometry (LDA): 
For measurements of hydrodynamic diameters, polyplexes were prepared as described 
above. 50 µl of the polyplex solution were pipetted into a disposable cuvette (UVette, 
Eppendorf, Wesseling-Berzdorf, Germany) and measured in the “General Purpose” mode, 
which best fits the correlation function of sizes measured with polyplexes. Attenuator and 
position were optimized by the device. Subsequently, polyplex solutions were diluted with 
5 % glucose solution to 800 µl and pipetted into a folded capillary cell (Malvern 
Instruments, Herrenberg, Germany) for zeta potential measurement. Measurements were 
performed in replicates of five using a Zetasizer Nano ZS (Malvern Instruments, 
Herrenberg, Germany) equipped with a 4 mW He–Ne laser at a wavelength of 633 nm at 
25 °C. Scattered light was detected at a 173° backward scattering angle. The viscosity and 
refractive index of water at 25 °C was used for data analysis with the Dispersion 
Technology Software 5.00 (Malvern Instruments, Herrenberg, Germany). The accuracy of 
the instrument was validated using reference polymer particles (Nanosphere Size Standards 
of 50, 100 and 200 nm, Duke Scientific Corp., Palo Alto, CA, USA) and with Zeta Potential 
Transfer Standard (Malvern Instruments, Herrenberg, Germany).  
 
Ethidium Bromide Quenching Assay: 
To investigate if condensation efficiency of the polymers used for conjugate synthesis 
would be influenced by coupling of PEG or the targeting ligand, 4 µg of herring testes 
DNA (Sigma-Aldrich Chemie GmbH, Schnelldorf, Germany) were complexed with 
polymers or conjugates at different N/P ratios. After incubation for 20 min at room 
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temperature, 20 µl of a 0.1 mg/ml ethidium bromide solution (Carl Roth GmbH, Karlsruhe, 
Germany) were added and shortly incubated in the dark after intensive mixing. 
Intercalation-caused fluorescence was quantified using a fluorescence plate reader (LS 50 
B, Perkin-Elmer, Rodgau-Jügesheim, Germany) at 518 nm excitation and 605 nm emission 
wavelengths. Experiments were performed in triplicates, results are given as mean relative 
fluorescence intensity values where intercalation of free DNA represents 100 % 
fluorescence and non-intercalating ethidium bromide in buffer represents 0 % remaining 
fluorescence.  
 
Hemolytic Activity: 
Surface activity leading to hemolysis was quantified after treating human erythrocytes with 
polyplexes made of polymers or conjugates. Therefore, erythrocytes were isolated from 
fresh citrated blood from healthy volunteers by centrifugation, washed with PBS buffer and 
diluted to 5*108 cells/ml. Polyplexes of 0.1 µg pDNA per ml were prepared at N/P 5, and 
50 µl aliquots of polyplex solutions, 1 % Triton-X 100 (100 % lysis) or 150 mM NaCl (0 % 
lysis) were mixed with 50 µl erythrocyte suspension. After incubation for 30 min at 37 °C, 
samples were centrifuged at 400 g. Hemolysis of replicates of three was measured 
spectrophotometrically in supernatants at 541 nm and is given as mean percentage of the 
released hemoglobin normalized to total hemolysis induced by 1% Triton-X 100.  
 
Cell culture: 
MeWo (human malignant skin melanoma; ATCC: HTB-65) and A549 (human non-small-
cell lung carcinoma; ATCC: CCL-185) cells were purchased from ATCC (Teddington, 
UK) and maintained in DMEM (PAA Laboratories, Cölbe, Germany) supplemented with 
10% fetal calf serum (Cytogen, Sinn, Germany) in humidified atmosphere with 5% CO2 at 
37 °C. 
 
Immunofluorescence Staining of Integrin ανβ3 Receptors on the Cell Surface: 
MeWo and A549 cells were seeded with 60000 cells per well on 24 well plates (Nunc, 
Wiesbaden, Germany). After incubation for 24 h, cells were washed with Earle’s Balanced 
Salt Solution (EBSS, Hyclone, Thermo Fisher, Schwerte, Germany) and incubated with 
either 3 % bovine serum albumin in phosphate buffered saline (PBS/BSA) only (blank cells 
and secondary antibody only cells) or with integrin ανß3 antibody ([BV3] (ab7166), Abcam, 
Cambridge, MA, USA) at a concentration of 1 µg/ml in PBS/BSA for 1 hour in the dark. 
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Cells were washed three times with ice cold PBS before all wells except for blanks were 
treated with a 1:100 dilution of a FITC-labeled goat polyclonal to mouse IgG H&L 
(ab6785, Abcam, Cambridge, MA, USA) antibody in PBS/BSA for 30 min in the dark. 
Afterwards, cells were washed three times with ice cold PBS before they were trypsinized 
with 100 µl trypsin/EDTA (PAA Laboratories,  Cölbe, Germany) and fixed with 200 µl of a 
1:1 mixture of FACSFlow (BD Biosciences, San Jose, CA) and 4% paraformaldehyde in 
PBS. Cell suspensions were stored refrigerated in the dark until analysis by flow cytometry.  
All experiments were performed with replicates of three. 
 
Binding Assay: 
MeWo and A549 cells were seeded with 60,000 cells per well in 24 well plates (Nunc, 
Wiesbaden, Germany). After incubation for 24 h, medium was aspirated and cells were 
supplied with cold serum-containing medium before they were transfected with polyplexes 
containing 1 µg DNA per well and FITC-labeled polymer or conjugate at N/P 5. Triplicates 
of cells were incubated with the polyplexes for 15 min at 4 °C before they were washed 
three times with PBS, trypsinized and fixed with a 1:1 mixture of FACSFlow (BD 
Biosciences, San Jose, CA) and 4% paraformaldehyde in PBS. Cell suspensions were 
stored refrigerated in the dark until analysis by flow cytometry.  
 
Flow Cytometry: 
Suspensions of fixed cells were measured on a FACScan (BD Biosciences, San Jose, CA) 
with excitation at 488 nm and the emission filter set to a 530/30 bandpass. Cells were gated, 
10,000 viable cells were evaluated in each experiment, and results are given as the mean of 
3 independent measurements. Data acquisition and analysis was performed using CellQuest 
Pro (BD Biosciences, San Jose, CA) and FCS Express V3.00 (DeNovo Software, Thornhill, 
Canada). Results were statistically analyzed using one-way ANOVA with Bonferroni post-
hoc test. 
 
Quantification of Uptake: 
MeWo and A549 cells were seeded with 60,000 cells per well in 24 well plates (Nunc, 
Wiesbaden, Germany). After incubation for 24 h, triplicates of cells were treated with 
polyplexes prepared of various amounts of pCMV-Luc and radiolabeled conjugate 5-2 at 
N/P 5. Cells were incubated for 4 h before they were treated as described by Haigler et al. 
(24) to make sure only internalized activity was measured. Briefly, the cells were first 
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treated with 0.5 ml acetic acid (0.2 M NaAc containing 0.5 M NaCl, pH 2.5) for 6 min at 
4°C followed by a quick washing with an additional amount of 0.5 ml acetic acid to remove 
any remaining membrane-bound activity. The cell-associated activity, which was extracted 
by treating the cells with 0.5 ml 1 M NaOH for 80 min at 37°C, was considered to be 
internalized. The extracts in 0.5 ml NaOH were collected and the wells were then washed 
with an additional 0.5 ml NaOH. Before analysis in the gamma counter, the samples were 
adjusted to neutral pH by adding drops of 3 M HCI. 
 
In vitro Cell Transfection: 
MeWo and A549 cells were seeded with 30000 cells per well in 24 well plates (Nunc, 
Wiesbaden, Germany). After incubation for 24 h, cells were treated with polyplexes 
prepared of the “gold standard” PEI 25 kDa, LMW-PEI, PEG-PEI or the various conjugates 
at N/P 5. After 4 h of incubation, medium was changed and cells were incubated for another 
44 h before they were washed with PBS and lysed with cell culture lysis reagent (CCLR, 
Promega, Mannheim, Germany). Lysates of triplicates were assayed for luciferase 
expression with a commercial luciferase assay reagent (LAR, Promega, Mannheim, 
Germany) on a luminescence plate reader LUMIstar OPTIMA (BMG Labtech, Offenburg, 
Germany). 
 
Competitive Inhibition of in vitro Cell Transfection: 
For competitive inhibition of cell transfection, MeWo and A549 cells were seeded with 
30000 cells per well in 24 well plates (Nunc, Wiesbaden, Germany). After incubation for 
24 h, cells were pre-treated with increasing amounts increasing from 0.05 to 1.5 nmol per 
ml of the free targeting ligand for 15 min at 37 °C. Polyplexes prepared of PEG-PEI or 
conjugate 5-2 at N/P 5 were added into the RGD-M containing medium. Replicates of 3 
were incubated for 4 h before medium was changed and thereafter treated as described 
above. 
 
2.4 Results and Discussion 
Synthetic Outcome: 
RGD-peptides were reported to be good targeting ligands for tumor endothelium using non-
viral lipoplexes (25, 26) or polyplexes containing siRNA (6, 27, 28) and pDNA (4, 5) or 
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protein delivery systems bearing antisense oligonucleotides (29). Integrin targeting is an 
approach adopted from nature: several pathogenic organisms, such as adenoviruses (30), 
use the integrin receptor to promote their cellular internalisation. While RGD-PEG-PEI has 
successfully been reported to efficiently deliver nucleic acids into tumors (6), cRGD 
bearing micelles did not show enhanced uptake but modulated intracellular trafficking (4). 
RGD-mimetics, on the other hand, have, to our knowledge, so far only been used as 
therapeutic agents, e.g. as angiogenesis inhibitors (31), inhibitors of monocyte-derived 
macrophages (32),  enhancers of osseointegration (33), as imaging tracers for 
atheriosclerotic plaques (34), and were recently described as ligands for 5-FU (35) or TNFα 
carrying liposomes (36). In this study we describe for the first time synthesis of five RGD-
M conjugates of different molecular composition in two different coupling approaches 
(compare Figures 2 and 3) for non-viral gene delivery by coupling of a 1-α-Z-2,3-
diaminopropionic acid substituted 4-amino-1H-pyrimidin-2-one. This small molecule (13), 
exhibits nanomolar affinity to the vitronectin receptor (IC50 = 1.3 nM) as determined by 
ELISA and therefore binds stronger than the physiologic ligand vitronectin (IC50 = 6 nM 
(37)) and is comparable to the cyclic pentapeptide Cilengitide (IC50 = 0.86 nM (38)) which 
is being studied in clinical trials. The advantages of this targeting ligand compared to 
peptides are its metabolic stability and low molecular weight. Two types of conjugates were 
synthesized either consisting of AB-block-copolymers of PEI (25 kDa) and PEG (30 kDa) 
directly coupled with RGD-M ligands attached to PEI amines (Figure 2) or of a low 
molecular weight PEI core which was PEGylated using a heterobifunctional PEG linker 
that was decorated with RGD-M molecules at the distal end of the PEG chains (Figure 3), 
similar to (6, 28).  Coupling of PEG to LMW-PEI in HBS buffer, pH 7.5, yielded coupling 
degrees of 70-80 % of the feed, as shown in Figures 3. Coupling of RGD-M to activated 
PEG did not only depend on the excess of RGD-M but also on the amount of PEG-linker 
present. Synthesis of Conjugate I, for which a 5-fold molar excess of PEG over PEI and 3-
fold molar excess of RGD-M over PEI was used, resulted in a conjugate which can be 
described as LMW-PEI-(PEG2k)4-RGD0.2 (final yield of LMW-PEI: 10.0%), whereas 
Conjugate II, for which the feed contained a 10-fold molar excess of PEG linker and a 10-
fold molar excess of RGD-M over PEI, yielded the conjugate LMW-PEI-(PEG2k)7-RGD6 
(final yield of LMW-PEI: 5.8%). Coupling of RGD-mimetic-Maleimide turned out to be 
strongly influenced by pH. PEG-PEI dissolved in double-distilled water produced a pH of 
10, where most of the amines in PEI are deprotonated and available for addition to RGD-
mimetic-Maleimide. Mixing the two components yielded quantitative reaction, whereas 
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only 50 % of the feed reacted with PEG-PEI in HEPES buffered saline adjusted to pH 7.5. 
Thus, Conjugate 10-1, where a 10-fold molar excess of RGD-M over PEI was added to 
PEG-PEI in water, reacted to a compound which can be described as PEG30k-PEI25k-
RGD10 (final yield of PEG-PEI: 86.0%). Conjugates 10-2 and 5-2, where 10- and 5-fold 
excess of RGD-M, respectively, was added to PEG-PEI in HBS, yielded in PEG30k-
PEI25k-RGD5 (final yield of PEG-PEI: 84.0%), and PEG30k-PEI25k-RGD2.5 (final yield of 
PEG-PEI: 88.0%). While LMW-PEI-PEG-RGD conjugates were purified in several steps 
by ion exchange chromatography and buffer was additionally exchanged by ultrafiltration, 
PEG-PEI-RGD conjugates were only ultrafiltrated and revealed much higher yields. All 
conjugates and their synthesis are depicted schematically in Figures 2 and 3 and Table 1.  
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Figure 1: A) Maleimide- and B) thiol-derivatives of the 1-α-Z-2,3-diaminopropionic acid 
substituted 4-amino-1H-pyrimidin-2-one RGD-Mimetic with a 2-aminobenzimidazole 
moiety connected to the piperidine ring via one methylene group which were used for 
coupling via PEG-linker (A) or direct coupling (B). 
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Figure 2: Synthesis of PEG-bPEI-RGD conjugates via direct coupling and. Feeds of 
different fold excess of RGD-Mimetic and synthesis at different pH yielded 3 conjugates 
(Conjugate 10-1, 10-2, and 5-2) schematically illustrated below the synthesis scheme. 
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Figure 3: Synthesis of LMW-PEI-PEG-RGD conjugates via heterobifunctional PEG. 
Feeds of different fold excess of RGD-Mimetic and PEG linker yielded 2 different 
conjugates (Conjugate I & II) schematically illustrated below the synthesis scheme. 
Chapter 2 
 
58 
 
 PEI 
25k 
PEG-
PEI 
Con 
5-2 
Con 
10-2 
Con 
10-1 
LMW-
PEI 
Con I Con 
II 
PEI Mw 
[kDa] 
25 25 25 25 25 5 5 5 
PEG 
Mw 
[kDa] 
- 1*30 1*30 1*30 1*30 - 4*2 7*2 
RGD 
[mol/ 
mol] 
- - 2.5 5 10 - 0.2 6 
Coupled - - directly directly directly - via 
PEG 
via 
PEG 
Size 
[nm] 
90.1 ± 
10.1 
162 ± 
5.34 
387 ± 
101 
271 ± 
6.3 
92.1 ± 
3.23 
116 ± 
2.07 
677 ± 
211 
597 ± 
111 
Zeta 
[mV] 
28.2 ± 
2.16 
10.9 ± 
1.21 
2.79 ± 
0.35 
9.33 ± 
1.03 
4.88 ± 
0.72 
20.2 ± 
1.02 
-27.9 
± 1.08 
-32.5 
± 6.05 
Table 1: Molecular composition of polymers and conjugates, and size and zeta potential 
of their complexes with pDNA. 
Hydrodynamic Diameter and Zeta Potential:  
Both PEI and PEGylated PEIs are known to efficiently form polyplexes with p-DNA  (39), 
hence we measured hydrodynamic diameters of self-assembled complexes containing 
plasmid DNA and conjugates and compared their sizes to polyplexes prepared with the 
polymers that had been used for synthesis. It was reported earlier, that PEI 25kDa formed 
smaller particles than LMW-PEI at low N/P ratios (40), which is in good agreement with 
our findings (compare Figure 4). Interestingly, conjugation of RGD-M to PEG-PEI 
influenced size of particles in different ways. In theory, conjugation shifts the ratio of 
primary:secondary:tertiary amines and thus the protonation profile. Additionally, the 
targeting ligand itself can be protonated and influence interaction with polyanions. 
Therefore its spatial orientation is most relevant. In our case, Conjugate 10-1, bearing 10 
molecules RGD-M, formed particles smaller (92.1 ± 3.23 nm) than unmodified PEG-PEI 
(162 ± 5.34 nm). Conjugate 5-2, on the other hand, which bears the smallest amount of 
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RGD-M molecules, formed larger complexes (387 ± 101 nm) than PEG-PEI, and 
Conjugate 10-2 (271 ± 6.3 nm), bearing twice as many RGD-M molecules than Conjugate 
5-2 and half as many as Conjugate 10-1, still formed bigger complexes than PEG-PEI but 
smaller ones than the conjugate bearing the least targeting ligands. Obviously, the targeting 
moiety affected complex formation, which resulted in the smallest complexes formed by 
the conjugate bearing the highest density of RGD-M. Surprisingly, conjugates of lower 
coupling degree formed significantly larger particles. This can be explained by spatial 
orientation of the targeting ligands which do not seem to be involved in complex formation 
if coupled in low density but may be oriented towards the surface of the complexes yielding 
non-spherical particles which can only hardly be measured concerning hydrodynamic 
diameters by dynamic light scattering. Conjugates I and II, on the other hand, both 
exhibited a strong hindrance in nanoplex formation compared to LWM-PEI. The LMW-PEI 
used in our study was less branched than PEI 25kDa, and coupling of PEG decreased 
electrostatic interaction of LMW-PEI with negatively charged DNA both by a shift of the 
ratio of primary:secondary:tertiary amines and by modification of a small (5 kDa) ionic 
polymer with a relatively large (2 kDa) non-ionic polymer, yielding in a small portion of 
PEI  in the overall copolymer conjugates, in fact less than 50 %. The increased number of 
targeting ligands in Conjugate II seemed to decrease size of polyplexes, which is a sign for 
interaction between the targeting ligand and DNA. But differences in size between 
Conjugate I (677 ± 211 nm) and II (597 ± 111 nm) were not significant. In a previously 
published paper, it was reported that  branched PEI 25k even after coupling of 40 molecules 
PEG and RGD peptide still formed small particles of about 200 nm at N/P ratio > 1 (28). 
Therefore, we hypothesized that LMW-PEI, which additionally to its shorter chain length 
contains a lower branching degree is not suitable for DNA condensation after PEGylation. 
It is known that particles < 200 nm in size are taken up by most cell lines and that larger 
particles sediment faster and thereby enhancing transfection efficiency under in vitro 
conditions (41). Polyplexes showing aggregation, on the other hand, are not suitable for 
systemic administration. Aggregation tendency, of course, has to be evaluated in the context 
of surface charge. Therefore, zeta potentials of the various complexes were measured by 
LDA, as shown in Figure 4. Polyplexes formed with PEI 25k revealed the highest surface 
charge, which can easily be understood as a function of the high number of protonable 
amines. LMW-PEI polyplexes, which have a lower branching degree (14) and therefore a 
smaller number of primary amines, exhibited a decreased zeta potential, followed by PEG-
PEI polyplexes, where the positive surface charge is believed to be shielded by non-ionic 
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PEG (42, 43). Polyplexes prepared with RGD-PEG-PEI conjugates showed slightly lower 
surface charges compared to PEG-PEI. This could be explained by the coupling of the 
targeting ligands which most probably are attached to secondary amines, which exhibit a 
high electron density but lower steric hindrance than tertiary amines. By coupling, 
secondary amines are turned into tertiary ones which are less prone to protonation than 
secondary amines, decreasing the protonation of the conjugate compared to the polymer. 
Additionally, it is possible that the targeting ligand, if oriented towards the surface of the 
polyplex, may shield the positive surface charges of the polyplexes as described for 
transferrin-PEI polyplexes (44), PEG-PEI conjugates with anti-OA3 Fab’ (45) and PEG-
PEI conjugates with trastuzumab (46). LMW-PEI-PEG conjugates, on the other hand, 
formed polyplexes with net negative surface charge which was probably caused by 
insufficient condensation of DNA. As already seen in size measurements, PEGylation of 
LMW-PEI impaired condensation of DNA. In the case of LMW-PEI conjugates, a 
relatively small polymer (5 kDa) was substantially modified with several comparably large 
PEG chains (2 kDa). Although the targeting moiety is a small molecule, the assumption that 
conjugation can influence complex formation (47) explained the differences in sizes 
between LMW-PEI conjugate complexes and LMW-PEI complexes. 
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Figure 4: Size (bars) and zeta potential (squares) of pDNA complexes formed with 
polymers and conjugates at N/P 5 were significantly affected by conjugation. Conjugates 
I and II synthesized by PEGylation of LMW-PEI were not able to condense DNA into 
small particles, also shown by the negative zeta potential, whereas sizes of directly 
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coupled PEG-PEI-RGD conjugates decrease with increasing ligand density and exhibit 
only slight differences in surface charge. 
Condensation of DNA: 
A means to quantify condensation and protection of DNA inside the core of polyplexes is 
detection of intercalation-caused fluorescence of double strands that are available for 
reaction with ethidium bromide. DNA condensation efficiency of the different polymers 
and conjugates at different N/P ratios was therefore measured in ethidium bromide 
quenching assays. PEG-PEI conjugates (see Figure 5A) showed an obvious trend: 
Unmodified PEI 25k incorporated and protected DNA best, showing full condensation at 
N/P 3 whereas PEG-PEI reached full condensation at N/P > 5.  By increasing the amount of 
RGD-M molecules per PEG-PEI, condensation efficiency was gradually increased, and 
Conjugate 10-1 showed similar values as PEI 25k. This was in line with the trends observed 
in dynamic light scattering, where Conjugate 10-1 formed polyplexes as small as PEI 25k. 
Better condensation and higher stability of PEG-PEI conjugate complexes compared to 
their unmodified counterpart were previously described for trastuzumab-coupled PEG-PEI 
conjugates (46). LMW-PEI-PEG conjugates (Figure 5B) yielded condensation properties 
strongly different from LMW-PEI. The latter exhibited condensation efficiency almost as 
good as PEI 25k with complete condensation above N/P 5. Conjugate I, on the other hand 
did not show sigmoidal dose-responsive condensation efficiency but a linear trend, which 
proves impairment of the usual condensation behavior of DNA by PEI. As already seen in 
size and zeta potential measurements, DNA seemed to be loosely bound to the conjugates at 
N/P 5 and was not well condensed into small polyplexes. Interestingly, at N/P 10, full 
condensation was reached, and it can be hypothesized that the small amount of targeting 
ligand in this conjugate gained importance only at higher N/P ratios. Conjugate II exhibited 
another profile, which was attributed to the higher graft density of RGD-M. At low N/P 
ratios, Conjugate II showed better condensation than Conjugate I, but full condensation was 
not reached at N/P 10. This assay of course only mirrors in vitro condensation. Complex 
stability in presence of serum is currently being addressed in our present study, and in vivo 
stability will eventually be subject to an in vivo study if biocompatibility of the conjugates 
proves to be suitable. 
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Figure 5: Quenching of intercalation caused ethidium bromide fluorescence upon 
condensation of DNA with A: PEI 25k, PEG-PEI or PEG-PEI conjugates and B: LMW-
PEI or LMW-PEI-PEG conjugates. Increase of ligand density increased condensation of 
DNA. While only minor differences were observed among PEG-PEI and its conjugates, 
condensation of LMW-PEI was strongly influenced upon conjugation. 
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Biocompatibility: 
Non-specific interaction of polyplexes with cell surfaces is known for polycations such as 
PEI, PPI, PLL or PAMAM and can provoke nano hole formation caused toxicity (48). 
PEGylation of polycations is an effective shielding approach to decrease interaction with 
blood components (15). Since all of the conjugates showed nearly neutral or even negative 
zeta potentials, strong decrease of non-specific interactions was expected.  In order to 
investigate blood compatibility of the conjugates, red blood cells were treated with 
polyplexes composed of DNA and polymers or conjugates and analyzed for hemolysis (see 
Figure 6). Polyplexes prepared with PEI 25k caused the strongest hemolytic effects, LMW-
PEI and PEG-PEI polyplexes showed significantly (*** p < 0.001) decreased hemolytic 
activity. Interestingly, conjugation with the targeting ligand increased hemolysis: Conjugate 
II, despite of its negative surface charge, caused significantly (*p < 0.05) higher hemolysis 
than LMW-PEI, and Conjugates 10-1 (*p < 0.05), 10-2 (**p < 0.01), and 5-2 (***p < 
0.001) showed stronger hemolysis than PEG-PEI. This could be an indication of surface 
activity or different spatial orientation of the targeting ligand depending on the coupling 
degree. RGD sequences do not only interact with integrin alpha v beta 3 (49). Since 
erythrocytes do not carry integrins but rather an integrin-associated protein (IAP) CD47 
(50), non-specific interactions in this assay could lead to cross reactivity of the conjugates 
with CD47. Agglutination of the red blood was strongly observed in cells treated with 
unmodified PEI 25k and slightly in LMW-PEI treated cells. PEG-PEI and conjugates did 
not cause agglutination despite of the slightly higher hemolytic effects of the conjugates 
(data not shown). In order to test the conjugates in an in vivo study, minimal hemolysis and 
crosslinking of cells is a prerequisite. Further toxicity assays will show if the conjugates we 
synthesized are safe enough to be applied intravenously in a tumor model. Other options 
could be intratumoral injections or local administration. 
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Figure 6: Percentage of hemolytic activity of pDNA complexes formed with PEI 25k, 
LMW-PEI, LMW-PEI-PEG conjugates, PEG-PEI or PEG-PEI conjugates compared to 
total hemolysis caused by 1 % Triton X. Both LMW-PEI and PEG-PEI caused less 
haemolytic effects than PEI 25 kDa while their conjugates displayed lower 
biocompatibility but still less hemolysis than PEI 25 kDa. 
Expression of Integrin Receptor: 
To test specific bioactivity of the conjugates in ανß3  integrin overexpressing cells 
compared to cells that do not show overexpression of this receptor, expression status of 
MeWo human melanoma and A549 carcinomic human alveolar basal epithelial cells, two 
cell lines previously used for integrin targeted gene delivery (51), was quantified after 
immunostaining by flow cytometry (Figure 7A). A549 cells treated with primary and 
secondary antibody did not show significantly stronger fluorescence than after treatment 
with secondary antibody only, proving that fluorescence was only cause by non-specific 
binding of the secondary antibody. MeWo cells, on the other hand, showed clear 
overexpression of CD51/CD61. A549 cells were therefore considered receptor-negative, 
whereas MeWo cells were considered receptor-positive.  
Cell Binding of Polyplexes: 
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Binding of fluorescently labeled polyplexes to the receptor expressing or non-expressing 
cell surface of MeWo or A549 cells, respectively, was tested at 4 °C, where energy 
dependent processes such as receptor mediated endocytosis are deactivated. Flow 
cytometric analysis proved that only Conjugates 10-2 and 5-2 with substitution degrees of 5 
and 2.5 RGD-M per molecule displayed differences concerning binding to receptor positive 
or receptor negative cells (Figure 7B). Conjugate 10-1, on the other hand, which bears the 
highest number of RGD-M molecules, did not show significantly higher binding to MeWo 
compared to A549 cells. Due to higher stability of the complex possibly at least parts of the 
targeting ligand in Conjugate 10-1 are involved in complex formation and are therefore 
either oriented towards the inside of the complex or hidden by DNA with which they 
interact. Therefore, Conjugate 10-1 forms the smallest particles, condenses DNA as well as 
PEI 25k and does not bind to MeWo cells specifically stronger than to A549 cells. 
Concerning substitution degree, linker chemistry and their correlation to specificity, there 
are contrary reports in literature. While Garg et al. (35) reported increasing specific uptake 
with increasing amounts of targeting ligand in a range of coupling degree below 8-10 mol 
%, they also described lipoplex destabilization above that degree. This amount is still much 
below the coupling degree of all the conjugates in our study and it is possible, that 
polyplexes could as well be destabilized at high coupling degrees. It must also be kept in 
mind that the RGD-M used for conjugate synthesis is a receptor antagonist. Vitronectin-
receptor antagonists are known to cause detachment of cells. The high amount of RGD-M 
present in Conjugate 10-1 did therefore detach cells effectively interacting with Conjugate 
10-1, what could be observed macroscopically. The detached cells were aspirated in one of 
the washing steps leading to low fluorescence values measured by flow cytometry. It was 
earlier reported that integrin dimerization, cluster formation and activation of downstream 
effects depend on ligand density and affinity (52). This could explain that conjugates 
bearing a higher ligand density have a stronger inhibitory effect on cell attachment than 
those with lower ligand density. 
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Figure 7A: Flow cytometric analysis of relative expression of integrin alpha v beta 3 in 
A549 and MeWo cells compared to blank cells and cells treated with the fluorescently 
labeled secondary antibody only. MeWo cells known to express a noticeable amount of 
integrin receptors proved significantly stronger binding of the primary antibody. 7B: 
Flow cytometric binding analysis of fluorescently labeled polymer and conjugate 
complexes to the surface of A549 and MeWo cells. Conjugate 10-2 with a medium ligand 
density shows the strongest differences concerning binding to receptor positive and 
receptor negative cells. Cells treated with Conjugate 10-1 were macroscopically observed 
to be detached from the plate. 
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Transfection Efficacy: 
To investigate if the strong interaction of the conjugates with MeWo cells was only a 
concentration-dependent surface effect of the targeting ligand, uptake, which was assumed 
to be receptor-mediated endocytosis due to a previous report (53), was studied in a 
radioactive assay. Here, surface-bound material could be removed and distinct information 
about internalization could be obtained. In order to test for concentration dependent effects, 
MeWo and A549 cells were treated with increasing concentrations of Conjugate 5-2/DNA 
polyplexes, which had caused strong non-specific effects in the hemolysis assay, which 
could be interpreted as an indication of a surface effect. But scintillation counting of cell 
lysates confirmed cell specificity of uptake at each concentration as shown in Figure 8. Up 
to 1 µg of DNA per well, an increasing abundance of RGD-M leads to increasing uptake of 
polyplexes without any sign of cell detachment.   
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Figure 8: Radioactive internalization analysis of radiolabeled conjugate 5-2 complexes into 
A549 and MeWo cells at different concentrations. Up to 1 µg DNA per ml, increasing 
uptake of radiolabeled polyplex is maintained with increasing concentration. 
Finally, transgene expression after transfection of receptor-positive and receptor-negative 
cells with polymer and conjugate complexes was measured. PEI 25k, the “gold standard” in 
polymeric non-viral gene delivery was used for comparison in each experiment (compare 
Figure 9A). LMW-PEI and PEG-PEI complexes exhibited lower transfection efficiency 
compared to PEI25kDa, due to decreased non-specific cell interaction. LMW-PEI-PEG 
conjugates were even inferior to LMW-PEI concerning transfection efficiency which can be 
explained by insufficient condensation and protection of DNA inside the complex. In a 
Chapter 2 
 
68 
previous study, it was shown that attaching the targeting ligand to PEI via PEG spacer 
achieved higher transfection efficiency than direct coupling (46), but in this panel of 
conjugates, PEGylated LMW-PEI conjugates did not exhibit desirable qualities. By 
PEGylation of LWM-PEI the interaction between polycation and polyanion was obviously 
impaired, shown by poor condensation and large polyplex sizes. In another report, 
conjugation of an RGD peptide to PEI via PEG was inefficient whereas coupling via SPDP-
mediated efficient and specific transfection efficiency (51), which is in accordance with our 
results. Directly coupled Conjugate 10-1 yielded higher transfection efficiency than PEG-
PEI but no specific differences in between the cell lines. This comparably low transfection 
efficacy of Conjugate 10-1 can again be explained by cell detachment which falsified the 
results. Conjugate 5-2, on the other hand showed 28-fold higher transgene expression in 
MeWo cells than PEG-PEI and highly significantly (***p < 0.001) stronger expression than 
in A549. The low ligand density in this conjugate obviously did not cause any inhibitory 
effects on cell attachment. Conjugate 10-2 achieved very good and specific (**p < 0.01) 
transfection efficiency in MeWo, as well, which was comparable to that of the PEI 25 kDa 
but might be decreased compared to Conjugate 5-2 due to cell detachment. The fact that 
some of the conjugates also showed better transfection efficiency in A549 cells compared to 
non-targeted PEG-PEI, can be explained by a constitutive expression of integrin receptor on 
almost all cells which was shown to be much lower in A549 than in MeWo cells but not 
fully absent (Figure 7A). 
Specificity of Transfection Efficacy: 
To ascertain receptor specificity of transfection efficiency, which had also yielded higher 
values for conjugates in A549 cells, uptake of conjugate complexes was competitively 
inhibited by free ligand. Eventually, transfection efficiency was measured and compared to 
that of non-targeted PEG-PEI complexes, as shown in Figure 9B. Conjugate 5-2 complexes 
again caused significantly higher (***p < 0.001) transfection efficiency in MeWo than 
PEG-PEI complexes, but transgene expression was decreased by increasing amounts of free 
ligand. At 0.1 nmol inhibitor per ml and higher concentrations, transfection efficiency in 
MeWo cells was not significantly different from that of PEG-PEI complexes. Interestingly, 
Conjugate 5-2 complexes also again caused slightly higher transgene expression in A549 
cells than PEG-PEI complexes, and this increase was reversed in A549 cells, too, in 
presence of free targeting ligand. Since A549 cells do express a low number of integrin 
receptors, this result is not very surprising. Conjugate 5-2 was exemplarily investigated in 
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this assay as it has shown the highest transfection efficacy in the absence of competing free 
RGD-M. Since we were able to prove the specificity of its receptor-mediated delivery of 
pDNA, we hypothesize that this uptake route is also true in case of the other conjugates. 
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Figure 9A: Transfection efficiency of polymer and conjugate complexes in A549 and 
MeWo cells. Conjugate 5-2 with the lowest ligand density revealed the highest transgene 
expression. 9B: Competitive inhibition of transfection efficiency of conjugate complexes 
in A549 and MeWo cells. At a concentration of 0.1 nmol/ml of free targeting ligand or 
higher, transfection efficiency of Conjugate 5-2 could be comparatively inhibited to 
values significantly higher than that of PEG-PEI. 
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2.5 Conclusion 
In conclusion, with our panel of differently synthesized conjugates, we have been able to 
investigate structure function relationships. The high affinity small molecule we used for 
integrin receptor targeting proved to be a suitable coupling reagent for in vitro gene delivery 
systems. Depending on the coupling route, more and less effective conjugates were 
obtained. Obviously, LMW-PEI lost its ability to condense DNA into small particles and to 
protect it upon coupling of substantial amounts of PEG. The RGD-M-coupled LMW-PEI-
PEG conjugates therefore did not perform well in vitro and did not generate high transgene 
expression. The PEG-PEI conjugates, where the targeting ligand was coupled to the PEI 
domain of a diblock-like copolymer, on the other hand, seemed to be very promising 
compounds. PEG-PEI was not strongly affected concerning DNA condensation upon 
conjugation which is shown by ethidium bromide quenching and size measurements of the 
polyplexes. The coupling degree of the targeting moiety had an impact on sizes, zeta 
potentials and complexation of DNA but even more strongly influenced bioactivity. 
Whereas Conjugate 10-1 lacked specific interaction with MeWo cells, Conjugates 10-2 and 
5-2 exhibited significantly higher binding and transgene expression in integrin receptor 
overexpressing cells, which could be inhibited by free targeting ligand.  In these conjugates, 
DNA was tightly bound, but targeting ligands were obviously well accessible for 
interaction with cell surface receptors. Considering the biologic effect of the RGD-M, 
conjugates with a rather low coupling degree revealed the best results in vitro, with 
transfection efficacy inversely correlating with coupling degree. In this study we were able 
to identified Conjugates 10-2 and especially 5-2 as promising candidates for in vivo cancer 
gene therapy. 
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3.1 Abstract 
A panel of eight, generation two triazine dendrimers differing in the number of amines, 
guanidines, hydroxyls and aliphatic groups on the periphery was synthesized and assayed 
for gene transfer in an attempt to correlate the effects of surface functionality on 
transfection efficiency. The physicochemical and biological properties of the dendrimers 
and dendriplexes, such as condensation of DNA, size, surface charge and morphology of 
dendriplexes, toxic and ultimately transfection efficiency in MeWo cells, was analyzed.  
The results from an ethidium bromide exclusion assay showed that the complexation 
efficiency of the dendrimers with DNA is moderately affected by surface groups.  
Increasing the number of surface amines, reducing the number of surface hydroxyl groups, 
or replacing the amine moiety with guanidines all help strengthen the complex formed.  
Results from dynamic light scattering and zeta potential analyses indicate that the smallest 
particles result from complexes that exhibit the highest zeta potentials.  Cytotoxicity was 
low for all compounds, particularly for the G2-5 dendrimer containing alkyl groups on the 
periphery, suggesting the benefit of incorporating such neutral functionality onto the 
surface of the triazine dendrimers.  Highest transfection efficiency was observed for the 
dendrimers that formed the smallest complexes, suggesting that this physicochemical 
property is the most accurate predictor for determining which dendrimers will show the 
highest transfection efficiency. 
3.2 Introduction 
While gene therapy has shown promise in clinical trials for the treatment of a variety of 
diseases, complications, including immunogenicity and the potential for genetic 
recombination, that are associated with using viral vectors as DNA carriers has motivated 
numerous chemists to design non-viral carrier systems (1). Non-viral vector systems 
include cationic polymers (2), peptides (3), liposomes (4), and dendrimers (5).  While 
nearly all of these systems show reduced transfection efficiency compared to viral 
analogues, their potential for large-scale production and reduced toxicity make these 
systems a more attractive alternative (6). 
Among the non-viral vector systems, dendrimers are advantageous because they can be 
synthesized to afford monodisperse products with multi-functional peripheries.  Various 
dendrimers including polyamidoamine (PAMAM) (7), polypropylenimine (PPI) (8), 
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dendritic poly-L-lysine (PLL) (9), phosphorus-containing dendrimers (10), and carbosilane 
dendrimers (11) have all shown success in a number of transfection studies.  However, a 
thorough analysis of dendrimers based on melamine as candidates for gene therapy is, thus 
far, unavailable.  Cationic triazine dendrimers have shown low cytotoxicity in vitro and in 
vivo (12). In addition, the synthesis of these compounds allows for the incorporation of 
multiple functionalities on the surface (13) to aid in overcoming the barriers associated with 
gene therapy.  With the recently completed kilogram-scale synthesis of a dendrimer based 
on melamine (14), commercial availability of these types of compounds could follow.   
The obstacles encountered for non-viral vector mediated gene transfer can generally be 
classified into three main groups:  1) toxicity of the vector, 2) affinity of the complex for the 
cell surface and cell penetration, and 3) stability of the vector-DNA complex.  Cytotoxicity 
of most non-viral carriers stems from their cationic nature, and accordingly, incorporating 
non-ionic groups to improve biocompatibility is common.  Derivatizing cationic dendrimers 
with neutral groups such as polyethylene glycol (PEG) (15), hydroxyl groups (16), or lipids 
(17) has helped reduce cytotoxicity.  Our library focuses on the potential of hydroxyl 
groups as well as alkyl groups to help reduce the toxicity of triazine dendrimers. 
To improve the association of non-viral complexes with the cell surface and to increase cell 
penetration, studies often aim at incorporating functionalities onto the surface of dendrimers 
that can mimic the effects seen for arginine-rich peptides (18-20). Guanidinylation is an 
effective and synthetically simple way to probe this effect.  Our library includes structures 
to compare amines and guanidinium groups.  Studies have also shown that PAMAM 
dendriplexes with hydrophobic groups on the surface display enhanced affinity for the cell 
surface (21). The hydrophobic nature of our dendrimer cores as well as the incorporation of 
alkyl groups on the surface are hypothesized to promote interactions with cell surface 
phospholipids.  Finally, the number of surface amine groups was varied to gain insight into 
dendrimer-DNA complex formation. 
In this paper we report the synthesis of a library of monodisperse dendrimers with various 
surface functional groups to investigate the effect of triazine dendrimer peripheries on 
transfection efficiency.  The physicochemical and biological properties of these structures, 
including complexation efficiency, zeta potential, hydrodynamic diameter, cytotoxicity, and 
finally transfection efficiency, were all assayed.  Correlations between these properties and 
the functionality on the peripheries of the triazine dendrimers are reported. 
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3.3 Results and Discussion 
Synthesis 
Synthesis of the dendrimers used in this study follows a divergent route in which a first 
generation triazine core, G1-C, which was synthesized as described elsewhere (22), is 
reacted with various monochlorotriazines (MCT1 to MCT5) to form the second generation 
structures (PG2-1 to PG2-5).  These Boc-protected structures were then deprotected to 
form dendrimers G2-1 through G2-5 (Scheme 1a).  Subsequently dendrimers G2-1 to G2-
3 were guanidinylated following previously described procedures (22) to form G2-1g to 
G2-3g (Scheme 1b).  All of the intermediates and products were characterized by 1H and 
13C NMR and/or mass spectrometry as described in the experimental section.  The results 
show nearly complete monodispersity for all of the final products. 
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Scheme 1: (a) Synthesis of amine terminated triazine based dendrimers proceeds by 
divergent route, (b) synthesis of guanidinylated triazine dendrimers 
Ethidium bromide quenching assay 
The association of dendrimers and DNA, a so-called dendriplex, can result in the formation 
of both tightly or loosely associated complexes, with the latter resulting in DNA being more 
accesible to nucleases and other species.  To quantify the extent of unassociated DNA, an 
ethidium bromide intercalation assay is utilized.  In this assay, dendrimer and DNA are 
complexed and then exposed to ethidium bromide.  If unassociated DNA exists, ethidium  
bromide intercalates and fluoresces.  If only tightly bound DNA is prescent, intercalation is 
hindered and fluorescence is absent.  Therefore, compounds that exibit low fluorescence 
typically correlate with highly compacted and protected DNA complexes, which is 
favorable for in vivo studies. The extent of intercalation quenching by triazine dendrimers 
is reported in Figure 1 and various trends that correlate the packaging of DNA with the 
surface functionality of the dendrimers are evident. 
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The choice of the peripheral group of the triazine dendimers appears to have notable effect 
on the packaging of DNA.  In all cases, the dendrimers that contain only six surface amines 
(G2-3 and G2-4) complexed weakly to DNA as compared to the analogues that contain 
twelve surface amines (G2-1 and G2-2 respectively). This suggests that condensation 
efficiency is moderately affected by the number of surface amines, with improved 
complexation seen for dendrimers with a higher number of surface amines.  
Guanidinylation appears to significantly increase packaging over primary amine analogues 
in nearly all cases.  This has been seen in earlier studies in which guanidinylated cholesterol 
derivatives were reported to interact more strongly with DNA than similar amine structures 
(23).  Like the amine analogues, more strongly complexed structures were formed using 
dendrimers with twelve peripheral guanidines (G2-1g and G2-2g) as compared to 
dendrimers with only six guanidines (G2-3g).   
The formation of strongly complexed structures decreases with increasing number of 
surface hydroxyl groups, suggesting that this neutral functionality may hinder interactions 
with DNA. However, for the alkyl group of G2-5, the formation of a strongly complexed 
dendriplex is observed.  In fact the alkylated compound outperforms PEI in complexation 
efficiency, suggesting this compound should be competitive in transfection efficiency 
assays.   
 
Figure 110: DNA condensation efficiency was quantified by ethidium bromide quenching 
assay. 
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Dynamic light scattering and zeta potential measurements 
Dynamic light scattering was used to determine the size of the triazine dendrimer-DNA 
complexes (Figure 2a).  In general, the size of the complex can affect both transfection 
efficiency and toxicity.  For in vitro studies, large polyplexes can sediment faster and may 
result in high transfection efficiency, but can also result in high cytotoxicity (24). However, 
complexes with diameters of less than 200 nm are endocytosed by most cell lines and are 
believed to be more practical for in vivo and clinical applications.   
In general, complex size appears to be independent of peripheral functionality.  The 
smallest complexes were formed using dendrimers G2-1 and G2-5, suggesting these 
compounds should be the most competitive in transfection efficiency assays.  Alternatively, 
both G2-1g and G2-2g formed complexes with sizes of approximately 1 µm, which is 
generally a size for which sedimentation occurs, suggested that the compounds may also 
exibit notable transfection efficiency in vitro. 
Zeta potential measurements were used to determine the surface charge of the 
dendrimplexes (Figure 2b).  In general, positively charged particles associate well with the 
cell surface and are internalized by the cell via endocytosis while negatively charged 
particles are usually repelled by the negatively charged plasma membrane.  Overall, the 
results of the zeta potential analysis are complementary to the data collected from DLS.  
The dendrimers that showed the highest surface charge (G2-1, G2-4, G2-3g, and G2-5) 
also formed the smallest complexes suggesting that these structures may exhibit notable 
transfection efficiency.  Only dendrimer G2-3 showed a negative zeta potential at an N/P 
ratio of 5, indicating that this compound will not likely be an effective gene transfer agent. 
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Figure 211: Hydrodynamic diameters (a) and zeta potentials (b) of various endriplexes at 
an N/P of 5 were determined in 10 mM HEPES buffer, pH 7.4. 
MTT-assays 
The cytotoxicity observed in this study derives from incubation of various concentrations of 
the dendrimer (0.001 – 0.5 mg/mL) with murine L929 fibroblasts.  The cell viability is 
quantified by mitochondrial enzyme activity, which reduces yellow 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) to its purple formazan.  The reduction is 
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quantified spectrophotometrically.  The quantified toxicity represents the “worst case 
scenario”: dendriplexes should display reduced toxicity due to the masking of cationic 
groups, and this trend has been reported in previous studies investigating the use of PPI for 
gene delivery (8).  The results are shown in Figure 3. 
The cytotoxicity results from this study correlate well with an earlier report that revealed an 
IC50 value of 0.1 mg/mL for a related triazine dendrimer (12).  In general there are no clear 
trends for correlating cytotoxicity with surface functionality.  None of the triazine 
dendrimers used in this study showed substantial cytotoxicity, indicating that this will not 
be a substantial factor that influences gene transfer activity. 
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Figure 312: Toxicity profiles of all the water soluble dendrimers according to the MTT 
assay were compared to that of PEI 25 kDa. For clarity, IC50 values are given. 
Transfection efficiency 
Transfection efficiency of the dendriplexes at three different N/P ratios was quantified 
using a commercial luciferase assay in a human melanoma cell line (MeWo).  The data is 
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reported in relative light units on a log scale.  The gene transfer activity was compared to 25 
kDa PEI, a gold standard in transfection (Figure 4). 
The highest transfection efficiency was seen for DNA complexed with either G2-1 or G2-5.  
These complexes have relatively small sizes (< 250 nm), which correlates with earlier 
studies that showed that high transfection efficiency is seen for small complexes (25, 26). 
However, at high N/P ratios (N/P = 7.5) high transfection efficiency was also seen for 
complexes with twelve guanidine surface groups despite the large size of these complexes.  
This high transfection efficiency may be due to a sedimentation effect exerted on these 
large complexes.  However, due to their large size these compounds would not be suitable 
for in vivo gene delivery studies.  For all of the complexes that contain only 6 terminal 
amines (G2-3, G2-4 and G2-3g), poor transfection efficiency correlates with low cation 
number. 
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Figure 413: Transfection efficiency of all the water soluble dendrimers at various N/P 
ratios in MeWo cells are given as relative light units detected by luciferase assay. 
3.4 Conclusion 
Triazine dendrimers join the growing list of macromoelcules capable of facilitating gene 
delivery.  Even within this small subset of architectures, trends in activity emerge that 
validate observations made in other classes of molecules. Perhaps surprisingly, small 
structural perturbations in the periphery of triazine dendrimers influence tranfection 
efficiency.  The competitive efficacy seen with G2-1 bodes well for future studies, 
Chapter 3 
 
88 
including those aimed at examining the influence of generation and core structure which we 
hope to communicate in due course. 
3.5 Experimental 
Materials 
All chemicals used for synthesis were of analytical grade.   The intermediate structures G1-
C and  MCT-2 were synthesized as described elsewhere.13, 22 
 
Synthesis 
Monochlorotriazine 1 (MCT1).  Cyanuric chloride (0.92 g, 5.00 mmol) and Boc-protected 
3,3’-bisaminopropylamine (1.66 g, 5.00 mmol) were each dissolved in 60 mL 
tetrahydrofuran and cooled to 0 °C.  The Boc-protected triamine was added dropwise to 
cyanuric chloride followed by the addition of DIPEA (1.75 mL, 10.05 mmol).  After 3 
hours, diethanolamine (0.53 g, 5.02 mmol) and DIPEA (1.75 mL, 10.05 mmol) were 
dissolved in 60 mL tetrahydrofuran, cooled to 0 °C, and added dropwise to the reaction 
mixture.  The mixture was warmed to room temperature.  After 20 hours the solvent was 
evaporated under reduced pressure.  The crude product was dissolved in dichloromethane 
and washed with distilled water.  The organic layer was dried and purified by column 
chromatography (10:1 CH2Cl2:ethyl acetate) to yield MCT1 (2.49 g, 91%).  1H NMR (300 
MHz, CDCl3) δ:  5.76 (b, 1H, OH) 5.36 (t, 2H, NHBoc), 3.77 (d, 4H, CH2OH), 3.67 (d, 
4H, NCH2CH2OH), 3.51-3.43 (br, 4H, NCH2CH2CH2), 3.01 (m, 4H, CH2NHBoc), 1.79-
1.67 (m, 4H, CH2CH2CH2), 1.37 (s, 18H, C(CH3)3).  13C NMR (75 MHz, CDCl3) δ:  168.4 
(C3N3), 165.0 (C3N3), 164.1 (C3N3), 156.3 (CO), 79.3 (OC(CH3)3), 61.7 (CH2OH), 51.7 
(NCH2CH2OH), 44.6 (NCH2CH2CH2), 38.0 (CH2NHBoc), 28.2 (C(CH3)3), 27.7 
(CH2CH2CH2).  MS (ESI):  calcd 547.29 (M+); found 548.30 (M + H+). 
Monochlorotriazine 3 (MCT3). Mono-Boc-protected 2,2′-(ethylenedioxy)bis(ethylamine)  
(0.33 g, 1.32 mmol) and cyanuric chloride (0.24 g, 1.33 mmol) were each dissolved in 
20mL tetrahydrofuran, and cooled to 0 °C.  The diamine solution was added dropwise to 
the cyanuric chloride solution followed by the addition of DIPEA (0.75mL, 4.31 mmol).  
After 3 hours, diethanolamine (0.11 g, 1.326 mmol) and DIPEA (0.75mL, 4.31 mmol) were 
dissolved in 20 mL tetrahydrofuran, cooled to 0 °C, and added dropwise to the reaction 
mixture.  The solution was warmed to room temperature.  After 18 hours the reaction 
mixture was dried under reduced pressure.  The crude product was dissolved in 
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dichloromethane and washed with distilled water.  The dichloromethane layer was dried 
and purified using column chromatography (10:1 CH2Cl2:ethyl acetate) to afford MCT3 
(0.49 g, 80%).  1H NMR (300 MHz, CDCl3) δ:  6.11 (br, 1H, OH), 5.38 (br, 1H, NHBoc), 
3.89 (br, 4H, NCH2CH2OH), 3.77 (br, 2H, NHCH2CH2O) 3.60 (s, 4H, OCH2CH2O), 3.54 
(m, 6H, OCH2CH2NHBoc, NCH2CH2OH), 3.29, (q, 2H, CH2NHBoc), 1.96 (br, 2H, OH), 
1.42 (s, 9H, C(CH3)3).  13C NMR (300 MHz, CDCl3) δ:  168.7 (C3N3), 165.9 (C3N3), 165.2 
(C3N3),  156.4 (CO), 70.6 (CH2OCH2CH2OCH2), 69.5 (OCH2CH2O), 61.8 (CH2OH), 52.3 
(NCH2CH2OH),  41.0 (HNCH2), 40.5 (CH2NHBoc), 28.6 (C(CH3)3).  MS (ESI):  calcd 
464.22 (M+); found 465.17 (M + H+). 
Monochlorotriazine 4 (MCT4). Mono-Boc-protected 2,2;-(ethylenedioxy)bis(ethylamine)  
(0.10 g, 0.40 mmol) and cyanuric chloride (0.07 g, 0.40 mmol) were each dissolved in 7mL 
tetrahydrofuran and cooled to 0 °C.  The diamine solution was added dropwise to the 
cyanuric chloride solution followed by the addition of DIPEA (0.21 mL, 1.21 mmol).  After 
3 hours, 2-(2-aminoethoxy)ethanol (0.04 mL, 0.40 mmol) and DIPEA (0.21 mL, 1.21 
mmol) were mixed in 7 mL tetrahydrofuran, cooled to 0 °C, and added dropwise to reaction 
mixture.  The solution was allowed to warm to room temperature.  After 18 hours the 
reaction mixture dried under reduced pressure, dissolved in dichloromethane, and washed 
with distilled water.  The dichloromethane layer was dried and the product was purified by 
column chromatography (1:1 CH2Cl2:ethyl acetate  1:1 CH2Cl2:ethyl acetate with 10% 
CH3OH) to afford MCT4 (0.16 g, 85%).  1H NMR (300 MHz, CDCl3) δ:  3.72 (s, 4H, 
NCH2), 3.62 (s, 8H, OCH2CH2O), 3.53 (t, 6H, OCH2CH2NH), 3.31 (t, 2H, CH2NHBoc), 
2.75 (s, 1H, OH), 1.42 (s, 9H, C(CH3)3). 13C NMR (300 MHz, CDCl3) δ:  166.2 (C3N3), 
165.8 (C3N3), 156.3 (CO), 79.3 (OC(CH3)3, 72.6 (OCH2CH2O), 70.6 (OCH2CH2NH), 61.8 
(CH2OH), 40.8 (NHCH2), 40.5 (CH2NHBoc), 28.6 (C(CH3)3).  MS (ESI):  calcd 464.22 
(M+); found 465.23 (M + H+). 
Monochlorotriazine 5 (MCT5).  Boc-protected 3,3’-bisaminopropylamine (0.48 g, 1.45 
mmol) and cyanuric chloride (0.27 g, 1.45 mmol) were each dissolved in 4:1 
CH2Cl2:CH3OH (30 mL) and cooled to 0 °C.  The triamine solution was added dropwise to 
cyanuric chloride followed by the addition of DIPEA (0.25 mL, 1.44 mmol).  After 3 hours, 
hexylamine (0.15 g, 1.45 mmol) and DIPEA (0.25 mL, 1.44 mmol) were dissolved in 15 
mL of 4:1 CH2Cl2:CH3OH, cooled to 0 °C, and added dropwise to the reaction mixture.  
After 12 hours reaction mixture was dried under reduced pressure, dissolved in 
dichloromethane, and washed with distilled water.  The dichloromethane layer was dried 
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and the crude product was purified by column chromatography (10:1 CH2Cl2:ethyl acetate) 
to afford MCT5 (0.72 g, 91%).  1H NMR (300 MHz, CDCl3) δ:  3.59-3.49 (t, 4H, NCH2), 
3.37 (q, 2H, NHCH2), 3.09 (m, 4H, CH2NHBoc), 1.78-1.69 (m, 4H, CH2CH2CH2), 1.57 
(m, 2H, NHCH2CH2), 1.44 (s, 18H, C(CH3)3), 1.31 (s, 6H, CH2), 0.88 (t, 3H, CH3).  13C 
NMR (300 MHz, CDCl3) δ:  168.7 (C3N3), 165.6 (C3N3), 165.4 (C3N3), 156 (CO), 79.1 
(OC(CH3)3), 44.0 (NCH2CH2CH2), 43.6 (NHCH2), 41.2 (NHCH2CH2), 37.8 (CH2NHBoc), 
37.0 (CH2NHBoc), 31.7 (CH2CH2CH3), 28.6 (C(CH3)3), 28.0 (CH2CH2CH2), 26.7 
(NHCH2CH2CH2), 22.8 (CH2CH3), 14.2 (CH3).  MS (ESI):  calcd 543.33 (M+); found 
544.33 (M + H+). 
Protected G2-1 (P-G2-1).  MCT1 (0.57 g, 1.04 mmol) and G1-C (0.18 g, 0.17 mmol) 
were each dissolved in 10 mL of 9:1 CH2Cl2:CH3OH.  The solutions were mixed at room 
temperature followed by the addition of DIPEA (0.5mL, 2.9 mmol).  The reaction mixture 
was heated to 70 °C.  After 10 days the reaction mixture was dried, re-dissolved in 
dichloromethane, and washed with distilled water.  The organic layer was condensed and 
purified by column chromatography (4:1 CH2Cl2:ethyl acetate with 1  3% CH3OH) to 
yield P-G2-1 (0.43 g, 61%).  1H NMR (300 MHz, CDCl3) δ:  5.64 (s, 12H, OH) 5.09 (s, 
12H, NHBoc), 3.87 (br, 24H, CH2OH), 3.81 (br, 72H, piperazine), 3.77 (br, 24H, 
NCH2CH2OH), 3.61 (br, 24H, NCH2CH2CH2), 3.11 (br, 24H, CH2NHBoc), 1.67 (br, 24H, 
CH2CH2CH2), 1.44 (s, 108H, C(CH3)3).  13C NMR (300 MHz, CDCl3) δ:  165.6 (C3N3), 
165.5 (C3N3), 156.2 (CO), 79.2 (OC(CH3)3), 62.0 (CH2OH), 51.3 (NCH2CH2OH), 44.2 
(NCH2CH2CH2), 43.6 (piperazine), 38.2 (CH2NHBoc), 28.7 (C(CH3)3), 27.9 
(CH2CH2CH2).  MS (MALDI):  calcd 4142.57 (M+); found 4142.71 (M + H+). 
G2-1.  P-G2-1 (0.38 g, 0.09 mmol) was dissolved in 3 M HCl:CH3OH.  After 2 days the 
reaction was condensed and neutralized with NaCO3 to pH=7.  NaCl byproduct was 
removed from the mixture using an Amicon apparatus and a millipore membrane with 
NMWL = 1,000 under 35 psi N2.  The solution remaining inside the Amicon vessel was 
dried in vacuo to afford G2-1 (0.25 g, 93%).  MS (MALDI):  calcd 2941.94 (M+); found 
4142.90 (M + H+).  HPLC (2:1 H2O with 0.14% TFA:acetonitrile):  3.196 min. 
G2-1g.  G2-1 (21.9 mg, 7.4 µmol) was dissolved in 1mL distilled water.  1H-pyrazole-1-
carboxamidine•HCl (0.13 g, 890 µmol) and DIPEA (0.31 mL, 1.78 mmol) were mixed in 
1mL acetonitrile.  When the acetonitrile solution became clear, the distilled water solution 
was added, and the mixture was stirred at room temperature.  After 5 days the solvents were 
removed and the mixture was re-dissolved in diionized water. Excess starting material was 
removed from the solution using an Amicon apparatus and a millipore membrane with 
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NMWL = 1,000 under 35 psi N2.  The solution remaining inside the Amicon vessel was 
dried in vacuo to afford G2-1g dendrimer (18.1 mg, 71%).  MS (MALDI):  calcd 3446.21 
(M+); found 3447.00 (M + H+).   
Protected G2-2 (P-G2-2).  MCT2 (0.30 g, 0.55 mmol) and G1-C (0.10 g, 0.09 mmol) 
were each dissolved in 3 mL 9:1 CHCl3:CH3OH.  The monochlorotriazine solution was 
added dropwise to the G1-C solution followed by the addition of DIPEA (0.40 mL, 2.30 
mmol).  After 5 days the reaction mixture was dried under reduced pressure, re-dissolved in 
dichloromethane, and washed with distilled water.  The organic layer was dried and purified 
by column chromatography (4:1 CH2Cl2:ethyl acetate and 37% CH3OH) to afford P-G2-
2 dendrimer (0.22 g, 58%).  1H NMR (300 MHz, CDCl3) δ:  5.26 (br, 18H, NHBoc), 3.82 
(br, 72H, piperazine), 3.75 (br, 36H, CH2OCH2CH2OH), 3.64 (br, 12H, NHCH2), 3.61 (br, 
24, NCH2), 3.08 (br, 24H, CH2NHBoc), 1.73 (br, 24H, CH2CH2CH2), 1.44 (s, 108H, 
C(CH3)3).  13C NMR (300 MHz, CDCl3) δ:  165.6 (C3N3), 165.2 (C3N3), 156.2 (CO), 79.3 
(OC(CH3)3), 72.5 (OCH2CH2OH), 70.2 (NHCH2CH2O), 61.8 (CH2OH), 43.3 (piperazine), 
42.5 (NCH2CH2CH2), 40.8 (NHCH2CH2O), 37.4 (CH2NHBoc), 28.7 (C(CH3)3), 28.0 
(CH2CH2CH2).  MS (MALDI):  calcd 4142.57 (M+); found 4143.15 (M + H+). 
 G2-2.  P-G2-2 (0.22 g, 0.05 mmol) was dissolved in 3M HCl:CH3OH.  After 3 days the 
reaction mixture was condensed, dissolved in distilled water and neutralized with 1M 
NaOH.  NaCl byproduct was removed from the solution using an Amicon apparatus and a 
millipore membrane with NMWL = 1,000 under 35 psi N2.  The solution remaining inside 
the Amicon vessel was dried in vacuo to afford G2-2 dendrimer (0.09 g, 59%).  MS 
(MALDI):  calcd 2941.94 (M+); found 4142.96 (M + H+).  HPLC (2:1 H2O with 0.14% 
TFA:acetonitrile):  3.256 min. 
G2-2g. G2-2 (14.6 mg, 5.0 µmol) was dissolved in 1 mL distilled water.  1H-pyrazole-1-
carboxamidine•HCl (0.09 g, 590 µmol) and DIPEA (0.21 mL, 1.21 mmol) were mixed in 
1mL acetonitrile.  When the acetonitrile solution became clear, the distilled water solution 
was added, and the mixture was stirred at room temperature.  After five days the solvents 
were removed and the mixture was redissolved in diionized water. Excess starting material 
was removed from the solution using an Amicon apparatus and a millipore membrane with 
NMWL = 1,000 under 35 psi N2.  The solution remaining inside the Amicon vessel was 
dried in vacuo to afford G2-2g (12.7 mg, 74%).  MS (MALDI):  calcd 3446.21 (M+); found 
3447.12 (M + H+). 
Protected G2-3 (P-G2-3).  MCT3 (0.30 g, 0.65 mmol) and G1-C (0.12 g, 0.11 mmol) 
were each dissolved in 3 mL 9:1 CH2Cl2:CH3OH.  The monochlorotriazine solution was 
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added to the G1-C solution followed by the addition of DIPEA (0.34 mL, 1.95 mmol).  The 
reaction mixture was heated to 70 °C.  After 4 days the reaction mixture was dried under 
reduced pressure, dissolved in dichloromethane, and washed with distilled water.  The 
organic layer was dried and purified by column chromatography using 4:1 CH2Cl2:ethyl 
acetate with 7% CH3OH to afford P-G2-3 (0.18 g, 47%).  1H NMR (300 MHz, CDCl3) δ:  
5.39 (br, 12H, NH), 3.82 (br, 24 + 12 + 72H, NCH2CH2OH, NHCH2, piperazine), 3.57 (s, 
36H, OCH2CH2O, NCH2) 3.53 (t, 24H, OCH2CH2NHBoc), 3.31 (q, 12H, 
OCH2CH2NHBoc), 1.88 (br, 12H, OH), 1.43 (s, 54H, C(CH3)3).  13C NMR (300 MHz, 
CDCl3) δ:  167.2 (C3N3), 165.5 (C3N3), 164.6 (C3N3),  156.7 (CO), 79.4 (OC(CH3)3), 70.5 
(CH2OCH2CH2OCH2), 70.1 (OCH2CH2O), 63.1 (CH2OH), 51.6 (NCH2CH2OH),  43.4 
(piperazine), 40.6 (NHCH2, CH2NHBoc), 28.6 (C(CH3)3).  MS (MALDI):  calcd 3644.13 
(M+); found 3645.86 (M + H+). 
G2-3.  P-G2-3 (0.18 g, 0.05 mmol) was dissolved in 3M HCl:CH3OH (10 mL).  After 5 
days the solvent was evaporated under reduced pressure and the product was re-dissolved in 
distilled water and neutralized with NaCO3 to pH=7. NaCl byproduct was removed from 
the solution using an Amicon apparatus and a millipore membrane with NMWL = 1,000 
under 35 psi N2.  The solution remaining inside the Amicon vessel was dried in vacuo to 
afford G2-3 (0.12 g, 77%).  MS (MALDI):  calcd 3043.82 (M+); found 3044.37 (M + H+).  
HPLC (2:1 H2O with 0.14% TFA:acetonitrile):  3.345 min. 
G2-3g.  G2-3 (19.3 mg, 6.3 µmol) was dissolved in 1 mL distilled water.  1H-pyrazole-1-
carboxamidine•HCl (0.06 g, 380 µmol) and DIPEA (0.13 mL, 750 mmol) were mixed in 
1mL acetonitrile.  When the acetonitrile solution became clear, the distilled water solution 
was added and the mixture was stirred at room temperature.  After five days the solvents 
were removed and the mixture was re-dissolved in diionized water.  Excess starting 
material was removed from the solution using an Amicon apparatus and a millipore 
membrane with NMWL = 1,000 under 35 psi N2.  The solution remaining inside the 
Amicon vessel was condensed in vacuo to afford G2-3g (18.3mg, 88%).  MS (MALDI):  
calcd 3295.95 (M+); found 2396.51 (M + H+). 
Protected G2-4 (P-G2-4).  MCT4 (0.15 g, 0.32 mmol) and G1-C (0.06 g, 0.05 mmol) 
were each dissolved in 3 mL 9:1 CH2Cl2:CH3OH.  The monochlorotriazine solution was 
added to the G1-C solution at room temperature followed by the addition of DIPEA (0.16 
mL, 0.92 mmol).  The reaction was heated to 70 °C.  After 4 days the reaction mixture was 
dried in vacuo, dissolved in dichloromethane, and washed with distilled water.  The organic 
layer was dried to afford P-G2-4 (0.18 g, 93%).  1H NMR (300 MHz, CDCl3) δ:  5.39 (br, 
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18H, NH), 3.80 (br, 72H, piperazine), 3.71 (br, 12, OCH2CH2OH), 3.61 (br, 96H, CH2), 
3.31 (br, 12H, CH2NHBoc), 1.43 (s, 54H, C(CH3)3).  13C NMR (300 MHz, CDCl3) δ:  
166.2 (C3N3), 165.6 (C3N3), 165.2 (C3N3), 156.3 (CO), 79.3 (OC(CH3)3), 72.7 
(CH2OCH2CH2OCH2), 70.4 (OCH2CH2O), 61.7 (CH2OH),  43.3 (piperazine), 40.6 
(NHCH2, CH2NHBoc), 28.6 (C(CH3)3).  MS (MALDI):  calcd 3644.13 (M+); found 
3645.49 (M + H+). 
G2-4.  P-G2-4 (0.16 g, 0.04 mmol) was dissolved in 3M HCl:CH3OH.  After 5 days the 
solvent was evaporated under reduced pressure and the product re-dissolved in distilled 
water and neutralized with NaCO3 to pH=7.  NaCl byproduct was removed from the 
solution using an Amicon apparatus and a millipore membrane with NMWL = 1,000 under 
35 psi N2.  The solution remaining inside the Amicon vessel was condensed in vacuo to 
afford G2-4 (0.05 g, 40%).  MS (MALDI):  calcd 3043.82 (M+); found 3043.62 (M + H+). 
Protected G2-5 (P-G2-5).  MCT5 (0.36 g, 0.67 mmol) and G1-C (0.06 g, 0.06 mmol) 
were each dissolved in 5 mL of 10:1 CH2Cl2:CH3OH.  The monochlorotriazine solution 
was added to the G1-C solution at room temperature followed by the addition of DIPEA 
(0.25 mL, 1.44 mmol).  The reaction was heated to 70 ºC.  After 5 days the reaction mixture 
was dried in vacuo, dissolved in dichloromethane, and washed three times with distilled 
water.  The organic layer was dried to afford P-G2-5 (0.20 g, 86%).  1H NMR (300 MHz, 
CDCl3) δ:  5.25 (br, 5H, NH), 4.91 (br, 8H, NH), 3.82 (s, 72H, piperazine), 3.58 (br, 24H, 
NCH2), 3.39 (q, 12H, NHCH2), 3.08 (br, 24H, CH2NHBoc), 1.77 (br, 24H, CH2CH2CH2), 
1.59 (p, 12H, NHCH2CH2), 1.44 (s, 108H, C(CH3)3), 1.32 (br, 36H, CH2), 0.89 (t, 18H, 
CH3).  13C NMR (300 MHz, CDCl3) δ:  165.6 (C3N3), 165.5 (C3N3), 165.3 (C3N3), 156.2 
(CO), 79.2 (OC(CH3)3), 43.3 (NCH2CH2CH2, NHCH2, piperazine), 41.0 (NHCH2CH2), 
31.8 (CH2CH2CH3), 30.1 (CH2), 28.7 (C(CH3)3, CH2CH2CH2), 26.8 (NHCH2CH2CH2), 
22.8 (CH2CH3), 14.3 (CH3).  MS (MALDI):  calcd 4118.82 (M+); found 4121.46 (M + H+). 
G2-5.  P-G2-5 (0.18 g, 0.04 mmol) was dissolved in 5 mL CH3OH.  Concentrated HCl (5 
mL) was added to the methanol solution.  After 18 hours the reaction mixture was 
condensed in vacuo and neutralized with 5 M NaOH.  At basic pH, product precipitated to 
yield G2-5 (0.12 g, 98%).  MS (MALDI):  calcd 2918.19 (M+); found 2919.32 (M + H+). 
 
Cell Culture.  L929 and MeWo cells were purchased from LG Promochem, Wesel, 
Germany, and were maintained in Dulbecco’s Modified Eagle Medium (DMEM) at low or 
high glucose (PAA Laboratories, Cölbe, Germany), respectively, supplemented with 10% 
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fetal calf serum (Cytogen, Sinn, Germany) in humidified atmosphere with 5% CO2 at 37 
ºC. 
 
Preparation of dendriplexes.  Dendriplexes were formed by adding a solution of 
calculated concentration of dendrimer to an equal volume of DNA solution (pCMV-Luc, 
Plasmid Factory, Bielefeld, Germany).  The two components were mixed and left for 20 
minutes to allow for complex formation.  Both pDNA and dendrimer dilutions were 
prepared in 10 mM HEPES buffer, pH 7.4, and the amount of dendrimer needed to afford a 
certain N/P ratio was calculated by considering the “protonable unit” of each dendrimer 
which represents the mass of dendrimer per protonable nitrogen atom.  For comparison, 
bulk polyethylenimine (Polymin, 25 kDa), a gift from BASF (Ludwigshafen, Germany), 
was used . 
 
Ethidium bromide quenching assay.  In order to investigate condensation efficiency of 
the dendrimers, 4 µg of herring testes DNA (Sigma-Aldrich Chemie GmbH, Schnelldorf, 
Germany) were mixed with increasing amounts of dendrimers in a final volume of 280 µL 
10 mM HEPES buffer and pipetted into opaque FluoroNunc™ 96 well plates (Nunc, 
Thermo Fisher Scientific, Langenselbold, Germany)..  After incubation for 20 minutes at 
room temperature, 20 µL of a 0.1 mg/mL ethidium bromide solution (Carl Roth GmbH, 
Karlsruhe, Germany) were added to each well and briefly incubated in the dark under 
constant shaking.  Intercalation-induced fluorescence was quantified using a fluorescence 
plate reader (LS 50 B, Perkin-Elmer, Rodgau-Jügesheim, Germany) at 518 nm excitation 
and 605 nm emission wavelengths.  Results are given as mean relative fluorescence 
intensity values with interacalation of free DNA representing 100% fluorescence and non-
intercalating ethidium bromide in buffer representing 0% remaining fluorescence.  Results 
are given as means of triplicate measurements +/- standard deviation (SD). 
 
Dynamic light scattering and zeta potential analysis.  For measurements of size and zeta 
potential by dynamic light scattering (DLS) and laser Doppler anemometry (LDA), 
respectively, dendriplexes of 0.6 µg pCMV-Luc and the according amount of dendrimer 
were formed as described above.  Complexes were incubated for 20 minutes and diluted to 
a total volume of 800 µL with 10 mM HEPES buffer, pH 7.4, to be measured into a folded 
capillary cell (Malvern Instruments, Herrenberg, Germany) using a Zetasizer Nano ZS, 
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Malvern, Herrenberg, Germany.    Measurements were conducted in triplicates in the 
“General Purpse” mode, where position and attenuator were optimized by the device.. 
 
MTT assay.  The influence of dendrimers on metabolic cell activity was investigated using 
the MTT assay. For this proliferation assay, murine L929 fibroblasts were seeded on 96-
well plates (Nunc, Wiesbaden, Germany) at a density of 8000 cells per well 24 hours before 
they were treated with dendrimer solutions of increasing concentrations in the range of 
0.001 to 1 mg/mL.  After another 24 hours, the medium was changed, and the MTT 
solution was added into fresh serum-free medium and incubated for 4 hours.  Cells were 
lysed with 200 µL DMSO per well, and remaining mitochondrial enzyme activity 
compared to untreated cells was determined by measuring the absorbance of enzymatically 
formed formazan at 580 nm with 690 nm background correction. 
 
Transfection experiments.  Human melanoma cells (MeWo) were seeded in 96-well 
plates (Nunc, Wiesbaden, Germany) at a seeding density of 8000 cells per well.  Twenty 
four hours later, cells were transfected with dendriplexes made of 0.25 µg pCMV-Luc per 
well and the according amount of dendrimer calculated to be N/P ratios of 2.5, 5, or 7.5.  
Branched 25 kDa PEI was used as a positive and free plasmid as a negative control.  
Dendriplexes were added to full serum-containing medium and cells were incubated for 4 
hours before medium was changed.  After additional 44 hours, cells were washed with PBS, 
lysed will Cell Culture Lysis Reagent, CCLR (Promega, Mannheim, Germany), and 
assayed for luciferase expression with a commercial luciferase assay kit (Promega, 
Mannheim, Germany) on a LUMIstar OPTIMA plate luminometer (BMG Labtech, 
Offenburg, Germany). 
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4.1 Abstract 
A family of generation one, two and three triazine dendrimers differing in their core 
flexibility was prepared and evaluated for their ability to accomplish gene transfection. 
Dendrimers and dendriplexes were analyzed concerning their physicochemical and 
biological properties such as condensation of DNA, size, surface charge, morphology of 
dendriplexes, toxic and hemolytic effects and ultimately transfection efficiency in L929 and 
MeWo cells. Flexibility of the backbone was found to play an important role with 
generation 2 dendrimer displaying higher transfection efficiencies than poly(ethylene 
imine) 25 kDa or SuperFect™ with lower cytotoxicity. This result is surprising as PAMAM 
dendrimers require generations 4 or 5 to become effective transfection reagents. The ability 
to delineate effects of molecular structure and generation of triazine dendrimers with 
biological properties yields valuable information for further modifying this promising class 
of non-viral delivery systems.  
4.2 Introduction 
Gene therapy has gained importance in recent years due to its potential for targeting genetic 
diseases and inhibiting tumor growth.  However, clinical application is limited by numerous 
biological barriers to delivering plasmid DNA (1). Both viral and non-viral vector systems 
have been developed to overcome these hurdles. Viral delivery systems, which include 
retroviruses, lentiviruses, and adenoviruses, have encountered potential safety problems 
such as recombination, insertional mutagenesis, and immunogenicity as well as scale-up 
difficulties (2).  Therefore, synthesis and evaluation of non-viral vector systems becomes 
increasingly important in spite of their comparatively lower transfection efficiency (3).   
Non-viral vectors such as cationic liposomes, linear and branched polycations and 
dendrimers have been shown to be effective transfection agents and offer advantages over 
viral vectors regarding safety and manufacturing. Several non-viral gene delivery systems 
based on poly(amidoamine) (PAMAM) (4-6), poly(propylene imine) (PPI) (7, 8), and 
poly(ethylene imine) (PEI) (9, 10) have yielded efficient transfection in vivo with relatively 
low toxicity. The potential of triazine dendrimers as gene delivery systems is largely 
unexplored, but has been described by us in a study involving generation 2 rigid structures 
(11), which reveal an optimized peripheral group for further study. These dendrimers may 
be attractive candidates as they can be synthesized in high yields via a divergent strategy 
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that creates multiple surface functionalities in a completely monodisperse manner (12).  In 
addition, triazine dendrimers show low toxicity, both in vitro and in vivo: mice tolerate i.p. 
doses up to 40 mg/kg (13). This level of toxicity is comparable to PAMAM (14) suggesting 
that triazine dendrimers could be considered as a platform for transfection studies. Here, the 
physicochemical properties, cytotoxicities and transfection efficiencies of a panel of triazine 
dendrimers were evaluated to establish structure function relationships. The effect of 
dendrimer size (generations) as well as core structure is probed in an attempt to maximize 
transfection efficiency. Increasing generation increases size and the number of available 
cations.   Changing the composition of the core affords dendrimers that differ in the 
flexibility, a characteristic that is thought to influence interactions with p-DNA (6). The 
dendrimers used in this study are shown in Figure 1. Here we present results from the 
synthesis, physicochemical and biological in vitro evaluation of a panel of 5 triazine 
dendrimers and compare them to commercially available PAMAM dendrimers of different 
generations to define structural parameters such as generation and core flexibility for the 
design of triazine dendrimers as non-viral gene delivery systems. 
4.3 Materials and Methods 
Materials 
Poly(ethylene imine) (Polymin™, 25 kDa) was a gift from BASF (Ludwigshafen, 
Germany), PAMAM (ethylenediamine core, amino surface) 2nd and 3rd generation was 
bought from Sigma-Aldrich Laborchemikalien GmbH, Seelze, Germany, and SuperFect™ 
from Qiagen, Hilden, Germany. All chemicals used for synthesis were obtained from 
Sigma-Aldrich (St. Louis, MO). 
 
Synthesis 
The synthesis of all dendrimers used in this study proceeded via a divergent strategy 
originating from cyanuric chloride.  The rigid, first generation dendrimer was synthesized 
by reacting a tris(piperazyl) triazine core with MCT1, followed by deprotection.  The rigid, 
second generation dendrimer, G2-1, was synthesized as previously described (11). To form 
the third generation rigid dendrimer, G3-1, the rigid, deprotected G1-dendrimer, G1-C was 
reacted with di(Boc-piperazyl)monochlorotriazine.  This second generation structure was 
deprotected and reacted with MCT1 to form the protected third generation compound, 
Chapter 4 
 
102 
which was deprotected using HCl (Supplementary Materials). A detailed description of the 
synthesis is provided in the supplementary material section. 
The flexible core dendrimer, F2-1, was synthesized by reacting cyanuric chloride with 
mono-Boc-protected O,O'-bis(3-aminopropyl)diethylene glycol.  This core was deprotected 
with HCl, reacted with Boc-piperazyl-dichlorotriazine, and capped with Boc-piperazine.  
After removal of the protecting groups with HCl, the compounds were reacted with MCT1 
and deprotected to form the flexible, second generation dendrimer, F2-1 (Supplementary 
Materials). A detailed description of the synthesis is provided in the supplementary material 
section. 
Finally, the second generation bow-tie structure, B2-1, was synthesized by reacting di(Boc-
piperazyl)monochlorotriazine with O,O'-bis(3-aminopropyl)diethylene glycol. This core 
structure was deprotected with HCl and reacted with di(Boc-piperazyl)monochlorotriazine 
to form a first generation bow-tie structure.  This structure was deprotected, reacted with 
MCT1, and deprotected again to afford the dendrimer B2-1 (Supplementary Materials). A 
detailed description of the synthesis is provided in the supplementary material section. 
 
Cell Culture: L929 murine fibroblasts and MeWo human melanoma cells were purchased 
from LG Promochem, Wesel, Germany, and maintained in DMEM low or high glucose 
(PAA Laboratories, Cölbe, Germany), respectively, and supplemented with 10% fetal calf 
serum (Cytogen, Sinn, Germany) in humidified atmosphere with 5% CO2 at 37°C. 
 
Preparation of Dendriplexes 
Dendriplexes were formed by adding 25 µl of a calculated concentration (depending on 
“protonable unit” and N/P ratio) of dendrimer to an equal volume of the DNA solution 
(pCMV-Luc, Plasmid Factory, Bielefeld, Germany) and then mixing the two components 
before letting them mature for 20 minutes. The final concentration of pDNA in the 
dendriplex solution was 0.02 µg/µl. Both pDNA and dendrimers were diluted with 10 mM 
HEPES buffer, pH 7.4, and the appropriate amount of dendrimer was calculated by 
considering the desired N/P ratio and the “protonable unit” of each dendrimer, which 
represents the mass of dendrimer per protonable nitrogen atom. For comparison, standard 
transfection reagents, including poly(ethylene imine) (PEI 25 kDa), second and third 
generation PAMAM (ethylenediamine core, amino surface), and SuperFect (Qiagen, 
Hilden, Germany) were used. Polyplexes with PEI 25 kDa and dendriplexes with 
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PAMAMs of 2nd and 3rd generation were formed as described above, whereas dendriplexes 
with SuperFect were prepared as recommended by the manufacturer. 
 
Ethidium Bromide Quenching Assay 
To quantify condensation efficiency of the dendrimers, an indirect dye-quenching assay 
was performed as previously reported (15). Briefly, 4 µg of herring testes DNA (Sigma-
Aldrich Chemie GmbH, Schnelldorf, Germany) was complexed with increasing amounts of 
dendrimer in a final volume of 280 µl 10 mM HEPES buffer. After incubation for 20 
minutes at room temperature, 20 µl of a 0.1 mg/ml ethidium bromide solution (Carl Roth 
GmbH, Karlsruhe, Germany) was added and incubated for 10 minutes in the dark following 
intensive mixing. Intercalation-caused fluorescence was quantified using a fluorescence 
plate reader (LS 50 B, Perkin-Elmer, Rodgau-Jügesheim, Germany) at 518 nm excitation 
and 605 nm emission wavelengths. Results are given as relative fluorescence intensity 
values where intercalation of free DNA represents 100% fluorescence and non-intercalating 
ethidium bromide in buffer represents 0% remaining fluorescence. Results are given as 
means of triplicate measurements ± standard deviation (SD). 
 
Dynamic Light Scattering and Zeta Potential Analysis 
Polyplex size and zeta potential were determined as previously reported (15). Briefly, 
dendriplexes of 0.6 µg pCMV-Luc and the corresponding amount of dendrimer were 
prepared as described above. Complexes were incubated for 20 minutes and then diluted to 
a total volume of 800 µl with 10 mM HEPES buffer, pH 7.4, to be measured using a 
Zetasizer Nano ZS, Malvern, Herrenberg, Germany. Position and attenuator were optimized 
by the device. The accuracy of the size measurements was routinely checked using 
reference polymer particles (Nanosphere Size Standards, 50, 100 and 200 nm, Duke 
Scientific Corp., Palo Alto, CA, USA), and the zeta potential values were calibrated with 
the Zeta Potential Transfer Standard (Malvern Instruments, Herrenberg, Germany). The 
data was analyzed using a High Resolution Mulitmodal algorithm. All measurements were 
conducted in triplicates. For better characterization of the size distributions, in addition to Z 
Average, the PDI of the distribution is given as the mean value of three independent 
measurements ± SD. 
 
Atomic Force Microscopy 
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The size and morphology of dried dendriplexes were analyzed by atomic force microscopy 
as previously described for polyplexes (16). Briefly, dendriplexes were prepared by mixing 
1 µg pCMV-Luc and a dendrimer at an N/P ratio of 5 as described above, incubating for 20 
minutes, and drying on silicon chips. Microscopy was performed on a NanoWizard (JPK 
instruments, Berlin, Germany). Commercial NSC16 AlBS-tips (Micromasch, Estonia) on 
an I-type cantilever with a length of 230 µm and a nominal force constant of 40 N/m were 
used. All measurements were performed in tapping mode to avoid damage to the sample 
surface. The scan frequency was 0.6 Hz and scan size was 5x5 µm. Multiple images were 
recorded, of which one representative topograph is presented. 
 
Erythrocyte Aggregation and Hemolysis 
Unspecific cell interaction was visualized by erythrocyte aggregation and quantified by the 
measurement of hemolysis according to previously described procedures (17). Briefly, 
human erythrocytes were isolated from fresh citrated blood from healthy volunteers by 
centrifugation, washed with PBS buffer, and diluted to 500.000.000 cells/ml. Dendriplexes 
of 0.1 µg pDNA per ml were prepared at N/P 5, and 50 µl aliquots of dendriplex solutions, 
1 % Triton-X 100 (100 % lysis) or PBS (0 % lysis) were mixed with 50 µl erythrocyte 
suspension. After incubation for 30 minutes at 37 °C, samples were centrifuged at 850 g. 
Hemolysis was measured by VIS-absorption of supernatants at 541 nm and the data is 
given as a mean percentage ( n = 3) of the released hemoglobin ± SD, normalized to total 
hemolysis induced by 1% Triton-X 100. Pelleted erythrocytes were resuspended in 50 µl 
PBS and microscopically examined to determine erythrocyte aggregation. 
 
Cell viability 
The cytotoxicity of the dendrimers was investigated using an MTT assay (15).  Murine 
L929 fibroblasts were seeded on 96-well plates at a density of 8000 cells per well 
approximately 24 hours before they were treated with dendrimer solutions of increasing 
concentrations in the range of 0.001 to 1 mg/ml. Another 24 hrs later, the medium was 
changed. MTT solution was added into fresh serum-free medium and incubated for 4 hours.  
The remaining mitochondrial enzyme activity as compared to untreated cells was 
determined by measuring the absorbance of enzymatically-formed formazane at 580 nm 
with 690 nm background corrections after cell lysis in 200 µl DMSO. The results are given 
as mean values of a replicate of 4 ± SD.  
 
Chapter 4 
 
105 
Transfection Experiments  
To compare transfection efficiency in different cell lines, murine 3T3 fibroblasts (L929) 
and human melanoma cells (MeWo) were seeded in 96-well plates at a seeding density of 
8000 cells per well. Approximately 24 hours later, the cells were transfected with 
dendriplexes consisting of 0.25 µg pCMV-Luc per well and the amount of dendrimer 
calculated to be N/P 2.5, 5 or 7.5. Branched PEI of 25 kDa, second and third generation 
PAMAM, and 4th generation SuperFect were used as standards and free plasmid was used 
as a negative control. 
Polyplexes were added to full serum-containing medium, and cells were incubated for 4 
hours before the medium was changed. Another 44 hours later, the cells were washed with 
PBS, lysed with CCLR (Promega, Mannheim, Germany), and assayed for luciferase 
expression using a commercial luciferase assay kit (Promega, Mannheim, Germany) on a 
BMG LUMIstar OPTIMA luminometer plate reader (BMG Labtech, Offenburg, Germany). 
Transfection assays were performed in triplicates and the mean values ± SD are given. 
 
4.4 Results and Discussion 
Nomenclature adopted.  Throughout the manuscript, the targets are named to reflect 
common and disparate features in structure with the core/generation-surface groups 
identified.  The cores increase in flexibility from G (standard) to B (bowtie) to F (flexible), 
and the effect of size is determined over three (1, 2, 3) generations using the standard core 
structure.  Each dendrimer contains a common surface group (1) that was previously 
reported to avoid obtaining variations in transfection efficiency that result from the 
peripheral functionalities (11).   
 
Synthesis and design criteria 
As the products of multistep organic syntheses, triazine dendrimers allow us access to well-
defined structures to investigate structure-activity relationships such as the influence of size 
and backbone structure on transfection efficiency and cytotoxicity. For this purpose, a 
preliminary panel of dendrimers was synthesized consisting of different generations (G1, 
G2, G3) with a rigid backbone and a common surface group (1), yielding 6, 12 or 24 
amino-groups in the periphery. With each increase in generation number, the number of 
primary amino groups presented in the periphery doubles.   
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In addition to generation number, the flexibility of the core could hypothetically affect 
transfection efficiency by influencing the distribution and accessibility of the peripheral 
groups for interacting with p-DNA (18). The role of flexibility has been supported 
experimentally by Szoka who showed enhanced transfection efficiency resulting from 
fragmentation of PAMAM dendrimers (6).  In this study, this effect was investigated with 
second generation triazine dendrimers, each having differing core flexibilities (G2-1, F2-1, 
B2-1). Synthetic yields and NMR data are provided within the Supporting Information. 
 The composition of the panel is summarized in Figure 1 and Table 1. Branched 
poly(ethylene imine) of 25 kDa (PEI 25kDa) was used as a control. The transfection 
efficiencies of the triazine dendriplexes were additionally compared to SuperFect™, a 
commercially available 4th generation fractured PAMAM dendrimer and to second and 
third generation PAMAM as dendrimer standards. 
 
 
Figure 1.  The dendrimer panel is given as chemical structures and sketches in a color code 
used throughout the study. Structure activity relationships of the dendrimers in Table 1 
were investigated in a two-dimensional approach: By variation of the generation (vertical 
arrows) and the core structure (horizontal arrows), influence of both parameters were 
investigated. 
Condensation properties of triazine dendrimers.  
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The formation of dendriplexes results from electrostatic interactions between polycationic 
dendrimers and negatively charged DNA. The quantification of condensation properties 
was performed using an ethidium bromide quenching assay (15) which reveals the fraction 
of uncomplexed DNA that is accessible for intercalation with ethidium bromide at a given 
N/P ratio. PAMAM dendrimers of generation 2 and 3 showed significant residual 
fluorescence leading to a plateau around N/P 7.5 (compare Figure 2).  A similar trend was 
seen for several triazine dendrimers, including G1-1, G2-1 and F2-1. The third generation 
triazine dendrimer, G3-1, yielded higher condensation than PEI, even at low N/P ratios. 
Interestingly, the bow-tie dendrimer B2-1 showed better DNA condensation than PEI, with 
a condensation profile comparable to the third generation rigid dendrimer G3-1. 
Similar to PAMAM, triazine dendrimers showed an increase in condensation efficiency 
with increasing generation. The first generation dendrimer G1-1 condensed DNA less 
effectively than the second generation analogue, G2-1, which in turn was less efficient than 
the third generation dendrimer, G3-1.  However, the effect of the core structure on 
condensation efficiency seems minimal. This may result from the type of amines present in 
the triazine core.  The reason that more flexible dendrimers are thought to complex with 
DNA more effectively than rigid analogues has been attributed to the increased capacity of 
flexible dendrimers to interact with DNA, as all amine groups, both inside the core and at 
the surface, contributed to the electrostatic interactions for binding (19).  This increased 
availability of internalized amines in flexible structures results in the formation of more 
compact complexes (7, 20, 21). However, in the case of triazine dendrimers, the nitrogen 
atoms in the core are part of a delocalized electron system and hence not available for 
protonation under physiologic conditions (pH 7.4). Therefore, only the primary amino 
functional groups at the dendrimer periphery contribute to DNA condensation due to their 
accessibility to protonation (22).  As the perhipheral groups are identical and the triazine 
core amines remain unprotonated at physiological pH, the trend of increased condensation 
efficiency for more flexible structures is not apparent; the semi-flexible bow-tie dendrimer 
B2-1 more effectively condenses DNA than either the rigid G2-1 or flexible F2-1 analogs.   
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Figure 2.  DNA condensation efficiency was quantified by ethidium bromide quenching 
assays and compared to PAMAMs of the same generations and PEI 25 kDa. 
Dendriplex sizes and surface charges.  
Polyplexes with diameters < 200 nm in size are internalized by most cell lines (23), while 
larger particles can sediment faster leading to enhanced transfection efficiency under in 
vitro conditions (24). A positive surface charge generally facilitates endocytosis, whereas 
negatively charged particles are often repelled by the negatively charged cell surface. 
Previous studies have shown that the complexation of DNA with PEI decreases polyplex 
sizes for increasing N/P ratios up to 20 (25). This trend could not be observed for the 
triazine dendrimers (data not shown). In the case of triazine dendriplexes, there seems to be 
an optimal N/P ratio at which minimal sizes can be achieved. When this N/P ratio is 
exceeded, larger dendriplexes (and possibly aggregates) form. By comparing rigid G1-1, 
G2-1 and G3-1 dendrimers (Figure 3 A), no clear trend between dendriplex sizes and the 
generation number emerges. Generally, dendrimers with a higher number of primary 
amines on the periphery tend to form smaller polyplexes with DNA, as shown for PAMAM 
in this study. This behavior is not observed for the rigid triazine dendrimers, G2-1, G2-1, 
and G3-1. Our findings indicated that the rigid second generation dendrimer, G2-1, forms 
the smallest complexes.  This may be due to the “nitrogen density” (26) or “charge density” 
(27, 28), a parameter that is known to influence the interaction of polycations with pDNA. 
This paramter is defined as the density of protonable amines in the polycation per molecular 
weight and can also be called the “protonable unit”. The protonable unit can therefore be 
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measured in g/mol N and helps to characterize polycations. The charge density of PEI, 
where every third atom is a nitrogen atom, is 43.1 g/mol N (29), which is a comparably 
high charge density considering that the charge density in our triazine dendrimers is about 
200 g/mol N: G1-1 has a density of primary amines of 211.27 Da/N atom, G2-1 has a 
density of 245.3 Da/N atom, and G3-1 has a density of 262.2 Da/N atom. Therefore, G2-1 
may form smaller complexes as compared to G3-1 because of the difference in charge 
density.  However, despite the lower charge density of G2-1, G2-2 formed smaller 
complexes, which can be explained by the twofold increase in primary amines per 
molecule. The formation of large dendriplexes using the flexible dendrimer, F2-1 and the 
bow-tie dendrimer, B2-1, may result partially from the low charge densities of these 
dendrimers (F2-1: 262.32 Da/N atom; B2-1: 262.2 Da/N atom).  These values may be too 
low for the formation of very small complexes.  Additionally, the size of dendriplexes 
formed with the flexible dendrimer, F2-1, were much larger than those of G2-1, suggesting 
that loose structures were obtained, in accordance with data from ethidium bromide 
quenching assay. The bow-tie dendrimer B2-1 formed the largest dendriplexes despite its 
DNA condensation efficiency, possibly caused by the formation of inter-dendriplex 
aggregates (7).  The dendriplex size distributions were monomodal but showed 
polydispersity indices around 0.2 (Figure 3A) as reported previously for dendriplexes (30-
32).  
Zeta potentials of the PAMAM dendriplexes generally increased as particle size decreased. 
For example, the PAMAM 2nd generation dendrimer did not condense DNA efficiently as 
illustrated by a negative zeta potential and large complexes sizes. As the number of primary 
amines on the periphery (generation) increases, the PAMAM dendrimers condensed DNA 
more efficiently (Figure 2) due to their very high number of primary amines (PAMAM G4 
= SuperFectTM: 64 surface amines) and charge density (PAMAM G4: 222.10 Da/N atom). 
The rigid triazine dendrimers (G1-1, G2-1, and G3-1) did not show a clear generation-
dependent trend for surface charge. G1-1 exhibited a zeta potential of -0.0513 mV. The zeta 
potential of G2-1 dendriplexes, which had proven to form the smallest particles among the 
rigid dendrimers, was observed to be strongly positive. By further increasing the generation 
of the rigid dendrimer, not only sizes increased (Figure 3A), but also the zeta potential 
decreased (Figure 3B).  Taken together, third generation dendrimers condense and protect 
DNA (Figure 2) efficiently, but may result in larger aggregates in solution. It is possible 
that, due to their rather low charge density at the same N/P ratio and molecular 
composition, G3-1 dendrimers do not shield the negative charge of DNA effectively, which 
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results in lower electrostatic repulsion and stronger aggregation of dendriplexes. According 
to the data acquired in the ethidium bromide assay (Figure 2B), the flexible dendrimer F2-1 
only loosely bound DNA and was not able to fully protect the complex. Therefore, it seems 
reasonable to assume that the net negative charge measured for F2-1 dendriplexes was 
caused by segments of free DNA which were not incorporated into any particle but were 
only bound to the surface of the flexible polycation. The dendriplexes formed with the bow-
tie dendrimer B2-1 exhibited a low but positive surface charge, which can again be 
explained by inter-dendriplex interaction. 
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Figure 3.  Hydrodynamic diameters (A) and zeta potentials (B) of various dendriplexes at 
an N/P of 5 were determined in 10 mM HEPES buffer, pH 7.4. 
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Atomic Force Microscopy.  
Although dynamic light scattering is an effective method for measuring particle size, the 
method is limited because it assumes spherically shaped particles.  Therefore atomic force 
microscopy (AFM) was used to characterize the morphology and heterogeneity of 
dendriplexes (33). The broad polydispersities observed with the dynamic light scattering 
experiments was also reflected in the AFM micrographs (Figure 4). The flexible core 
dendrimer F2-1, produced two populations or particles: very small complexes (<50 nm) as 
well as larger ones (>100 nm). The bow-tie dendrimer, B2-1, formed clusters of aggregates, 
which supports the assumption of inter-dendriplex interactions (7). The third generation 
dendrimer G3-1 showed the most uniform distribution.  
Both the formation of clusters and the discrepancy between size measurement of dried 
particles and complexes in solution are not surprising:  Similar observations have been 
made for PAMAM dendriplexes (21). The sizes measured for F2-1 and G3-1 dendriplexes 
by DLS are confirmed by AFM. In AFM, a distribution of 20-100 nm (F2-1) and narrow 
size distribution of particles of 100 nm (G3-1) could be observed. The larger sizes 
measured by DLS can be explained by the high number of short ethylene glycol chains that 
might be hydrated in solution but carry no weight after drying the sample for AFM.  The 
picture of the B2-1 dendriplex-clusters confirmed the DLS determined size of ~900.  
 
 
Figure 4. Morphology and density of dendriplexes were investigated by AFM revealing 
spherically shaped nanoplexes. Differing polyplex sizes as measured by dynamic light 
scattering are probably due to sample preparation (drying). 
Erythrocyte Aggregation and Hemolysis.  
Red blood cells can be used to visualize and quantify the membrane interactions of 
dendriplexes by determining erythrocyte aggregation or hemolysis. Positive surface charges 
can lead to unspecific binding, membrane interactions and the cytotoxicity associated with 
G2-10 
F2-1 B2-1 G3-1 
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amino groups (34). The concentration dependent hemolysis and perturbation of red blood 
cells after incubation with PAMAM, diaminobutane (DAB), diamonoethane (DAE) and 
poly(ethylene oxide) (PEO) grafted carbosilane (CSi–PEO) was reported previously (35).  
Generation-dependent hemolysis similar to PAMAM was seen with triazine dendrimers as 
well, though not as pronounced (Figure 5A). The hemolytic activity of triazine dendrimers 
seems to depend on their core structure, as hemolysis of the flexible dendrimer, F2-1, was 
markedly decreased compared to the rigid analogue, G2-1. However, dendriplexes formed 
from the bow-tie dendrimer, B2-1, caused hemolytic effects comparable to G3-1 
dendriplexes. A possible explanation is the strong aggregation of B2-1 dendriplexes, which 
could facilitate electrostatic interactions with cells. The extent of hemolytic activity of a 
dendriplex was clearly shown to be influenced by the zeta potential.  
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Figure 5. (A) Hemolysis after incubation with dendriplexes at an N/P of 5 was UV-
metrically quantified and (B) morphologic changes of erythrocytes were microscopically 
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captured. Hemolysis depended strongly on the core structure, whereas erythrocyte 
aggregation increased by generation. 
Cytotoxicity.  
Cell viability or cytotoxicity can routinely be measured by quantification of mitochondrial 
enzyme activity using an MTT assay. In order to mimic the “worst case scenario”, murine 
fibroblasts (L929) were incubated with various concentrations of free dendrimer, ranging 
from 0.001 to 1 mg/ml (Figure 6). The half enzyme-inhibitory concentrations (IC50) were 
determined. While PEI 25 kDa exhibited the strongest toxic effects for the panel 
investigated, there was a clear trend between cytotoxicity and generation number for the 
rigid triazine dendrimers. For G1-1, we determined an IC50 value of 501.2 µg/ml, which is 
about 100 fold higher than the IC50 value of PEI 25 kDa (4.9 µg/ml, compare Figure 6). The 
IC50 values decreased with increased generation among the rigid dendrimers, which can be 
explained by the increasing number of peripheral primary amino groups. Nontheless, G3-1, 
the dendrimer that contains the highest number of primary amines per molecule, was 
approximately 5 fold less toxic than PEI 25 kDa and showed a 2.5 fold lower IC50 value 
than the third generation PAMAM (35). The F2-1 dendrimer showed a higher toxicity 
profile than G2-1, which can be explained as resulting from an increased accessibility of 
both the core and the terminal amine groups, although the hemolytic activity which we 
measured for F2-1/DNA complexes was comparably low. The effect on remaining cell 
viability, on the other hand, which is expressed in the IC50 values, can have various reasons. 
Highly surface active substances are expected to strongly impede the phospholipids double 
layer, leading to decreased cell viability and cell death. But substances that do not exhibit 
strong membrane toxicity can still alter cellular mechanisms, leading to decreased cell 
viability. It is therefore not surprising that F2-1, which shows comparably low hemolysis, is 
more toxic than G2-1 and B2-1, which have higher hemolytic potentials.  
 The bow-tie dendrimer B2-1, on the other hand, exhibited lower toxicity than the rigid 
dendrimer G2-1, despite causing comparable hemolytic effects. For all of the triazine 
dendrimers, our cytotoxicity results are in line with an earlier report (13) revealing an IC50 
value of 0.1 mg/ml for a related melamine structure. Triazine dendrimers seem to be less 
toxic than PEI and therefore more suitable for possible in vivo studies. Moreover, 
cytotoxicity strongly depends on the core structure and can be significantly reduced by 
dendriplex formation. 
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Figure 6. Toxicity profiles of all the dendrimers according to the MTT assays were 
compared to that of PEI 25 kDa, and for clarity IC50 values are given. 
Transfection Efficiency.  
The primary interest for non-viral vectors is the efficiency of transfection. This property 
was studied using a luciferase-expressing plasmid in two different cell lines, namely murine 
L929 fibroblasts (Figure 7A) and human MeWo (Figure 7B) melanoma cells. The 
transfection efficiency of dendriplexes at different N/P ratios was quantified using a 
commercial luciferase assay and was compared to the transfection efficiencies of PEI 25 
kDa, SuperFect™, and second and third generation PAMAM.  
PAMAM (2nd and 3rd generation) dendrimers showed little transfection efficiency with 
increasing N/P ratios, as reported in the literature (5). An increase in transfection efficiency 
with increasing generation was revealed for rigid triazine dendrimers (G1-1, G2-1, and G3-
1). The lowest generation dendrimer, G1-1, did not induce transgene expression in L929 or 
MeWo cells, while G2-1 successfully transfected MeWo and L929 at N/P ratio > 7.5.  
Interestingly, G3-1 yielded a maximum luciferase expression at N/P 5 in both cell lines.  
The reduced transfection efficiency at a higher N/P ratio for the higher generation 
dendrimer may be caused by cytotoxic effects. In both cell lines, F2-1 achieved the highest 
transgene expression, even higher than the expression of PEI 25 or SuperFect. The bow-tie 
dendrimer, B2-1, exhibited moderate transfection efficiency at N/P ratio of 5 in L929 and at 
N/P 5 and 7.5 in MeWo cells. 
These results demonstrate that triazine dendrimers could provide a promising platform for 
gene delivery systems as they induce transfection at generation two, while established 
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transfection reagents such as PAMAM are ineffective at that size. Similarly, the 
phosphorous containing dendrimers of Majoral show a transfection optimum at generation 
5 (36). Higher generation, flexible triazine dendrimers are therefore under investigation 
with the goal of providing more efficient transfection reagents.  
Because the flexible dendrimer, F2-1, formed larger complexes than the third generation 
dendrimer, G3-1, it presumably sedimented faster (24). This could have contributed to the 
higher transfection efficiency seen for this dendriplex. However, this route of endocytosis 
may not prove viable for in vivo applications. But also a higher availability to RNA 
polymerase inside the nucleus of DNA in these less compact dendriplexes, as reported by 
Yamagata et al. (37), might be an explanation. Hence the colloidal stability and the 
systematic variation of the triazine dendrimer surface are further goals for synthetic 
modifications.  
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Transfection efficiency in fibroblasts and melanoma
cells
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Figure 7. Transfection efficiency of the dendrimers at various N/P ratios in (A) L929 and 
(B) MeWo cells are given as relative light units detected by luciferase assay. F2-1 and 
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Superfect exhibited significantly (***p < 0.01) higher transgene expression than PEI 25 
kDa and all other dendrimers. 
 
Generation-1 
rigid 
Generation-2 
rigid 
Generation-3 
rigid 
Generation-2 
flexible 
Generation-2 
bow-tie 
Primary amines 6 12 24 12 16 
Amine density 
[Da/N atom] 211.27 245.30 262.20 262.32 262.20 
DNA 
condensation at 
plateau [%] 48.0 30.2 4.2 36.4 5.9 
Size [nm] 338.3 154.8 230.2 426.3 882.0 
Zeta potential 
[mV] -0.05 22.6 17.7 -7.5 3.1 
Hemolysis [%] 12.6 10.9 12.9 6.11 13.0 
Toxicity (IC50) 
[µg/ml] 501.2 64.3 20.1 22.8 115.3 
Transfection 
efficiency (N/P 
5, MeWo) 
[RLU/s] 2480.0 4948.3 7087.3 44184.0 4487.0 
Table 1.  Summary of properties of the screened dendrimers concerning in vitro parameters 
4.5 Conclusion 
Efforts to optimize the triazine dendrimers will require consideration of a number of lessons 
learned from these studies.  The first generation rigid dendrimer, G1-1, yielded very low 
condensation efficiency, and although the structure had a good biocompatibility profile it 
did not show any transfection efficiency. The second generation rigid dendrimer G2-1 
showed improved DNA condensation, formed small dendriplexes, and was less toxic but 
more hemolytic than PEI.   However, it showed intermediate transfection efficiency. The 
G3-1 dendrimer condensed DNA well, formed small particles within a narrow size 
distribution, but exhibited erythrocyte aggregation. Transfection efficiency of this 
dendrimer was possibly limited by toxic effects at higher N/P ratios.  
The change in core structure had the most profound impact on physicochemical as 
well as biologic properties of the triazine dendrimers. While the rigid, second generation 
dendrimer, G2-1, formed comparably small dendriplexes, both B2-1 and F2-1 assembled 
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DNA into larger complexes with lower or even negative surface charge. DNA condensation 
was affected differently: DNA condensation with F2-1 and G2-1 were similar, whereas B2-
1 protected DNA even better than PEI 25 kDa. The flexible dendrimer F2-1 was most 
effective in transfection experiments. The low density particles exhibited the lowest 
hemolytic effect and almost no erythrocyte aggregation. 
The bow-tie dendrimer, B2-1, caused the most pronounced hemolytic effects which are 
attributed to the formation of aggregates and clusters as observed with DLS and AFM. Due 
to their large size, B2-1 dendriplexes were not effectively taken up by L929 or MeWo cells, 
leading to low transfection efficiency. We remain optimistic that triazine dendrimers 
demonstrate a promising platform for non-viral delivery systems, meriting further 
investigations, while our most important result is that flexible triazine dendrimers that are 
well biocompatible may be highly efficient vectors for non-viral gene delivery at 
comparably low generations. This is especially true for the flexible dendrimer F2-1, which 
exhibits higher transfection efficacy than SuperFect. 
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5.1 Abstract 
Single Photon Emission Computed Tomography (SPECT) imaging provides a three-
dimensional method for exactly locating gamma emitters in a non-invasive procedure under 
in vivo conditions. For characterization of siRNA delivery systems, molecular imaging 
techniques are extremely helpful to follow biodistribution under in experimental animal 
studies. Quantification of biodistribution of siRNA and non-viral delivery systems using 
this technique requires efficient methods to stably label siRNA with a gamma emitter (e.g. 
111In or 99mTc) and to purify labeled material from excesses of radio label or linkers. In the 
following study, we have optimized labeling and purification of siRNA which was then 
applied as free siRNA or after complexation with polyethylenimine (PEI) 25 kDa for in 
vivo real-time gamma camera and SPECT imaging. Quantification of scintillation counts in 
regions of interest (ROIs) was compared to conventional scintillation counting of dissected 
organs, and the data acquired by imaging was shown to corroborate that of scintillation 
counting. This optimization and proof of principle study demonstrates that biodistribution 
and pharmacokinetics of siRNA and the corresponding polyplexes can be determined using 
SPECT leading to comparable results as conventional methodology. 
5.2 Introduction 
Single Photon Emission Computed Tomography (SPECT) imaging is an attractive method 
which allows three-dimensional localization of gamma emitters such as 111In (Eγ=171 and 
245 keV) or 99mTc (Eγ=140 keV) using a non-invasive procedure under in vivo conditions. 
Such techniques would be extremely helpful for assessing siRNA and their corresponding 
non-viral delivery systems with regard to biodistribution and targeting. 
SPECT, compared to Positron Emission Tomography (PET), is less elaborate and 
expensive and shows additionally a higher resolution in small animals. The disadvantage of 
SPECT and PET providing only functional but no morphological information can be 
alleviated by either combining SPECT or PET and Computed Axial Tomography (CT), 
magnetic resonance imaging (MRI) or anatomical landmarking. For the latter, bones are 
visualized using radioactively 99mTc labeled bisphosphonates. Dual-isotope SPECT 
recordings can then be recorded in separate channels for each energy window and 
superimposed to generate 3D images. This dual-isotope SPECT method has not been 
utilized to investigate siRNA delivery systems so far. Although it doesn’t provide the same 
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information as SPECT/CT or SPECT/MRI, it, of course, gives a better insight than single-
isotope SPECT. 
The field of siRNA delivery has rapidly evolved in recent years, however, only few in vivo 
studies combining siRNA delivery with non-invasive molecular imaging techniques such as 
SPECT or PET appeared in the literature (1, 2). Several groups have labeled siRNA with 
32P (3, 4) which is a beta emitter and can only be determined using scintillation counting or 
autoradiography in an endpoint study but not in in vivo imaging. Phosphodiester and 
phosphorothioate siRNA has been reported to be labeled with 123I and 125I (5), but 
radiometal labeling is usually preferred over radiohalogen labeling because of stability 
reasons (6, 7). In an earlier report, siRNA had been labeled with 111In, but biodistribution 
was only quantified invasively (8). A recent PET/bioluminescence study (2) using DOTA 
chelated 64Cu was the first report of assessing siRNA delivery by PET imaging. An earlier 
study (9) quantitated distribution of  99mTc labeled single strands using a gamma camera, 
but unfortunately allowed only for an estimation of biodistribution of duplexes. SPECT, 
compared to PET, provides better spatial resolution in small animals and doesn’t require 
synthesis of short live and high energy emitters. Additionally, using high resolution SPECT 
imaging based on multi pinhole collimation, which is a prototype of the latest small animal 
scanners, allowed us to use a clinical camera (10). 
Quantification of biodistribution of siRNA and their delivery systems using SPECT or two-
dimensional gamma camera imaging, requires efficient methods for stably labeling siRNA 
with a gamma emitting isotope as well as fast and efficient purification of labeled materials 
from excesses of radiolabel or linkers.  
The fate of pDNA after intravenous application of different non-viral vectors, such as poly 
ethylenimine (PEI) or PEGylated PEI (PEG-PEI), has been reported previously (11, 12), 
but it cannot be assumed that siRNA polyplexes would perform identically under in vivo 
conditions. In fact, several studies demonstrated differences between siRNA and DNA 
containing polyplexes (13, 14). Hence, dual isotope SPECT would be of interest for in vivo 
live imaging the biodistribution of siRNA polyplexes. As 111Indium can be complexed with 
chelators such as p-SCN-Bn-DTPA, we have developed an optimized a method (8) for 
covalently labeling amine-modified siRNA and applied this labeled siRNA in real time live 
imaging of the distribution of our previously in vitro investigated PEI/siRNA polyplexes 
(15).  
Chapter 5 
 
128 
5.3 Materials and Methods 
Materials: 
Amine-modified luciferase GL3 siRNA with a C6-NH2 linker at each 3’ of the double 
strand was purchased from Dharmacon (Lafayette, CO, USA). 2-(4-isothiocyanatobenzyl)-
diethylenetriaminepentaacetic acid (p-SCN-Bn-DTPA) was purchased from Macrocyclics 
(Dallas, TX, USA), Arsenazo(III), Yttrium(III) chloride and Diethyl pyrocarbonate (DEPC) 
from Sigma-Aldrich Laborchemikalien GmbH (Seelze, Germany). The purification 
columns miRACLE were purchased from Stratagene (La Jolla, CA, USA), RNeasy Mini 
from Qiagen (Hilden, Germany), and PD-10 from Amersham Pharmacia Biotech (Freiburg, 
Germany). The radioactive substances 111InCl3 and 99mTc-alendronate were purchased from 
Covidien Deutschland GmbH (Neustadt a.d. Donau, Germany), and balb/c mice from 
Charles River WIGA (Sulzfeld, Germany).  
Polyethylenimine, PEI 25 kDa (Polymin ™, 25 kDa) was a gift from BASF (Ludwigshafen, 
Germany), all other chemicals used were of analytical grade. All buffers were treated with 
0.1 % Diethyl pyrocarbonate (DEPC).  
 
Methods: 
p-SCN-Bn-DTPA-coupling: 
Amine-modified luciferase GL3 siRNA was dissolved in siRNA buffer provided by the 
manufacturer. Coupling of p-SCN-Bn-DTPA was accomplished by a previously described 
method (8). Briefly, 20 nmol siRNA in 10 µl siRNA buffer, adjusted to pH 8.5 with an 
equal volume of 0.2 M NaHCO3, was mixed with a 50 fold excess of the chelator dissolved 
in 36 µl DMSO. In our experiments, we used the amine reactive variant of DTPA (p-SCN-
Bn-DTPA) instead of DTPA-dianhydride (cDTPA). Incubation times were varied from 45 
minutes as reported to 3 hours. The coupling degree was determined after purification by 
quantification of DTPA in a non-radioactive assay described by Pippin et al.(16). Briefly, 
absorption of a complex of Arsenazo(III) and Yttrium(III) at 652 nm is measured, and 
sample DTPA content can be calculated or a calibration curve can be recorded due to 
decreasing absorption of the complex falling apart after addition of DTPA. 
 
PD-10 size exclusion chromatography (SEC): 
One method used for separation of labeled siRNA from p-SCN-Bn-DTPA or radiolabel was 
size exclusion chromatography SEC employing a PD-10 Sephadex G25 prepacked column. 
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The column was equilibrated with 50 ml DEPC-treated PBS before the reaction mixture 
was applied to the column. Fractions of 13 droplets each were collected. RNA content was 
measured UV-metrically at 260 nm using a Pharmacia Ultrospec 2000 UV/VIS, Pharmacia 
Biotech (Freiburg, Germany), and radioactive signal in 10 µl of each fraction was 
determined using a Gamma Counter Packard 5005 (Packard Instruments, Meriden, CT, 
USA). 
 
miRACLE and RNeasy purification: 
Spin column purification was conducted as described for the miRACLE columns. Briefly, 1 
or 100 µg siRNA for miRACLE or RNeasy columns, respectively, were diluted to 600 µl 
with 2 M sodium acetate, ethanol and guanidinium salts containing “Binding Buffer” 
provided in the miRACLE kit and applied to a spin column. Columns were centrifuged for 
2 minutes at 16,000 g, and washed 3 times with 600 µl “Low Salt Wash Buffer” by 
centrifugation for 1 minute at 16,000 g. The membranes were dried by a fifth centrifugation 
step without applying any solution. RNA was then eluted by incubating the membrane with 
50 µl 60 °C warm DEPC-treated RNase free water for 2 minutes and following 
centrifugation for 1 minute at 16,000 g. This step was repeated and followed by a third 
incubation where 25 µl DEPC-treated 0.5 M sodium acetate, pH 4.5, were applied instead 
of water to achieve a final concentration of 0.1 M sodium acetate in the siRNA solution. 
 
Radio labeling: 
Radio labeling of the p-SCN-Bn-DTPA-coupled siRNA was accomplished in 0.1 M sodium 
acetate buffer, pH 4.5. For the validation of the method, small amounts of 10 nmol siRNA 
were incubated with 16.2 MBq InCl3 for 30 minutes at room temperature. For in vivo 
experiments, 111 nmol siRNA were incubated with 28.9 MBq InCl3 for 30 minutes at room 
temperature, followed by either PD-10 SEC or spin column binding, washing and elution or 
a combination of both methods. For in vivo experiments, siRNA was purified using a PD-
10 column first. Fractions 5-9 (compare figures 4A and 4B), which showed both a high 
radioactive signal and the strongest UV absorption at 260 nm and don’t contain any free p-
SCN-Bn-DTPA or Indium, were combined and further purified as well as concentrated 
using RNeasy columns as described above. 
 
Animal studies: 
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All animal experiments were carried out according to the German law of protection of 
animal life and approved by an external review committee for laboratory animal care. 
For in vivo experiments in 4 weeks old balb/c mice (~ 20 g), 35 µg Bn-DTPA coupled 
thiourea derivative of siRNA, corresponding to 2.57 nmol and 0.255 MBq, were either 
administered as free siRNA or after complexation at an N/P of 6 with 25 kDa branched PEI. 
Free siRNA or complexes were injected i.v. to the tail vein and biodistribution was 
followed by perfusion live imaging and static imaging acquired with a Siemens e.cam 
gamma camera (Siemens AG, Erlangen, Germany). Biodistribution 2 hours post injection 
was investigated by high-resolution SPECT imaging using a custom built multiplexing 
multipinhole collimator, mounted on the Siemens e.cam gamma camera, quantified by 
analysis of regions of interest (ROIs) in the planar gamma camera images and was 
eventually compared to conventional gamma counting of dissected organs. 
For anatomical landmarking in the SPECT images, mice were additionally injected with 4 
MBq 99mTc-labeled phosphonate 4 hours before imaging.  
 
Statistics: 
Analytical measurements were conducted in triplicates. Animal experiments include 5 
animals per group; results are given as mean values. Two way ANOVA and statistical 
evaluation was accomplished using GraphPad Prism 4.03 (GraphPad Software, LaJolla, 
USA). 
5.4 Results and Discussion 
While labeling of amine modified siRNA with p-SCN-Bn-DTPA was accomplished 
different from the method previously reported (8), and could not be improved by variation 
of incubation time, purification of the reaction mixture, on the other hand, was extensively 
optimized. For coupling the amine modified siRNA, we preferred the use of p-SCN-Bn-
DTPA over cyclic DTPA anhydride (cDTPA) (8) since in the coupling reaction with the 
latter one of the chelating teeth is used for amide formation in a ring opening reaction. The 
advantage of formation of a thiourea derivative in a standard reaction of amines and the 
benzyl-isothiocyanate modified DTPA is the fact that each chelating tooth is available for 
complex formation after DTPA is unaffected by the reaction of the benzyl spaced 
isothiocyanate, which is shown in Figure 1.  
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Figure 1: Reaction of amine-modified siRNA and p-SCN-Bn-DTPA in formation of a 
thiourea derivative. Both strands bear a C6-NH2 linker, but a coupling degree of 2 mol/mol 
could not be achieved. 
In search of a faster purification method than extensive dialysis which would yield in a 
higher percentage of siRNA recovery and protect the siRNA from degradation, a method 
was employed which is known from RNA isolation from cells or tissues. First of all, spin 
columns specifically developed for miRNA isolation (miRACLE, Stratagene) were used to 
validate the method and to quantify the yield. The basic principle of this purification or 
isolation method is the binding of RNA in presence of chaotropic salts to the silica 
membrane of the spin columns. Additionally, RNA is made insoluble by a high 
concentration of ethanol of at least 70 % v/v in the presence of 10 % v/v 2 M sodium 
acetate buffer, and therefore can be washed extensively but fast with low salt buffers 
containing 70 % v/v ethanol. Finally, the RNA is eluted with water or TE buffer. Due to the 
chelating activity of EDTA in TE buffer, which could later complex parts of radioactive 
Indium, all siRNA was eluted with DEPC-treated water.  
The miRACLE spin columns proved to be applicable for siRNA as the yield of eluted 
siRNA was 92.6 ± 6.4 % and the coupling degree determined after purification was 16.9 ± 
2.1 % (compare Figure 2A). Because of their low binding capacity (1 µg RNA per column) 
and bigger reaction feeds needed for in vivo application, the use of RNeasy Mini columns 
(Qiagen) that hold 100 µg of RNA was validated in the next step. Since the buffer 
composition of the binding and washing buffers in the RNeasy kit is proprietary, buffers 
from the miRACLE kit, which were assured to be free of chelators, were used for all spin 
column purifications. The yield of the siRNA recovery could extensively be increased from 
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40 % which had been eluted with 25 °C warm DEPC-water to 79.6 ± 4.1 % after incubating 
the siRNA on the membrane for 2 minutes with 60 °C warm DEPC-water.  
Coupling degree of such purified siRNA was determined to be 32.9 ± 1.8 % as shown in 
Figure 2A.  
 
Figure 2A: Yields and p-SCN-Bn-DTPA coupling degrees analyzed after different methods 
of siRNA purification, 2B: Purification with a PD-10 column didn’t effectively separate 
siRNA from an excess of unreacted p-SCN-Bn-DTPA, RNeasy columns didn’t desalt from 
InCl3, and therefore, a combined purification after annealing was employed. 
For purification after radiolabeling, in the first approach, PD-10 (Amersham) SEC was 
employed as described by Van de Water et al. (8). After analysis of the collected fractions 
for UV-metrically determined siRNA concentration and gamma-counted radioactivity, 
RNA peak fraction and peak fraction of the radioactivity seemed to be shifted, as shown in 
Figure 3A, and the radioactive signal slowly decreased before a second peak appeared. Due 
to the principle of SEC, big particles are eluted first, smaller ones in later fractions. Since 
Chapter 5 
 
133 
the siRNA had only been brought into contact with DEPC-treated buffers upon receipt, we 
precluded degradation. One possible explanation was that siRNA had not been fully 
annealed, and possibly only the single strands had been effectively labeled with p-SCN-Bn-
DTPA. To prove this, radio labeling was repeated a) without annealing and b) with 
annealing of the siRNA strands by heating up to 94 °C for 2 minutes after p-SCN-Bn-
DTPA-labeling, and with c) pre-annealed siRNA. To make sure that the annealed double 
strands would not be separated on the membranes of the spin columns or under harsh 
conditions such as 16,000 g centrifugal force, this reaction mixture was purified on a PD-10 
column. Here, a mathematically calculated coupling degree of theoretically 323 % and 
therefore an excess of at least 123 % of free p-SCN-Bn-DTPA was determined, as shown in 
Figure 2A.  
The same amounts of free Indium (grey circles, Figure 3C) or free p-SCN-Bn-DTPA-
chelated Indium (grey squares, Figure 3C) which had been in the reaction mixtures were 
each applied to a PD-10 column in separate experiments. This allowed us to detect when 
free Indium and when Indium chelated by residual free p-SCN-Bn-DTPA would be eluted 
from the PD-10 column and which peak in the chromatographs represented each of those 
two compounds. Free Indium showed a peak at fraction 17, p-SCN-Bn-DTPA-Indium at 
fraction number 12. The overlay of each Indium signal in Figure 3C allowed to clearly 
identify the second, smaller peak in 3A and 3B to be the free Indium.  
Re-annealing of the pre-coupled siRNA strands finally caused concurrence of the 
radioactivity and the siRNA peak, which is shown in Figure 3B. Without annealing, again a 
shift of both peaks was observed (compare Figure 3A). But still the decrease of the 
radioactivity signal of the re-annealed sample (3B) fell less steep than the RNA signal. In 
the pre-annealed sample (black circles in Figure 3C), that obviously contained a high 
amount of free p-SCN-Bn-DTPA (compare Figure 2A), the Indium peak was even broader 
and didn’t show a free Indium-peak after fraction 15. 
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Figure 3: PD-10 size exclusion chromatographs of purified siRNA. A: RNeasy purified 
siRNA without annealing. Radioactivity and RNA peaks are shifted. B: RNeasy purified 
siRNA after post-annealing. Peaks are concurrent but radioactivity signal decreases slowly. 
C: Overlay of radioactivity signals. p-SCN-Bn-DTPA-Indium appears after fraction 7 and 
is the reason for slow decrease of signal in RNeasy purified siRNA and the broad peak in 
PD-10 purified pre-annealed siRNA (black circles).  Free Indium peaks at fraction 17 and 
is not apparent in PD-10 purified pre-annealed siRNA due to excess of free p-SCN-Bn-
DTPA.  
Since spin column purification after p-SCN-Bn-DTPA coupling had proven to be extremely 
more effective than SEC, it was next employed for purification after radiolabeling of 
another sample of which small aliquots were either applied to a PD-10 column for quality 
control without further treatment (Figure 4A) or after re-annealing (Figure 4B). The 
chromatographs of those two aliquots didn’t show significant differences, but finally the 
peaks of RNA concentration and radioactivity matched both in peak and valley. But as a 
second, smaller peak appeared again after fraction 15, it must be admitted, that the spin 
column purification is highly effective for separation of siRNA (approx. 13.6 kDa) from 
small molecules like p-SCN-Bn-DTPA (650 Da), but cannot fully separate siRNA from 
large excesses of salts like InCl3. The best strategy therefore seemed to be a combination of 
SEC and spin column purification, as another benefit of a following spin column 
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purification is the fact that the peak fractions from SEC can be combined and concentrated 
on the columns, as shown in Figure 2. Annealing of siRNA should be accomplished after p-
SCN-Bn-DTPA coupling to achieve a high coupling degree. 
The final yield after combined purification of 125 nmol siRNA of which 111 nmol siRNA 
were labeled with 28.8 MBq was 81.2 % with a specific activity of 99 MBq/µmol.  
Functionality of the labeled siRNA was investigated in vitro and found not to be 
significantly different from a non-labeled duplex of the same sequence (data not shown). 
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Figure 4: PD-10 size exclusion chromatographs of siRNA that was purified with RNeasy 
spin columns after coupling and after radiolabeling. RNA and radioactivity peaks are 
concurrent in climax and anticlimax but substantial amount of free Indium is left in 
solution. 
In the in vivo experiments, labeled and purified siRNA was either administered as free 
siRNA, as reported earlier (8), or after complexation with 25 kDa branched PEI, which has 
earlier been characterized concerning in vivo biodistribution and pharmacokinetics after 
complexation of pDNA and ODNs (11, 17, 18) and has lately been used for in vivo siRNA 
delivery (19-24). 
In the real-time perfusion study, rapid accumulation of PEI-complexed siRNA in the liver 
and in the kidneys could be observed, as well as an increasing signal in the bladder, as 
shown in Figures 5B, 6B, and Movie 4, supplementary data. Quantification of scintillation 
counts in the ROIs as a function of time, as shown in Figure 6B, reveal that the half life of 
PEI-complexed siRNA in the blood pool (triangles, Figure 6B and 6C) is only 168.5 
seconds, which is in good agreement with published data (25). The signal in liver and 
kidneys decreases to a plateau after initial accumulation (circles, Figure 6B) and the signal 
of residual radioactive material in the injection site (diamonds, Figure 6B) decreases as well 
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to a certain extent. Free siRNA, on the other hand, showed initial uptake into liver and 
kidneys, as shown in Figure 6A (circles), but no accumulation. Our real time perfusion 
recording shows very rapid excretion into the bladder (Figure 5A and Movie 1), which is 
visualized and quantified in Figure 6A. While activity in the liver and kidneys decreases 
(Figure 6A, circles), it increases to the same extent in the bladder (Figure 6A, squares).     
 
Figure 5: Planar gamma camera perfusion movie with regions of interest for lifetime 
quantification after injection of 35 µg siRNA, corresponding to 2.57 nmol and 0.255 MBq 
111In, A: as free siRNA and B: complexed at N/P of 6 with 25 kDa bPEI. 
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Figure 6: Normalized graphical analysis of activity in regions of interest in Figures 5A and 
5B. 6A: PEI-complexed siRNA, 6B: Free siRNA, 6C: Pharmacokinetic analysis of siRNA in 
circulation. 
SPECT images recorded 2 hours post injection corroborated the observation of 
accumulation of PEI complexed siRNA in liver, kidneys and bladder by providing more 
tree-dimensional, regional information (compare Figure 7B and Movie 2), and gamma 
scintillation counting of dissected organs confirmed that PEI 25 kDa-complexed siRNA 
accumulated in the liver and was renally excreted as it was found to be in the urine and not 
in the bladder tissue (compare Figure 8A). Confirmation of non-invasive data by invasive 
data which has been reported in drug delivery (26) and gene therapy (27) studies was the 
critical part of this investigation and was successfully achieved. 
Free siRNA could be measured in the kidneys, as earlier reported (8), partly in the liver but 
was also eliminated through the bowel. Due to their instability in serum, free siRNA 
duplexes are rapidly degraded upon injection. Therefore, small fragments bearing the label 
supposedly circulate in the blood pool and show a different behavior than macromolecules 
or nanoplexes.  
Fast renal clearance and a high signal in the urine in biodistribution studies with PEI/pDNA 
polyplexes had so far been interpreted as degraded plasmid being excreted (28). In our 
study, on the other hand, we found higher signals in the urine for PEI-complexed siRNA 
compared to free siRNA, 2 hours after injection. One reason could be that the free siRNA 
had been excreted to the bladder faster than PEI complexed siRNA and got lost by urination 
Chapter 5 
 
139 
before the the animals were sacrificed. But the signal in the urine can not only be caused by 
degradation products, knowing that renal clearance might even be faster than siRNA 
degradation (25). In fact, free siRNA, which for sure had partly been degraded after 
injection, showed a different profile from complexed siRNA. In the case of free siRNA, no 
distinct deposition in any certain organ could be observed (Figure 8A), and the percentage 
of injected dose which was still in circulation after 2 hours was 9 % per ml blood compared 
to 1 % for PEI25-complexed siRNA (Figure 8). Half life of free siRNA was 692.8 seconds 
(compare Figures 6A and 6C). SPECT images of mice treated with free siRNA (Figure 7A) 
showed no distinct depostition in any organ either, except for the bladder. One explanation 
for this could be long circulation and almost no deposition of small fragments of degraded 
siRNA or a binding of amine-modified siRNA to blood components. It is known that 
siRNA is degraded rapidly in vivo by serum nucleases and that this can be prevented or 
retarded by chemical modification of the nucleotides or by complexation with an 
appropriate delivery system (29-31). In our earlier publication, we showed that bPEI 25 
kDa as well as PEGylated derivatives do have the potential to protect siRNA from RNase 
degradation (15). As formulation with the polymer seemed to drive kinetics and 
distribution, PEI-complexed siRNA showed a clear accumulation in the liver of 15 % 
injected dose per organ (Figure 8A), although not as prominent as observed with pDNA, 
which had been reported to be up to 40 % (11). Accumulation in the spleen could not be 
observed either, although more labeled polymer (2.9 %, data not shown) than labeled 
siRNA (0.9 %, Figure 8A) was found to be taken up – possibly by macrophages. This again 
supports the assumption by Merdan et al (11) of polyplexes at least partly falling apart into 
free polymer, which is then especially taken up by the liver and spleen, and into siRNA, 
which is excreted or degraded upon release from the complex.  
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Figure 7: SPECT image of 4 weeks old male balb/c mouse injected with 35 µg siRNA, 
corresponding to 2.57 nmol and 0.255 MBq 111In (purple, blue and orange), and 8 MBq 
99mTc-labeled phosphonate (greyscale) for anatomical landmarking. A: free siRNA, B: 
complexes at N/P 6 with 25 kDa bPEI. 
A primary deposition in the lungs and secondary redistribution, which had been assumed 
for PEI/pDNA complexes earlier (11, 32), could not be observed in our perfusion studies. 
Neither did we observe acute or lethal toxicity which had been described by several groups 
investigating biodistribution and kinetics of PEI/pDNA polyplexes (33). The fact that we 
did not observe any lethality or lung accumulation is in good agreement with former reports 
that explained death of laboratory animals after embolism to be caused by entrapment of 
aggregates of polyplexes and blood components in the lung capillaries (34). 
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The disadvantage of imaging techniques not differentiating between free label, degraded or 
intact labeled compound can only be overcome by verification using autoradiography or 
after specific siRNA isolation and purification of intact 21mers and photometric 
quantification. 
This aspect also stresses the importance of efficient purification after the labeling process. 
A shortcoming of the imaging compared to gamma scintillation of dissected organs is the 
fact that planar pictures don’t allow for differentiation between organs in the same plane of 
projection, such as liver and kidneys or urine and bladder (Figure 8). Regions of interest 
always express the total scintillation counts of all organs in the plane of projection and 
organs, that don’t show significant uptake, can hardly be analyzed. In our study, only the 
liver, kidneys, urine and bladder showed strong signals and could easily be detected in 
planar images, but the significant difference in uptake to the liver of free siRNA and 
PEI/siRNA polyplexes could only be shown after dissection of organs (Figure 8A).  
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Figure 8A: Scintillation analysis of regions of interest 2 hours after injection. 8B: 
Scintillation analysis of dissected organs 2 hours after injection expressed as % injected 
dose per organ. 
5.5 Conclusion 
In summary, we developed an optimized and simple method for coupling p-SCN-Bn-DTPA 
to siRNA and purification of those radiolabeled siRNA complexes with high yields of these 
expensive materials. Once the siRNA bears the radioactive label, it can be applied in non-
invasive perfusion, kinetics and biodistribution studies which corroborate the results from 
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end point scintillation counting methods but offer the advantage of live imaging and 
examination at various time points in the same animal, reducing the number of animals 
needed compared to conventional techniques. Dual isotope SPECT and gamma camera 
imaging are very useful methods to follow biodistribution of polyplexes especially with 
respect to the kinetic of distribution. For determination of exact scintillation counts in every 
single organ, the latter have to be dissected. But imaging clearly is able to assess siRNA 
delivery, biodistribution and even pharmacokinetics, if a ROI is placed in the blood pool, 
without sacrificing animals. This proof of principle allows us to investigate distribution and 
kinetics of a variety of our vectors by multiple methods, including double labeling of vector 
and load, in the future. 
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6.1 Abstract 
In search of optimizing siRNA delivery systems for systemic application, one critical 
parameter remains their stability in blood circulation. In this study, we have traced 
pharmacokinetics and biodistribution of each component of siRNA polyplexes formed with 
polyethylenimine 25 kDa (PEI) or PEGylated PEIs by in vivo real-time gamma camera 
recording, SPECT imaging, and scintillation counting of blood samples and dissected 
organs. In vivo behavior of siRNA and polymers were compared and interpreted in the 
context of in vivo stability of the polyplexes which had been measured by fluorescence 
fluctuation spectroscopy (FFS). Both pharmacokinetics and biodistribution of polymer-
complexed siRNA were dominated by the polymer. PEGylated polymers and their siRNA 
polyplexes showed significantly less uptake into liver (13.6-19.7 % ID of PEGylated 
polymer and 9.5-10.2 % ID of siRNA) and spleen compared to PEI 25 kDa (liver 
deposition: 36.2 % ID of polymer and 14.6 % ID of siRNA). With non-invasive imaging 
methods we were able to predict both kinetics and deposition in living animals allowing the 
investigation of organ distribution in real time and at different time points. FFS 
measurements proved stability of the applied polyplexes under in vivo conditions which 
explained the different behavior of complexed from free siRNA. Despite their stability in 
circulation, we observed that polyplexes dissociated upon liver passage. Therefore, 
siRNA/(PEG-)PEI delivery systems are not suitable for systemic administration, but only if 
the first-pass effect can be circumvented, which is the case in local application.  
 
6.2 Introduction 
Systemic delivery of siRNA remains a challenging objective. Uncomplexed siRNA which 
is not chemically stabilized by modification of backbone or sugars will be fast degraded 
under in vivo conditions by serum nucleases (1-5). Therefore, appropriate formulations of 
siRNA are a prerequisite for systemic application, and biocompatible vectors that are stable 
in circulation and release their payload after endocytosis are required. A new method which 
allows quantification of integrity of siRNA/carrier systems under serum concentration 
comparable to in vivo conditions, Fluorescence Fluctuation Spectroscopy (FFS), has lately 
been described (6) and allows the measurement of polyplex integrity in serum-containing 
fluids as well as prediction of in vivo stability. As earlier described, FFS uses ultra-sensitive 
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avalanche photodiode detectors to monitor fluorescence intensity fluctuations caused by the 
diffusion of fluorescently labeled molecules throughout the excitation volume of a 
microscope (6).  
As we reported earlier, Single Photon Emission Computed Tomography (SPECT) and 
planar imaging offers the possibility of assessing real-time pharmacokinetics and 
biodistribution in living animals (7). Radionuclide imaging with PET and SPECT, 
especially, combine the advantages of high sensitivity and good three-dimesional (3D) 
imaging (8). Pharmacokinetic parameters have, to our knowledge, only been reported for 
siRNA (9, 10), but not for their vectors. Other reports describing biodistribution of siRNA 
only mentioned fast renal clearance (11, 12) or effect on pharmacokinetics by formulation 
with cationic carriers (13), but in none of these, pharmacokinetic parameters, such as 
elimination half-lives, area under the curve (AUC) or clearance were determined.  
Soutschek et al. were the first to compare elimination half-lives and clearance of free and 
cholesterol-conjugated siRNA (10). Free siRNA was rapidly excreted through the kidneys 
with a half-life of 6 minutes, whereas the conjugate was shown to bind albumin and 
circulated much longer, exhibiting an elimination half-life of 95 minutes.  
Our group previously described the fate of pDNA/(PEG-)PEI polyplexes after intravenous 
application of different non-viral vectors. But siRNA displayed different complexation 
behavior and siRNA complexes showed differences in physico-biological parameters 
compared to pDNA complexes (14-16). Therefore, monitoring pharmacokinetics and 
biodistribution of siRNA complexes by real-time gamma camera imaging, 3D localization 
using SPECT and scintillation counting of blood and organ samples were thought to give a 
more detailed insight into the biological performance and distribution of siRNA polyplexes 
after intravenous (i.v.) application in mice. In our earlier study, we were able to show that 
PEI 25 kDa as well as its PEGylated derivatives efficiently complex siRNA and offer 
protection against RNase degradation in vitro (17). But instability of pDNA/PEI complexes 
in vivo has been assumed in several reports (18-21). A double labeling approach of pDNA 
polyplexes showed differences in kinetics and deposition of load and vector and led to the 
conclusions that polyplexes dissociate after i.v. injection (20). Stability of siRNA/PEI 
complexes has, to our knowledge, not yet been quantified under in vivo conditions. As 
previously reported, we have already investigated stability of siRNA/(PEG-)PEI polyplexes 
in a competition assay with the polyanion heparin under in vitro conditions (17). But to 
determine in vivo stability, which would allow for predicting their behavior after i.v. 
injection, we made now use of fluorescence fluctuation spectroscopy (FFS). Combining this 
Chapter 6 
 
151 
method and determination of pharmacokinetic parameters and biodistribution of both vector 
and load permitted to finally quantify in vivo stability of siRNA/(PEG-)PEI delivery 
systems. 
Additionally, PEGylation of cationic polymers has been reported to increase colloidal 
stability of the polyplexes and to reduce non-specific interaction with blood components 
(22), which in turn results in decreased uptake by the reticuloendothelial system (RES) and 
significant prolongation of circulation time of the PEGylated polyplexes (23). On the other 
hand, PEGylated polyplexes were reported to be less stable in blood, concerning integrity of 
the pDNA/PEG-PEI system (20, 24). This was explained by steric hindrance of polyplex 
formation due to PEG chains in the core of the polyplexes, a decreased number of primary 
amines and thermodynamic destabilization (20, 25). Yet, three other groups demonstrated  
significant prolongation of pDNA blood levels using PEGylated cationic polymers for 
packaging of the plasmid (23, 26, 27).  
Another assumption which so far has not been investigated for siRNA/PEG-PEI polyplexes 
is the observation of a primary deposition of pDNA complexes in the lungs and a secondary 
redistribution (20, 28). Ishikawa et al. showed quantitative accumulation of pDNA-bearing 
positively charged liposomes in the lungs, which decreased from 90 % ID to 20 % ID over 
120 minutes (28). In order to investigate if positively charged siRNA-bearing polyplexes 
would exhibit the same behavior, we employed planar gamma camera imaging and 3D 
SPECT imaging which allow for in vivo real-time and 3D-recording of pharmacokinetics 
and biodistribution, respectively (7).  
6.3 Materials and Methods 
Materials: 
Amine-modified luciferase GL3 siRNA with a C6-NH2 linker at each 3’ of the double 
strand as well as the unaltered GL3 duplex and a non-specific siCONTROL duplex number 
IX was purchased from Dharmacon, Lafayette, CO, USA. Fluorescently labeled GL3 
siRNA with Alexa488 (λex = 495 nm, λem = 519 nm) at the 5’ end of the sense strand was 
purchased form Eurogentec (Seraing, Belgium). 2-(4-isothiocyanatobenzyl)-
diethylenetriaminepentaacetic acid (p-SCN-Bn-DTPA) was purchased from Macrocyclics 
(Dallas, TX, USA), Arsenazo(III), Yttrium(III) chloride, 2,4,6-Trinitrobenzenesulfonic 
Acid (TNBS), and Diethyl- pyrocarbonate (DEPC) from Sigma-Aldrich Laborchemikalien 
GmbH (Seelze, Germany). The miRACLE purification columns were purchased from 
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Stratagene (La Jolla, CA, USA), RNeasy Mini from Qiagen (Hilden, Germany), centricon 
YM-10 from Millipore (Millipore, Schwalbach, Germany), Vivaspin 2 MWCO 30 kDa 
from Sartorius Stedim Biotech GmbH (Göttingen, Germany), and PD-10 from Amersham 
Pharmacia Biotech (Freiburg, Germany). The radioactive substance 111InCl3 was purchased 
from Covidien Deutschland GmbH (Neustadt a.d. Donau, Germany), and balb/c mice from 
Charles River WIGA (Sulzfeld, Germany). OptiMEM was purchased from Invitrogen 
(Merelbeke, Belgium), DMEM from PAA Laboratories (Cölbe, Germany), and fetal bovine 
serum (FBS) from Cytogen (Sinn, Germany). Polyethylenimine, PEI 25 kDa (Polymin ™, 
25 kDa) was a gift from BASF (Ludwigshafen, Germany), polyethylene glycol grafted PEIs 
(PEG-PEIs) were synthesized as described previously (22), all other chemicals used were of 
analytical grade. All buffers used for siRNA-coupling were treated with 0.1 % DEPC.  
 
Methods: 
DTPA-coupling: 
Amine-modified luciferase GL3 siRNA was coupled with p-SCN-Bn-DTPA as previously 
described (7, 29). Briefly, siRNA in siRNA buffer, adjusted to pH 8.5 with 0.2 M NaHCO3, 
was mixed with a 50 fold excess of p-SCN-Bn-DTPA dissolved in DMSO. The reaction 
mixture was incubated under constant shaking for 1 hour at room temperature, before 0.1 M 
citrate buffer, pH 5.0, were added to stop the reaction.  
For DTPA-coupling of polymer, 5 mg PEI or 10.9 mg PEG-PEI (equivalent to 5 mg PEI) 
were dissolved in 250 µl water and adjusted to pH 8.5 with 0.2 M NaHCO3 buffer. In order 
to achieve a DTPA coupling degree which would yield an amount of chelator per N/P 6 
polyplex comparable to the amount obtained with the labeled siRNA, 2.9 µmol of the 
amines in 5 mg should be modified with DTPA. Therefore, 0.5 mg of p-SCN-Bn-DTPA in 
29 µl DMSO were added to the polymer solution and reacted for one hour at room 
temperature. This reaction as well was stopped by addition of 0.1 M citrate buffer, pH 5.0, 
before the reaction mixture was purified by ultrafiltration using centricon YM-10 spin 
columns (Millipore, Schwalbach, Germany) as described below. 
 
RNeasy spin column purification: 
The DTPA-siRNA conjugate was purified from the excess of p-SCN-Bn-DTPA by using 
RNeasy columns. First of all, an ethanol precipitation was used to remove DMSO, which 
might interfere with the spin columns. This was accomplished by adding 737,5 µl 2 M 
sodium acetate buffer, pH 4.0, and 5.2 ml ethanol, which yielded in a total percentage of 70 
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% ethanol. The mixture was stored at -80 °C for 2 hours before it was centrifuged at 13,000 
g for 15 minutes. The supernatant was discarded and the pelleted siRNA was resolved in 
2.0 ml guanidinium salts containing “Binding Buffer” provided in the miRACLE kit, a kit 
especially designed for miRNA isolation. Purification was accomplished as previously 
described using RNeasy Mini spin columns (7). The coupling degree was determined after 
purification by quantification of DTPA in a non-radioactive UV-metric assay described by 
Pippin et al. (30).  
 
Ultrafiltration: 
Purification of polymers from non reacted p-SCN-Bn-DTPA was performed by 
ultrafiltration using centricon YM-10 ultrafiltration spin columns (Millipore, Millipore, 
Schwalbach, Germany) with a cut-off of 10 kDa. These columns were used as 
recommended by the manufacturer. Briefly, the reaction mixture was added to the column 
and centrifuged for about 2 hours at 5,000 g, until, except for a small amount of solution the 
whole sample had flown through. The columns were filled with water up to the 2 ml mark 
and the filtration procedure was repeated twice. After the second desalting step, the residual 
volume in the column was saved and diluted with 0.1 M sodium acetate buffer, pH 4.5, to 1 
ml. The concentration of the purified sample was determined at 405 nm after formation of a 
picrate with 2,4,6-Trinitrobenzenesulfonic Acid (TNBS) in an assay previously described 
(31).  
 
Radiolabeling: 
Radiolabeling of the DTPA-coupled siRNA or polymer was accomplished in 0.1 M sodium 
acetate buffer, pH 5.4. Briefly, DTPA-coupled siRNA was annealed at 94 °C for 2 minutes 
and incubated with 30 MBq InCl3 for 30 minutes at room temperature, followed by PD-10 
size exclusion chromatography (SEC) and spin column concentration of peak fractions as 
described earlier (7). For polymer labeling, 300 µg DTPA-PEI (equivalent to 653 µg PEG-
PEI) in 0.1 M sodium acetate buffer, pH 5.4, were incubated with 30 MBq 111InCl3 for 30 
minutes at room temperature, followed by PD-10 SEC and concentration of peak fractions 
using centricon ultrafiltration. 
 
PD-10 size exclusion chromatography (SEC):  
SEC using PD-10 Sephadex G25 prepacked columns is a fast and easy method for desalting 
and can be used to remove free Indium after radiolabeling macromolecules. Radiolabeled 
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siRNA was treated as previously described (7), radiolabeled polymer was applied to the 
PD-10 column in the same way. Briefly, the column was equilibrated with PBS, the sample 
was applied and the flow through collected in fractions of 13 droplets each. RNA content 
was measured UV-metrically at 260 nm using a Pharmacia Ultrospec 2000 UV/VIS, 
Pharmacia Biotech, Freiburg, Germany, and radioactive signal in 10 µl of each fraction was 
determined using a Gamma Counter Packard 5005, Packard Instruments, Meriden, CT, 
USA. 
Those fractions that showed both a high radioactive signal and the strongest UV absorption 
at 260 nm for siRNA and at 405 nm for PEI after addition of TNBS, were combined and 
further purified as well as concentrated using spin columns as described above. 
 
Polyplex preparation: 
Polyplexes were formed in a self-assembly process relying on electrostatic interactions 
(32). A defined amount of positively charged polymer was added to a solution of negatively 
charged siRNA to yield different N/P ratios. For instance, 1.8 ng PEI correspond to 1 pmol 
of a 21mer duplex, if an N/P ratio of 1 is desired. Polyplexes were formed in 10 mM 
HEPES buffer by adding the polymer solution to the siRNA solution. Polyplexes were 
incubated for 10 minutes before they were further utilized for measurements or 
transfections. 
 
FFS measurements: 
Fluorescence fluctuation spectroscopy (FFS) measurements were performed on a 
MRC1024 Bio-Rad confocal laser scanning microscope equipped with a water immersion 
objective lens (Plan Apo 60X, NA 1.2, collar rim correction, Nikon, Japan). The laser beam 
was focused at about 100 µm on a glass slide (Menzel-Gläser, Braunschweig, Germany), 
which contained the free Alexa488-siRNA or Alexa488-siRNA containing polyplexes 
(final concentration of 88.9 nM Alexa488-siRNA in all samples, except for blanks, for in 
vitro like experiments). Polyplexes were prepared in 10 mM HEPES buffer, pH 7.4 as 
described above, at N/P ratios 5, 10, and 15, and were added to either OptiMEM, OptiMEM 
containing FBS or  pure fetal bovine serum (FBS) to result in 0 %, 10 % or 90 % FBS.  
In order to mimic in vivo conditions, in a second setup, polyplexes of a concentration of 
17.33 µM siRNA were prepared at an N/P ratio of 6, of which 30 µl were added to 400 µl 
FBS, resulting in final concentration of 1.2 µM siRNA and 93 % serum. The polyplexes 
were prepared by mixing polyplexes containing Alexa488-labeled (0.068 µM final 
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concentration) and polyplexes containing non-labeled siRNA (1.14 µM final 
concentration). This approach was first of all chosen to avoid too many fluorescent particles 
that would generate overlapping peaks and would therefore impede the determination of an 
accurate baseline value, and second to adjust the fuorescence to that in the aforementioned 
measurements. Acquisition time for each measurement was 30 seconds. The first 
measurement was started after addition of polyplexes to medium, kinetics were observed 
over 60 minutes (0, 10, 20, 30, 60 minutes time points). The intensity of the two baselines 
(free and complexed siRNA) in the fluorescence fluctuations profiles were determined as 
previously described (6).  
 
Size and Zeta-Potential measurements: 
Dynamic light scattering (DLS) was employed to determine hydrodynamic diameters of the 
polyplexes, and laser Doppler anemometry (LDA) was utilized to measure their zeta 
potentials. Polyplexes were formed as described above by mixing 50 pmol DTPA-coupled 
or unaltered siRNA and the according amount of polymer for N/P 10. Complexes were 
incubated for 10 minutes and diluted to a total volume of 800 µl with 10 mM HEPES 
buffer, pH 7.4, to be measured using a Zetasizer Nano ZS (Malvern, Herrenberg, 
Germany). Position and attenuator were optimized by the device. Measurements were 
conducted in triplicates. 
 
Cell Culture:  
HeLa cells were purchased from Clontech (Saint-Germain-en-Laye, France) and transfected 
with a Luciferase Reporter Vector pTRE2hyg-Luc (Clontech, Saint-Germain-en-Laye, 
France) containing the luciferase reporter gene and a hygromycine resistance gene, as 
previously reported (33). Briefly, the plasmid was mixed with Lipofectamine and PLUS 
reagent (Invitrogen, Karlsruhe, Germany) as recommended by the manufacturer. Stably 
transfected cells were selected by treating the cells with a culture medium containing 
200µg/ml hygromycine B (Invitrogen, Karlsruhe, Germany). Clones were propagated and 
characterized concerning luciferase expression and proliferation rate. One of the clones was 
picked to be further propagated. Cells were maintained in DMEM (PAA Laboratories, 
Cölbe, Germany), supplemented with 10 % fetal bovine serum (Cytogen, Sinn, Germany), 
in humidified atmosphere with 5 % CO2 at 37°C. 
  
In vitro transfection experiments: 
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For transfections, HeLa/Luc cells were seeded in 96 well plates (Thermo Fisher Scientific 
(Nunc GmbH & Co. KG), Langenselbold, Germany) with a density of 8,000 cells per well. 
Medium was changed 24 hours later and polyplexes of 20 pmol siGL3 or siCONTORL per 
well (88.9 nM) and an N/P ratio of 10 were added in the full serum-containing medium. 
Control cells were treated with free siRNA only. As a positive control, siGL3 was added as 
lipoplexes formed with Lipofectamine2000 (Invitrogen, Karlsruhe, Germany); lipoplexes of 
Lipofectamine and siCONTROL were considered the negative control. The medium was 
changed 4 hours post transfection, and cells were incubated for another 44 hours before 
they were washed with PBS, lysed with CCLR (Promega, Mannheim, Germany), and 
assayed for luciferase expression with a commercial luciferase assay kit (Promega, 
Mannheim, Germany) on a BMG LUMIstar OPTIMA luminometer plate reader (BMG 
Labtech, Offenburg, Germany).  
 
Albumin binding assay: 
Binding of siRNA to plasma proteins like albumin was detected in an albumin binding 
assay previously described by Geary et al. (34). Briefly, an albumin stock solution of 450 
mg/ml and 0.005 % Tween 80 was prepared in phosphate buffered saline (PBS), pH 7.4. 
Polyplexes at N/P 6 or free radioactively labeled siRNA were added to DMEM containing 
no, 4.5 mg/ml or 45 mg/ml albumin, which is a physiological concentration. According to 
Zini et al. (35), these concentrations equal monomer concentrations of 3.37 or 16.77 mg/ml, 
respectively, assuming a Kd of 150 µM for the monomer-dimer equilibrium. Final siRNA 
concentration was chosen to be 1.2 µM as in the in vivo experiments. Solutions were 
incubated for one hour at 37 °C and loaded to low binding polyethersulfone (PES) Vivaspin 
columns (Sartorius Stedim Biotech GmbH, Göttingen, Germany) with a molecular weight 
cut-off of 30,000 Da. After centrifugation for 15 minutes at 735 g, aliquots of unfiltered and 
filtered solutions were measured for siRNA content using a scintillation counter. 
 
Animal studies: 
All animal experiments were carried out according to the German law of protection of 
animal life and were approved by an external review committee for laboratory animal care. 
For in vivo experiments, 4 weeks old balb/c mice (~ 20 g), were injected with 35 µg DTPA-
siRNA, corresponding to 2.57 nmol and 255 kBq. siRNA was either administered as free 
duplexes or after complexation at N/P 6 with 25 kDa branched PEI, PEI(25kDa)-
PEG(2kDa)
 10, or PEI(25kDa)-PEG(20kDa)1. Pharmacokinetics of each component were 
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observed over 2 hours by retroorbitally drawn blood samples of 25 µl at certain time points. 
Biodistribution over a period of about 25 minutes, depending on the individual depth of 
anesthesia in each animal, was observed non-invasively by dynamic real-time gamma 
camera imaging acquired with a Siemens e.cam gamma camera (Siemens AG, Erlangen, 
Germany) (7). Static planar and SPECT images were taken at later time points using a 
custom built multiplexing multipinhole collimator mounted on the Siemens e.cam gamma 
camera. Two-dimensionally acquired data was quantified by analysis of regions of interest 
(ROIs) as previously described (7). Two hours after i.v. injection, animals were sacrificed; 
organs were dissected and analyzed for deposition of radioactive material by gamma 
scintillation counting on a Packard 5005 Gamma Counter (Packard Instruments, Meriden, 
CT, USA).  
 
Data analysis and statistics: 
Analytical measurements were conducted in triplicates, transfection experiments in 
quadruplets. Animal experiments included 5 animals per group; results are given as mean 
values +/- standard deviation (SD). Two way ANOVA and statistical evaluation was 
performed using Graph Pad Prism 4.03 (Graph Pad Software, LaJolla, USA). 
Pharmacokinetic parameters were determined using Kinetica 4.4.1 (Thermo Electron 
Corporation, Karlsruhe, Germany). 
6.4 Results and Discussion 
Since neither stability under in vivo conditions nor pharmacokinetic parameters of 
siRNA/(PEG-)PEI polyplexes have so far been investigated, in this study, we addressed the 
stability issue under serum concentration comparable to in vivo conditions by FFS 
measurements and the pharmacokinetics by detection of radiolabeled polyplexes. To 
investigate the influence of PEGylation, we chose three polymers: branched PEI 25 kDa 
(PEI 25) and two PEGylated derivatives with different grafting degree but the same 
percentage of PEI content, being 46 % of the copolymer. The PEGylated PEIs used in this 
study were one copolymer with 10 short 2 kDa PEG chains, which can be described by the 
formula PEI(25kDa)-PEG(2kDa)
 10, and another PEI derivative with only one long PEG 
chain, named PEI(25kDa)-PEG(20kDa)1. 
 
Radiolabeling: 
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The optimized procedure for radiolabeling and purification of coupled and labeled siRNA, 
which we have reported lately (7), enabled us to track kinetics and deposition of siRNA. 
But in order to investigate in vivo behavior of both vector and load, which would allow us 
to compare kinetics and distribution of the vector to that of the load, and would therefore 
provide us with information on in vivo stability of the polyplexes, it was necessary to 
radiolabel the polymers as well. The polymers could easily be separated from p-SCN-Bn-
DTPA by ultrafiltration. This can be explained by their high reactivity due to an excess of 
primary amines that can be coupled. Therefore, it can be assumed that no or only small 
amounts of unreacted p-SCN-Bn-DTPA were left in the reaction mixture. Purification after 
radiolabeling was not necessary as shown in Figure 1A-C. Quality control SEC on a PD-10 
column showed neither significant amounts of DTPA (peaks at fractions 10-12) nor of free 
Indium (peaks at fractions 15-19, compare (7)). In order to investigate if parts of the hot 
Indium had not stably been chelated by DTPA but non-specifically bound by free valences 
of PEI and would therefore be released upon complexation of siRNA, we formed 
complexes with a small aliquot of radiolabeled PEI and applied it on a PD-10 column. In 
the eluted fractions, the UV signal for siRNA and the radioactive signal showed 
concurrence, and free Indium was not observed (see Figure 1D).  
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Quality Control of Labeled Polymer and Polyplex
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Figure 1: PD-10 size exclusion chromatograph of A-C: radiolabeled polymers. Neither free 
DTPA nor Indium was observed in later fractions. The tailing of the polymer peak can be 
explained by the polydispersity of the polymer. D: radiolabeled PEI after complex 
formation.  
Fluorescence Fluctuation Spectroscopy (FFS): 
One of the aims of this study was to correlate biodistribution and pharmacokinetics of our 
polyplexes with their stability in serum. Therefore, we used fluorescence fluctuation 
spectroscopy (FFS), a sophisticated method for detection of release of siRNA from 
polyplexes under cell culture and in vivo conditions. As previously described (6), the 
amount of free fluorescently labeled siRNA can be quantified in presence of serum in an 
FFS measurement. In a solution of free fluorescently labeled siRNA, the fluorescence 
signal is proportional to the concentration of siRNA. When the siRNA is complexed in 
nanoplexes, the fluorescence baseline, caused by freely moving siRNA, drops and highly 
fluorescent peaks, that originate from nanoplexes containing large amounts of siRNA, 
occur. Since the fluorescence baseline is proportional to the amount of free siRNA that is 
present, the degree of association and dissociation can be calculated proportionally to the 
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differences between the signals for blank, free siRNA, and complexed siRNA as described 
by Buyens (6).  
Little is known about structural changes and instability of polyplexes in vivo. To our 
knowledge, so far polyplexes made of PEG-PEI and siRNA have only been characterized 
prior to administration which doesn’t allow for a prediction of their in vivo behavior. 
Instability (20) and premature polyplex unpacking (21) have been assumed in various 
reports and have been made responsible for a different in vivo biodistribution of polymer 
and load (20) or the delivery of the load to a lesser extent (21), but this assumption has not 
been verified by quantification under serum concentration comparable to in vivo conditions. 
The FFS measurements we performed, finally allowed us to interpret biodistribution and 
pharmacokinetics in the context of complex stability in vivo.  
In order to mimic in vitro conditions of our actual transfection experiments, all 
concentrations were chosen to match the standard transfection procedure. Since we were 
interested in the influence of serum on polyplex stability, we observed siRNA release from 
polyplexes at N/P 5, 10 or 15 at 0 %, 10 % and 90 % FBS, as shown in Figure 2A. While 
10 % serum didn’t seem to affect stability of PEI complexes at an N/P of 10 or higher, 
release of 75 % for N/P 5 and about 55 % for N/P 10 and 15 were observed in the first 10 
minutes upon addition to 90 % serum-containing medium. After 60 minutes of incubation 
in this medium, complexes of N/P 5 released almost the total load of siRNA, and 
complexes of N/P 10 and 15 still showed very low stability and a release of about 70 % of 
the load. Very similar profiles were observed for the PEGylated PEIs (data not shown). As 
for cell culture experiments the relevant concentration of serum is 10 %, all release profiles 
at this concentration are shown in Figure 2B. Interestingly, strong differences could be 
observed for the various polymers. The unmodified PEI 25 kDa exhibited the most stable 
complexes, which can easily be explained by the charge density of the polymer. But even 
the two differently PEGylated PEIs showed remarkable differences in their release profiles. 
To our surprise, PEI-PEG(20k)1 offered less stability than PEI-PEG(2k)10 although it had 
protected siRNA better from RNase degradation in an in vitro assay in our earlier 
publication (17). In the aforementioned assay, polyplexes were formed in 5 % glucose 
solution and treated with increasing amounts of RNase. No serum or high ionic strength 
buffers had been used. But in the heparin competition assay, concentrations as low as 0.07 
IU/µg RNA released almost the complete load (17). The comparison to only about 50 % 
release of pDNA at a heparin concentration of 0.25 IU/µg DNA (36) emphasizes the fact 
that siRNA/(PEG-)PEI polyplexes are even in vitro less stable than pDNA polyplexes.  
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N/P 5 in 10% serum
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Figure 2A: FFS measurements showing siRNA release from PEI 25 kDa polyplexes 
prepared at 88.9 nM final siRNA concentration and N/P 5, 10, and 15 in 0-90 % serum-
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containing medium. Figure 2B: FFS measurements showing siRNA release from PEI 25 
kDa and PEG-PEI polyplexes prepared at 88.9 nM final siRNA concentration and N/P 5, 
10, and 15 in 10 % serum-containing medium. 
In the FFS assays, relationships (i) between stability and N/P ratio, and (ii) between stability 
and PEG chain length were found. At N/P 5, both PEGylated polymers were not able to 
form stable complexes, reflected in a fast and almost complete release of siRNA in 10 % 
serum-containing medium. But by increasing the N/P ratio to 10, differences in stability 
depending on the PEGylation pattern became clearer. While PEI-PEG(20k)1 complexes 
released more than 50 % of siRNA,  PEI-PEG(2k)10 complexes showed only 40 % release 
during an incubation period of 60 minutes. These differences became even more prominent 
at N/P 15, where PEI-PEG(2k)10 complexes showed only a slightly different release profile 
from PEI complexes, but PEI-PEG(20k)1 complexes still released more than 50 % of their 
load during 60 minutes of incubation at 37 °C. Stability of polyplexes in 90 % serum-
containing medium was observed at the same concentration as used in the in vivo 
experiments and at N/P 6, which had been chosen for i.v. injections. As shown in Figure 3 
and assumed earlier (20), stability is very much depending on polyplex concentration. At 
this about 13.5 fold higher concentration, differences in the profiles of the two PEGylated 
polymers were much less prominent than at the in vitro concentration. PEI 25 kDa again 
exhibited the most stable polyplexes which showed almost no release of siRNA. The 
PEGylated polymers, on the other hand, set 12.6 % (PEI-PEG(2k)10) or 15.5 % (PEI-
PEG(20k)1) of their load free over 60 minutes of incubation at 37 °C, which encouraged us 
to apply polyplexes of an N/P ratio as low as 6 in our in vivo study. 
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Figure 3: FFS measurements showing siRNA release from PEI 25 kDa and PEG-PEI 
polyplexes prepared at 1.2 µM final siRNA concentration and N/P 6 in 90% serum-
containing medium. 
Physical characterization of polyplexes: 
To further characterize the polyplexes and to determine if the C6-thiourea coupled Bn-
DTPA would affect siRNA complex formation, we measured sizes and zeta potentials of 
polyplexes formed with the unmodified duplex siGL3 and the Bn-DTPA coupled thiourea 
derivative of siGL3. No significant differences (p > 0.05) concerning size (Fig. 4A) or 
surface charge (Fig. 5B) were found in between the groups of the same polymer but 
different duplexes. Interestingly, PEI-PEG(2k)10 formed much bigger complexes with 
siRNA in HEPES buffer than PEI or PEG(20k)1. This is in accordance with our previous 
findings reporting that a large amount of PEG chains impedes electrostatic interaction 
between polycation and polyanion and therefore hampers condensation into small particles 
(17, 37). The influence of PEGylation on zeta potential is shown in Figure 4B and can be 
explained by the core-shell structure which has been stated by us and others (17, 29, 38). 
According to the findings of our FFS measurements, this hypothesis of a PEG corona only 
holds true for measurements in the absence of serum. But this outer PEG shell is drawn for 
the decrease of surface charge, which is especially dramatic for the copolymer bearing the 
20 kDa PEG chain. 
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Figure 4A: Sizes of PEI 25 kDa and PEG-PEI polyplexes prepared with siGL3 or the Bn-
DTPA coupled thiourea derivative of siGL3 (siGL3-DTPA), determined by dynamic light 
scattering. 4B: Zeta potentials of PEI 25 kDa and PEG-PEI polyplexes prepared with 
siGL3 or the Bn-DTPA coupled thiourea derivative of siGL3 (siGL3-DTPA) determined by 
laser Doppler anemometry. Derivatization of siRNA did neither affect size nor zeta 
potential significantly. 4C: Transfection of HeLa/Luc cells stably expressing firefly 
Luciferase with siGL3, the Bn-DTPA coupled thiourea derivative of siGL3 (siGL3-DTPA) 
or a scrambled control sequence (siCONTROL) after complexation of siRNA with 
Lipofectamine 2000 (LF), PEI 25 kDa or PEG-PEI. Derivatization of siRNA did not affect 
knockdown efficacy significantly. 
In vitro bioactivity of polyplexes: 
Functionality of the labeled siRNA was investigated in vitro in siRNA transfection 
experiments of the stably luciferase expressing cell line HeLa/Luc. Sequence specific 
knockdown of luciferase expression was checked for by comparison of the effects of a 
random control duplex. Since FFS measurements had revealed that PEG-PEI-complexes at 
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N/P 5 were not stable in 10 % serum, polyplexes were formed at N/P 10 for in vitro 
transfections. 
As a result, we found no significant differences between the knockdown efficiency of the 
non-labeled and the labeled duplex of the same sequence. Downregulation of luciferase 
expression in the constitutively luciferase expressing cell line compared to non-specific 
control was highly significant (*** p < 0.001) for Lipofectamine 2000 and significant (** p 
< 0.01, * p < 0.05) for PEG-PEI polyplexes (compare Figure 4C). No effect was observed 
for PEI polyplexes, as earlier reported (17). Considering the stability of these polyplexes, it 
can be hypothesized that siRNA is too tightly bound to PEI and therefore not available for 
incorporation into RISC inside the cell. PEI-PEG(20k)1 which had shown lowest stability in 
the FFS measurements yielded the highest knockdown efficiency among the polyplexes. 
PEI-PEG(2k)10 polyplexes which had proven higher stability mediated less downregulation 
of luciferase expression which could also be explained by the larger size of these 
polyplexes. 
 
In vivo experiments: 
After thorough characterization of the polyplexes, pharmacokinetics and biodistribution of 
both the vector and the load were determined in two different sets of experiments. An 
optimal experiment would enable simultaneous detection of double-labeled polyplexes. 
Double-isotope detection is possible, but the signal of 111In would, e.g., interfere with the 
detection of 99mTc. Therefore, in the first set, radioactively labeled siRNA was 
intravenously applied either as free siRNA, as reported earlier (12), or after complexation 
with PEI or PEG-PEI. These materials have earlier been characterized concerning in vivo 
biodistribution and pharmacokinetics after complexation of pDNA and ODNs (20, 24, 39) 
and have recently been used for in vivo siRNA delivery (40-45).  
For a better understanding of the fate of each component of the polyplexes, seen in the 
context of stability of polyplexes, we performed another set of experiments. Here, 
polyplexes were formed with radiolabeled polymer and non-labeled siRNA. The same 
amount of polyplex as in the first set was applied by i.v. injection. Data from scintillation 
counting of blood samples were analyzed with Kinetica 4.1.1 (Thermo Electron 
Corporation, Karlsruhe, Germany) and fitted to a biphasic exponential IV bolus equation 
(C(t) =Ae− αt + Be− βt). 
 
Pharmacokinetics of vector and load: 
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Analysis of blood clearance of labeled siRNA revealed strong differences between 
complexed and free siRNA. As shown in Figure 5A, all profiles of complexes, no matter if 
siRNA or polymers were labeled, exhibited a fast and steep alpha phase, in which the 
polyplexes are assumed to be deposited in a deeper compartment. Statistic analysis of alpha 
(elimination constant of alpha phase) and A (coefficient of alpha phase) values revealed 
neither significant differences between the different polyplexes nor between vector and load 
(p > 0.05). The rapid deposition phase, which lasted only a few minutes for each component 
observed, can be characterized by t1/2 alpha half-lives of 4.0 minutes, 2.7 minutes, and 1.6 
minutes for complexed siRNA and 0.6 minutes, 1.3 minutes, and 1.5 minutes for the 
polymers PEI 25kDa, PEI-PEG(2k)10, and PEI-PEG(20k)1, respectively (compare Figure 
5B). The alpha phase was followed by a flatter beta elimination phase. Half-lives t1/2 beta 
determined for complexed siRNA, were 84.9 minutes (PEI 25kDa), 55.1 minutes (PEI-
PEG(2k)10), and 44.8 minutes (PEI-PEG(20k)1), a trend that mirrors stability of the 
different polyplexes. The values calculated for the different polymers (10.7 minutes, 20.1 
minutes, and 19.9 minutes, respectively) did not reveal strong differences, as shown in both 
Figures 5A and 5B. Both alpha and beta half-lives of polymers and nucleic acids are in very 
good agreement with values previously described for pDNA/(PEG-)PEI polyplexes (20). 
Alpha and beta half-lives of free siRNA are comparable to values reported for 64Cu-DOTA 
labeled 5’-amino-C6-modified siRNA ( t1/2 alpha = 2.4 minutes and t1/2 beta= 61.9 minutes) that 
was applied in a comparable concentration (2.5 mg/kg vs. 1.75 mg/kg in our study) and 
investigated by PET (46).   
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Figure 5A: Pharmacokinetics of each single component of polyplexes containing 35 µg 
siRNA in balb/c mice. Labeled polymers (circles) showed more rapid elimination from 
circulation than labeled siRNA (squares). 5B: Kinetic parameters of labeled siRNA (upper 
half), free siRNA and labeled polymers (lower half) are listed in the table. AUC, area under 
the curve; alpha, half-life in alpha phase; beta, half-life in elimination (beta-) phase; CL, 
clearance; MRT, mean residence time; Vss, steady state volume of distribution.  
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Figure 6: Analysis of kinetics parameters: Analysis of the values for area under the curve 
(AUC, left y axis in min*%ID/ml) revealed significant differences between PEI and PEG-
PEI complexed siRNA (***p < 0.001) as well as between load and vector for each type of 
polyplex. Analysis of alpha (right y axis in %ID/ml) showed strong differences in the 
rapidness of clearance from circulation between PEI and PEG-PEI as well as between load 
and vector. 
Differences between area under the curve (AUC) values of load and vector were highly 
significant (p < 0.001) for each polyplex, which is in agreement with previously reported 
data concerning pDNA polyplexes (20). AUC of free siRNA was found to be highly 
significantly (p < 0.001) larger than all of the AUC values of complexed siRNA. 
Interestingly, we also observed highly significant (***p < 0.001) differences between AUC 
of PEI and PEG-PEI complexed siRNA as shown in Figure 6. The difference in this 
parameter can be explained by a difference in stability of the polyplexes as determined by 
FFS, but it also has to be seen in context of deposition of the polyplexes. As Figure 8 
shows, PEI complexes were held back by the liver to a much higher extent than PEG-PEI 
complexes. This causes a lower bioavailability, shorter circulation time and smaller AUC 
value. AUC values and other pharmacokinetic parameters for free and complexed siRNA 
have previously been reported by Li et al. (9). In their study, FAM-labeled siRNA was 
applied at a dose of 1.2 mg/kg, and data were acquired by fluorescence detection. The 
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elimination half-life of only 15 min reported for free siRNA in tumor-free mice is much 
shorter than in our study or in the one described by Bartelett et al. (46). This is probably due 
to the C6-modification of the siRNA used by us and Bartelett. Other parameters such as 
Clearance, AUC, Mean Residence Time (MRT) and Steady State Volume of Distribution 
(Vss) were affected by this modification, as well. Free siRNA circulated much longer in our 
study, leading to a longer elimination time, a bigger AUC, a slower clearance, a longer 
MRT and a larger Vss. The nanoparticles described by Li et al., on the other hand, showed 
enhanced circulation, characterized by a longer elimination half-life, a strongly greater 
AUC, a much slower clearance, much longer MRT and smaller Vss in tumor-free mice. 
Obviously, their nanoparticles were stable and did not show high uptake by the RES. 
 
Albumin binding of modified siRNA: 
An unexpected result was that free siRNA seemed to stay in circulation longer than any 
other component. Since the profiles of complexed siRNA were obviously driven by the 
polymer, differences between free siRNA and complexed siRNA confirmed that polyplexes 
were stable in circulation to a certain extent. But unmodified siRNA is actually known to be 
renally excreted even faster than it can be degraded (47). In our particular case, this was not 
true and was assumed to be caused by the C6-modification or the coupling of DTPA. As 
siRNA is degraded rapidly in vivo by serum nucleases, the radioactive signal measured in 
the blood samples most likely was caused by fragments of siRNA still bearing the label. As 
previously stated (7), it is one of the major drawbacks of radioactive end-labeling 
techniques that the signal measured does not differentiate between intact and degraded 
material. In order to find out, why these labeled fragments remained longer in circulation 
than complexed siRNA, binding of the C6-modified siRNA to serum proteins was 
investigated in an albumin binding assay. It has been reported that lipophilic siRNA, such 
as 2’-O-(2-Methoxyethyl)-modified siRNA (34) or lipid-conjugated siRNA, in contrast to 
unmodified siRNA (48) substantially binds to albumin which prevents glomerular filtration 
yielding in prolonged circulation times and higher bioavailability. As shown in Figure 6, the 
C6-thiurea-DTPA conjugated siRNA we used exhibited strong binding to albumin both at a 
low concentration of 4.5 mg/ml and the physiologic concentration of 45 mg/ml. But since 
the addition of an end-label did not protect siRNA from nuclease digestion, the higher AUC 
value and the longer circulation time observed for our free siRNA has to be interpreted 
critically. Degradation of siRNA can be prevented or retarded by chemical modification of 
the nucleotides, the backbone or by complexation with an appropriate delivery system (49-
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51). In our earlier publication, we showed that PEI 25 kDa as well as PEGylated derivatives 
protected siRNA from RNase degradation (17). The albumin binding assay data express the 
percentage of siRNA which freely diffuses in the solution that had been examined. As 
expected, siRNA (13.6 kDa) complexed with PEI (25 kDa) or PEG-PEI (45 kDa) formed 
larger particles than 30 kDa, which cannot be detected in the flow through of the test 
solution. In the case of free siRNA, we interpreted the low percentage of remaining siRNA 
after filtration, which was comparable to the amount filtrated after complexation with 
polymer, as a result of binding to albumin which explained the circulation time and AUC 
shown in Figures 5A and 5B. It is important though to keep in mind that this behavior did 
not represent an enhancement of siRNA bioavailability due to lack of protection against 
enzymatic degradation.  
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Figure 7: The albumin binding assay proved strong binding of Bn-DTPA coupled siGL3 to 
serum proteins even at low albumin concentration of 4.5 mg/ml. 
Biodistribution of vector and load: 
As shown in Figure 8, strong accumulation of PEI 25 kDa (36.2 % injected dose (ID)/ 
organ) was observed in the liver as reported earlier for pDNA/PEI complexes (20, 24, 52). 
Lower accumulation of both PEG-PEIs and of free or formulated siRNA was statistically 
significant (***p < 0.001) compared to PEI 25 kDa. This means that even if PEI 25 kDa 
polyplexes were stable in circulation, they probably dissociated after uptake into the liver. 
Separation during liver passage was reported for pDNA/PEI complexes and probably 
resulted from vector unpackaging due to PEI binding to extracellular matrix (ECM) 
components (21). In that case, PEI was taken up into the liver cells (21), whereas DNA was 
found in interstitial space (21). The differences in liver deposition of vector and siRNA 
shown here could explain the dissimilar kinetic profiles. The fate of siRNA can be 
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explained by taking into account the excretion profiles. Amounts of polymer and 
complexed siRNA found in the urine were significantly (***p < 0.001) different for each 
pair of vector and load, as well. PEGylated PEIs showed comparably less (***p < 0.001) 
uptake into the liver. This supports our hypothesis of decreased interaction of PEGylated 
PEIs with blood components and macrophages (20, 24) due to the shielding effect of PEG. 
In fact, PEG chain length also played an important role in liver uptake, reflected in a 
significantly (***p < 0.001) lower uptake of PEI25k-PEG(20k)1 compared to PEI25k-
PEG(2k)10. This trend is also true for complexed siRNA: PEI 25 kDa-complexed siRNA is 
deposited in the liver to a significantly (**p < 0.01) greater extent than PEG-PEI-
complexed siRNA. This again underscores the importance of polyplex stability in blood 
circulation: PEG-PEIs, which form less stable complexes, release siRNA earlier, yielding 
lower liver uptake and significantly higher (**p < 0.01) excretion of siRNA in the urine. In 
fact, liver uptake of siRNA correlates very well (R2 = 0.9903) with the amount of siRNA 
released, as shown in Figure 9. High stability of polyplexes led to stronger uptake of siRNA 
into the liver. The more siRNA was released from polyplexes in presence of serum, the 
more it bound to albumin and circulated longer than siRNA that was stably complexed and 
deposited in the liver. Other organs did not show relevant uptake. Only PEI 25 kDa showed 
uptake into the lung (3 % ID/ organ) which had earlier been reported to cause lethal events 
in animal studies investigating pDNA/PEI complexes (20, 23). Lethality and acute toxicity 
were explained on the basis of embolism due to entrapment of aggregates of polyplexes and 
blood components in the lung capillaries (53). In our study, we did neither observe 
accumulation in the lungs, as shown in Figure 8, nor did animals die from the treatment 
(two mice died from anesthesia).  Values of up to 9 % ID/ organ in the case of PEI 25 kDa 
were measured in the kidneys. Accumulation of radiolabeled siRNA in the kidneys has 
earlier been reported for free siRNA (12). In our study, deposition of PEI 25 kDa had been 
even more prominent and can be explained by the lack of glomerular filtration of 
macromolecules or complexes > 60 kDa (54). Another explanation is that highly positively 
charged PEI is most probably held back by the negatively charged basal membrane of the 
bowman’s capsules. PEGylated PEIs on the other hand, where the charges are shielded and 
which are more water soluble, didn’t get stuck in the kidneys. Free siRNA didn’t show any 
distinct deposition but accumulation in the bladder and the urine. Fast renal clearance and a 
high signal in the urine in biodistribution studies with pDNA/PEI polyplexes had so far 
been interpreted as excretion of degraded plasmid (55). siRNA, on the other hand, is more 
rapidly excreted than degraded (47). Although radiolabeled siRNA which is released from 
Chapter 6 
 
174 
polyplexes in circulation or in the liver passages is most likely to be bound to albumin, as 
discussed above, the amount of radioactivity found in the urine samples of mice treated 
with free or complexed siRNA is significantly different (PEI 25 kDa *p < 0.05, PEI25k-
PEG(20k)1 and PEI25k-PEG(2k)10 ***p < 0.01). Our results calculated as % ID per gram 
(data not shown) prove that PEGylation decreases uptake by macrophages, shown in 
significantly lower (*p < 0.05) uptake of PEG-PEIs into the spleen. In this context it seems 
to us that post-PEGylation of pre-formed polyplexes could reveal higher stability attributed 
to PEI-complexes but lower recognition of the particles by the RES. This could be 
combined with bioreversible crosslinking via disulfide bond formation, which has 
previously been reported. Mere PEGylation of siRNA would certainly prolong its 
circulation time, but would not offer protection against nuclease degradation. 
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Figure 8: Scintillation analysis of dissected organs 2 hours after injection given as 
percentage of injected dose per organ.  
Chapter 6 
 
175 
Data correlation
0 10 20 30 40
0
10
20      r² 0.9903
siRNA release [%]
liv
er
 
u
pt
ak
e 
[%
]
 
Figure 9: Correlation of siRNA uptake into the liver and siRNA release from polyplexes as 
measured by FFS  
Non-invasive determination of pharmacokinetics and biodistribution: 
Additional to scintillation counting of blood samples and organs, we performed real-time 
perfusion imaging studies to record kinetics and biodistribution during the first 25 minutes 
after injection. This non-invasive procedure was performed by quantifying radioactivity in 
“Regions of Interest” (ROIs) in living animals. We generally observed rapid accumulation 
in liver and kidneys and very fast renal excretion, as shown in Figures 10B (and Supporting 
Information for each single polymer). As previously described for siRNA/PEI complexes 
(7), a primary deposition in the lungs and secondary redistribution, which had been 
quantified for pDNA lipoplexes (28) and assumed for pDNA complexes earlier (20), was 
neither observed for polymer nor for siRNA in our perfusion studies. Regions of interest 
were again analyzed 2 hours after injection and are shown in Figure 10A. This graph clearly 
showed the same trends as Figure 8, but the drawback of two-dimensional imaging is that 
liver and kidneys, for example, are in the same plane of projection and can therefore not be 
differentiated. As a result, Figure 10A shows the sum of activity of both kidneys and the 
liver. Other organs, that did not show accumulation of radioactive material, could not be 
evaluated at all.  
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Figure 10A: Scintillation analysis of regions of interest 2 hours after injection for 
evaluation of biodistribution. 10B: Planar gamma camera perfusion movie with regions of 
interest for real-time quantification after injection of 35 µg siRNA, corresponding to 2.57 
nmol and 0.255 MBq 111In, complexed at an N/P of 6 with 25 kDa bPEI.  
The imaging techniques used here provided information on three-dimensional localization 
of polyplexes and their kinetic behavior. As shown in Movie 1, Supporting Information, 
polyplexes made of 111Indium-labeled PEI 25k extensively accumulate in the liver and 
kidneys. If siRNA is radioactively labeled and the same polyplexes are applied, much less 
activity is measured in the liver after 2 hours (compare SPECT images Supporting 
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Information). This again supports the data from scintillation counting of dissected organs 
(Figure 8). In case of PEG-PEI complexes made of radioactively labeled siRNA, 
accumulation in the liver is so faint that SPECT images only indicate accumulation in the 
bladder (compare images Supporting Information).  
6.5 Conclusion 
Aim of this study was to correlate serum stability of polyplexes with their in vivo behavior 
and to predict pharmacokinetics and biodistribution. By measuring siRNA release from a 
vector in presence of serum, using fluorescence fluctuation spectroscopy, we were able to 
determine stability under serum concentration comparable to in vivo conditions. As 
expected, complexation of siRNA drove in vivo behavior and the most stable polyplexes 
experienced fast deposition in the liver. PEGylated polyplexes, which on the one hand are 
less stable in serum-containing media, showed better transfection efficiency in vitro and 
less uptake into liver and spleen in vivo, on the other hand. By physico-chemical and in 
vitro characterization we demonstrated that labeling did not affect polyplex formation or 
functionality of siRNA. 
Additionally, we used nuclear imaging techniques to predict and determine 
pharmacokinetics, deposition, and to prove that there is no redistribution of polyplexes from 
the lungs to the liver. During the very first 25 minutes after application, we already 
observed differences in the behavior of the various polyplexes by real-time gamma camera 
imaging which are confirmed by scintillation counting of blood samples. Two hours after 
injection, SPECT images non-invasively exposed differences in organ distribution which 
had also been found by scintillation counting of dissected organs. 
Taken together, we were able to show that stability of polyplexes has a strong influence on 
kinetics and distribution of each component of the polyplexes and we could prove 
correlation of stability and liver deposition. After radiolabeling siRNA and polymers, 
behavior of both vector and load could be followed non-invasively and showed that 
complexes which were stable in circulation dissociated during liver passage. Polyplexes 
made of siRNA and (PEG-)PEI are therefore not suitable for systemic but possibly for local 
application, such as inhalation or direct injection into organs.  
In conclusion, this study proved that fluorescence fluctuation spectroscopy and nuclear 
imaging were able to predict and clarify in vivo behavior of siRNA polyplexes and can be 
used for optimizing more advanced vectors for systemic application. 
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7.1 Abstract 
Objective: This study describes the physico-biological characterization of PEI- and PEG-
PEI polyplexes containing partially 2’-OMe modified 25/27mer dicer substrate siRNAs 
(DsiRNAs) and their in vivo behavior regarding biodistribution and systemic bioavailability 
after pulmonary application as well as their ability to knock down gene expression in the 
lung. 
Methods: Biophysical characterization included circular dichroism of siRNA in 
polyplexes, condensation efficiency of polymers and in vitro stability. After in vivo 
application, biodistribution and kinetics of radiolabeled polyplexes was quantified and 
recorded over time in three-dimensional SPECT images and by endpoint scintillation 
counting. The influence on lung tissue and on the humoral and cellular immunosystem was 
investigated, and finally knock down of endogenous gene expression in the lung was 
determined qualitatively. 
Results: While all of the polymers used in our study were proven to effectively condense 
siRNA, stability of the complexes depended on the PEG grafting degree. Interestingly, PEI 
25 kDa which showed the least interaction with mucin or surfactant in vitro, performed 
poorly in vivo. Our nuclear imaging approach enabled us to follow biodistribution of the 
instilled nanocarriers over time and indicated that PEGylated nanocarriers are more suitable 
for lung application. While moderate proinflammatory effects were attributed to PEI25k-
PEG(2k)10 nanocarriers, none of the treatments caused histological abnormalities. Our 
preliminary in vivo knock down experiment suggests that PEG-PEI/siRNA complexes are 
promising nanomedicines for pulmonary siRNA delivery. 
Conclusion: These results encouraged us to further investigate possible adverse effects and 
to quantify in vivo gene silencing in the lung after intratracheal instillation of PEG-
PEI/siRNA complexes. 
7.2 Introduction 
Delivery is still the major hurdle in RNAi therapy. Due to the instability of siRNA and 
rapid excretion upon systemic injection (1), most of the clinical trials involving siRNA 
based drugs utilize local administration to the eyes, targeting macular degeneration and 
diabetic retinopathy (Acuity Pharmaceuticals, Alnylam Pharmaceuticals, Inc. and Sirna 
Therapeutics, Inc), or direct delivery to the brain or the lung (Alnylam Pharmaceuticals, 
Chapter 7 
 
186 
Inc.), and a recent study has demonstrated the advantages of local pulmonary application of 
both drugs and nucleic acids over systemic i.v. injection (2). Lung cancer is already the 
leading cause of cancer death in the United States (3) and the number 8 cause of death 
worldwide, while lower respiratory infections are number 3, chronic obstructive pulmonary 
disease is number 4, and tuberculosis is number 7, according to the World Health 
Organization (WHO) (4).  Therefore, efficient therapies that lead to high and prolonged 
local drug concentration in the lung are needed to avoid any of these respiratory diseases 
becoming the number one cause of death. The lung with its vast surface area and strong 
perfusion is indeed well suited to take up small, hydrophobic drug molecules. It is, on the 
other hand, only permeable to a limited extent for large, hydrophilic biopharmaceuticals, 
such as siRNA. Yet, successful local siRNA therapy, e.g. protection from SARS infection 
(5), inhibition of RSV (5, 6) and influenza A (7) virus replication has been reported. While 
most of the in vivo studies of siRNA based therapy used 21mer duplexes that mimic 
naturally occurring products of Dicer (8), Kim et al showed that 27mer blunt double strands 
can be up to 100-fold more potent than 21mer duplexes (9). Different approaches to 
enhance the stability of siRNA have been reported (10), including modification of the 
backbone and/or ribose (11). In particular, methylation of the ribose 2’ hydroxyl group (2’-
OMe) offers the additional benefit of diminishing immunostimulatory effects (12, 13). The 
first study of pulmonary delivery of siRNA reported successful down regulation of heme 
oxygenase-1 even after application of naked siRNA (14), and Li et al. only used isotonic 
dextrose solution (DW5) as carrier 5. Bitko et al. showed enhanced effects, compared to 
naked siRNA, with a cationic lipid transfection reagent TransIT-TKO (6), and in the 
meantime, a limited number of nanocarriers such as surfactants (15), mucoadhesive 
chitosan (16), and Oligofectamine (17) have been used for improved in vivo pulmonary 
delivery. In our study, we have investigated how formulation of a 25/27mer 2’-OMe siRNA 
with polyethylene imine (PEI) and polyethylene glycol (PEG) grafted PEI (PEG-PEI) into 
nanosized complexes influences biodistribution, absorption, and clearance of vector and 
load after intratracheal instillation. These parameters were studied by non-invasive nuclear 
imaging and were compared for PEG-PEIs of different grafting degrees. Additionally, the 
encapsulation of the modified siRNA, induction of immunostimulatory effects, pulmonary 
histology after instillation, and finally knock down of target protein expression were 
investigated. 
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7.3 Experimental Section 
Materials: 
Poly(ethylene imine), PEI 25 kDa (Polymin ™, 25 kDa) was a gift from BASF 
(Ludwigshafen, Germany), the block copolymers poly(ethylene glycol)-poly(ethylene 
imine) PEI25k-PEG(20k)1 and PEI25k-PEG(2k)10 (18) were synthesized as described 
earlier. 2’-O-Methylated 25/27mer DsiRNA targeting EGFP (19), fluorescent TYE563- and 
5’-sense strand C6-amine modified DsiRNA with the same sequence were obtained from 
Integrated DNA Technologies (Leuven, Belgium), all other reagents were of analytical 
quality. BALB/c mice were bought from Harlan Laboratories (Horst, The Netherlands), and 
C57BL/6-Tg(CAG-EGFP)1Osb/J Actin-EGFP expressing mice were bought from The 
Jackson Laboratory (Ben Harbour, Maine, USA) and bred in house.  
 
Polyplex formation: 
Polyplexes were formed by mixing equal volumes (25 µl each) of siRNA and polymer 
diluted in 10 mM HEPES buffer, unless otherwise stated, to obtain the desired nitrogen to 
RNA phosphate ratio (N/P ratio). Briefly, the appropriate amount of polymer was added to 
an siRNA solution (2 µM) to yield a final concentration of 1 µM siRNA, vortexed for 10 
seconds and incubated for polyplex formation for 10-20 minutes.  
 
SYBR® Gold Dye Binding Assay: 
To investigate the condensation of siRNA by the various polymers, 1 µg EGFP siRNA 
(IDT, Leuven, Belgium) was complexed with polymers at different N/P ratios and pipetted 
into opaque FluoroNunc™ 96 well plates (Nunc, Thermo Fisher Scientific, Langenselbold, 
Germany). After incubation for 20 minutes at room temperature, 50 µl of a 1x SYBR® 
Gold solution (Invitrogen, Karlsruhe, Germany) were added to each well and incubated for 
10 minutes in the dark under constant shaking on a sample shaker TH 15 (Edmund Bühler, 
Hechingen, Germany). Intercalation-caused fluorescence was quantified using a 
fluorescence plate reader (SAFIRE II, Tecan Group Ltd, Männedorf, Switzerland) at 495 
nm excitation and 537 nm emission wavelengths. Experiments were performed in replicates 
of four, and the results are given as mean relative fluorescence intensity values +/- the 
standard deviation (SD), where intercalation of free siRNA represents 100 % fluorescence 
and non-intercalating SYBR® Gold in buffer represents 0 % remaining fluorescence.  
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Fluorescence Quenching Assay: 
To investigate the condensation efficiency of the polymers used in this study in a direct 
approach, 1 µg Tye563-labeled DsiRNA (IDT, Leuven, Belgium) was complexed with 
polymers at different N/P ratios and pipetted into opaque FluoroNunc™ 96 well plates 
(Nunc, Thermo Fisher Scientific, Langenselbold, Germany). Remaining fluorescence was 
quantified using a fluorescence plate reader (SAFIRE II, Tecan Group Ltd, Männedorf, 
Switzerland) at 549 nm excitation and 563 nm emission wavelengths. Experiments were 
performed in replicates of four, and the results are given as mean relative fluorescence 
intensity values +/- SD, where free siRNA represents 100 % fluorescence and polymer in 
buffer represents 0 % fluorescence.  
 
Circular Dichroism (CD): 
To investigate the complexation behavior of the different polymers and their effect on short 
RNA double strands, we employed circular dichroism spectroscopy, a method widely used 
in RNA analytics and lately described for characterization of siRNA complexes (20). 
Briefly, 2 nmol siRNA in 100 µl was mixed with 100 µl polymer solution to form 
complexes of different N/P ratio. The polyplexes were incubated for 10 minutes before they 
were diluted with 200 µl 10 mM HEPES buffer, pH 7.4 and pipetted into a 0.2 cm quartz 
cuvette. CD spectra were recorded on a Jasco J 810s spectropolarimeter (Jasco Labor- und 
Datentechnik GmbH, Groß-Umstadt, Germany) at 20 °C at a scanning speed of 200 
nm/min from 200 nm to 320 nm. As described in (20) the response time was 1 second, the 
bandwidth and data pitch 1 nm, and each spectrum was the accumulated from 5 scans.  
 
Stability of Polyplexes in the Presence of Mucin and Lung Surfactants: 
Stability of polyplexes was determined by release of siRNA from the complex upon 
interaction with mucin or Aleveofact®, respectively. Therefore, an assay similar to the 
SYBR® Gold dye binding assay was performed with all polyplexes formed at N/P 6. After 
polyplex formation, 50 µl of a 1x SYBR® Gold solution were added and incubated for 10 
minutes in the dark under constant shaking. Afterwards, increasing concentrations of mucin 
(mucin from porcine stomach Type II, Sigma-Aldrich Chemie Gmbh, München, Germany) 
or Alveofact® (Boehringer-Ingelheim, Germany), (0-0.33 µg/µl final concentration), 
respectively, were added and incubated with the polyplexes for another 20 minutes before 
fluorescence was quantified using a fluorescence plate reader (SAFIRE II, Tecan Group 
Ltd, Männedorf, Switzerland) at 495 nm excitation and 537 nm emission wavelengths. 
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Experiments were performed in replicates of four, and the results are given as mean relative 
fluorescence intensity values +/ SD, where free siRNA represents 100 % fluorescence and 
SYBR® Gold in buffer represents 0 % fluorescence.  
 
In vivo Biodistribution and Kinetics after Intratracheal Application:  
All animal experiments were carried out according to the German law of protection of 
animal life and were approved by an external review committee for laboratory animal care. 
Polymers and siRNA were radioactively labeled after coupling to p-Bn-SCN-DTPA as 
previously described (21, 22). Briefly, amine-modified siRNA or polymers, respectively, 
were mixed with p-Bn-SCN-DTPA at pH 8.5 and reacted for 45 minutes. Polymers were 
easily purified using centricon YM-10 spin columns (Millipore, Schwalbach, Germany), 
siRNA was precipitated in absolute ethanol and purified using RNeasy Mini columns 
(Qiagen, Hilden, Germany). DTPA-coupled polymers or siRNA were then incubated for 30 
minutes with 111InCl3 (Covidien Deutschland GmbH, Neustadt a.d. Donau, Germany) in 0.1 
M sodium acetate buffer, pH 5.4 for radiolabeling before siRNA was purified from free 
111InCl3 by size exclusion chromatography (SEC) on PD-10 Sephadex G25 (GE Healthcare, 
Freiburg, Germany) and RNeasy spin column purification, and polymers were purified by 
SEC only. 
Four to six week old BALB/c mice were anaesthetized with Xylacin/Ketamin and fixed in a 
supine position on a 60° incline board by holding their upper incisor teeth. The tongue was 
gently extended using coated tweezers as previously described (23). Mice were intubated 
through mouth and trachea using the flexible tube of a 24-gauge catheter (BD InsyteTM, 
Becton Dickinson GmbH, Heidelberg, Germany). Polyplexes prepared in PBS containing 
35 µg siRNA and the corresponding amount of polymer for N/P 6 were formed with either 
radiolabeled siRNA or radiolabeled polymers in order to differentiate between the 
biodistribution of vector and payload. Polyplexes were incubated for 10 minutes and 
instilled into the murine lungs through the BD InsyteTM tubus. Blood samples were 
withdrawn retroorbitally 1, 3, 5, 15, 30, 60, and 120 minutes after instillation. Three-
dimensional SPECT and planar gamma camera images were recorded 2, 24, and 48 hours 
after instillation using a Siemens e.cam gamma camera (Siemens AG, Erlangen, Germany) 
on which a custom built multiplexing multipinhole collimator was mounted. Planar images 
were analyzed for radioactivity in regions of interest (ROIs) by Syngo software (Syngo, 
Siemens Medical Solutions, Erlangen, Germany). Dual-isotope SPECT images were 
recorded 15 minutes after an additional tail vein injection of 4 MBq 99mTc-labeled macro-
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agglomerated albumin (MAA, Mallinkrodt, Hennef/Sieg, Germany). SPECT images were 
recorded for each isotope separately and later superimposed by the software (Syngo, 
Siemens Medical Solutions, Erlangen, Germany). After 48 hours, animals treated with 
111In-labeled polyplexes only were sacrificed and biodistribution of radiolabeled material in 
dissected organs was measured using a Gamma Counter Packard 5005 (Packard 
Instruments, Meriden, CT, USA). Radioactive decay of the isotope was factored in to the 
calculations and results are given as mean percentage of the injected dose (% ID). Control 
animals were either instilled with PBS only (PBS control) or were anaesthetized but not 
instilled (anaesthesia control) in order to assess stress levels caused by bolus instillation or 
anaesthesia, respectively.  
  
Broncho-Alveolar Lavage (BAL): 
Animals were sacrificed 48 hours after treatment. BAL was performed as previously 
described (24). Briefly, tracheae were cannulated using a BD InsyteTM catheter, lungs were 
rinsed ten times with 1 ml fresh PBS supplemented with cOmplete Protease Inhibitor 
Cocktail (Roche Diagnostics, Mannheim, Germany). BAL fluids of each animal were 
pooled, and the total number of leukocytes captured by lavage was determined using a Casy 
TT cell counter (Schaerfe Systems, Reutlingen, Germany). Aliquots of 100.000 cells were 
spun down on glass slides (100 x g, 5 min) to prepare cytospins, and BAL cells were 
stained for differentiation with Diff-Quick (DADE Diagnostics, Unterschleissheim, 
Germany). 100 cells were counted and classified concerning morphology and staining. 
Secretion of 22 pro- and anti-inflammatory cytokines was measured in cell-free BAL fluids 
by Luminex technology (Luminex System, Bio-Rad Laboratories, Germany) as previously 
described (25).  
 
Lung Histology: 
The influence of exposure of lung tissue to nanomaterials was also examined histologically. 
Therefore, lungs were inflated via the trachea with and after dissection fixed in a 4 % 
paraformaldehyde solution before they were paraffin-embedded. Paraffin sections (8 µm) 
were deparaffinized and stained with hematoxylin and eosin (H&E).  
 
In vivo Knock Down: 
Four to six week old C57BL/6-Tg(CAG-EGFP)1Osb/J mice were anaesthetized with 
Xylacin/Ketamine and fixed in a supine position and intubated as described above. 
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Polyplexes containing 50 µg siRNA and the corresponding amount of polymer PEI25k-
PEG(2k)10 for N/P 6 were formed in 5 % glucose solution (total volume per mouse: 50 µl), 
and instilled into murine lungs using the tubus. Control mice were treated with 5 % glucose 
only. Animals were sacrificed 5 days after instillation and lungs were inflated with 4 % 
paraformaldehyde, dissected and stored in 4 % paraformaldehyde in the dark, before they 
were embedded in paraffin. The deparaffinized slices (3 µm) were counterstained with 1 
µg/ml 4'6-diamidino-2-phenylindole (DAPI) (Molecular Probes, Invitrogen, Karlsruhe, 
Germany) solution in PBS for 30 minutes under light exclusion, and embedded with 
FluorSave (Calbiochem, Merck Biosciences, Darmstadt, Germany) to protect the 
fluorophores. 
 
Confocal Laser Scanning Microscopy (CLSM): 
A Zeiss Axiovert 100 M microscope coupled to a Zeiss LSM 510 scanning device (Zeiss, 
Oberkochen, Germany) was used for confocal microscopy. For excitation of EGFP 
fluorescence, an argon laser with an excitation wavelength of 488 nm was used. 
Fluorescence emission was detected using a 505 nm long-pass filter. Transmission images 
were obtained in the same scan. In a second scan of the multi-track image, DAPI was 
detected using a Coherent Enterprise II 653 laser (Coherent, Inc., Santa Clara, CA) with an 
excitation wavelength of 351 nm and a 385-470 nm bandpass emission filter. All confocal 
images were acquired with the same settings with respect to laser intensity, filter block, and 
detector gain. 
 
Flow Cytometric Quantification of Knock Down: 
C57BL/6-Tg(CAG-EGFP)1Osb/J mice were instilled as described above with 50 µg siRNA 
(either siEGFP targeting EGFP or siFLuc targeting firefly luciferase as negative control) 
complexed with PEI25k-PEG(2k)10 at N/P 6. As blanks, C57BL/6 mice not expressing 
EGFP were treated the same way. Animals were sacrificed 5 days after instillation, 
exsanguinated and perfused with PBS via the left ventricle. BAL was performed as 
described above before lungs were excised. Lung homogenates were obtained by 
incubating the excised lungs in 2 ml of a 1 mg/ml Collagenase D solution (Roche, 
Mannheim, Germany) at 37 °C for 20 minutes before processing the tissue through a nylon 
Cell Strainer 100 µm (BD Falcon, Heidelberg, Germany). Cells were then suspended in 10 
ml PBS, centrifuged at 350 g for 10 minutes. The supernatant was decanted, the cells were 
resuspended, once again centrifuged and resuspended in 500 µl CellFIX (BD Biosciences, 
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Heidelberg, Germany) for flow cytometry. The residual EGFP expression in the fixed cells 
was quantified on a FACScan (BD Biosciences, Heidelberg, Germany) flowcytometer with 
an excitation laser of 488 nm and an bandpass filter of 530/30 nm by counting 10,000 
events. Data acquisition and analysis was performed using CellQuest Pro (BD Biosciences, 
Heidelberg, Germany) and FCS Express V3.00 (DeNovo Software, Thornhill, Canada). 
Results are given as the average mean fluorescence intensity (MFI) ± SD of the gated viable 
cells. 
 
Statistics: 
All analytical assays were conducted in quadruple, and all in vivo experiments included 5 
animals per group. Results are given as mean values +/- standard deviation (SD). Two way 
ANOVA, statistical evaluation and calculation of the AUC was done using Graph Pad 
Prism 4.03 (Graph Pad Software, La Jolla, USA). 
7.4 Results and Discussion 
In our earlier study, we had shown that the polymers we used here were all able to condense 
siRNA into complexes of 150 nm hydrodynamic diameter (26). Zeta potentials were found 
to be positive (22 mV for PEI 25k) and slightly decreased for PEG-PEI complexes (15 and 
16 mV for PEI(25k)-PEG(2k)10 and PEI(25k)-PEG(20k)1, respectively). Stability against 
RNase degradation and competition with other polyanions has also been described (26), and 
serum stability of these complexes has been investigated by Fluorescence Fluctuation 
Spectroscopy in a later study 21.  In this study, we mainly focused on stability in biological 
fluids present in the lung such as mucin and surfactants, and we also quantified 
condensation efficiency of siRNA by the polymers used as follows:  
  
SYBR® Gold Dye Binding Assay: 
Condensation efficiency of the polymers considered the complexation of nucleic acids 
which are not accessible to intercalating dyes can be quantified in indirect approaches such 
as the ethidium bromide quenching assay (27). Due to the costs of siRNA, SYBR® Gold 
staining, which is 25-100 times more sensitive than ethidium bromide, is much more 
suitable and gives rise to sufficiently high signals in the micromolar range. In the assays we 
performed with 1 µg siRNA (59 pmol), we observed good condensation of siRNA even at 
low N/P ratios (Figure 1A).  Unmodified branched 25 kDa PEI showed full condensation at 
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N/P 1 already, whereas the condensation profiles of the PEGylated PEIs varied depending 
on their PEGylation pattern. PEI25k-PEG(20k)1 exhibited the worst condensation profile 
which corroborates our data obtained in polyacrylamide gel electrophoresis assays (data not 
shown). This polymer has also been reported to form polyplexes of low stability in the 
presence of serum (22). PEI25k-PEG(2k)10, on the other hand, showed only slight 
differences at N/P 1 compared to PEI 25k. The long PEG chain in PEI25k-PEG(20k)1 
seems to be disadvantageous for complex formation whereas a higher PEG density of short 
PEG chains affects complex formation only at low N/P ratios. Unmodified 21mer siRNA 
was shown to be fully condensed at N/P 3 with all of the polymers used in a recent study 
(26). Since gel electrophoresis utilized in the latter report is a more qualitative method, we 
cannot rule out that slight differences observed in the condensation behavior of unmodified 
versus 2’-OMe modified siRNA are significant. 
 
Fluorescence Quenching Assay: 
Another approach for investigating condensation efficiency is the use of assays involving 
directly labeled nucleic acids that do not require a staining step. Thus, we condensed 
fluorescently labeled siRNA of the same sequence at the same N/P ratios and the same 
concentrations as described above. This assay revealed a peculiarity that has previously 
been described by Van Rompaey et al (28) for oligonucleotide containing poly- and 
dendriplexes. Interestingly, each curve had a minimum of fluorescence at N/P 1, before 
fluorescence increased again upon increasing the N/P ratio (Figure 1B). Van Rompaey et al. 
have described this phenomenon as a reorganization of the polyplexes. They explained that 
at the minimum of fluorescence a large number of fluorescently labeled molecules are 
entrapped in one polyplex, quenching each other due to their close spatial proximity. At 
higher N/P ratios, polyplexes apparently do not “layer up”, forming additional layers of 
polymer on top of the polyplexes, but a redistribution of the number of nucleic acid 
molecules per polyplex occurs. Therefore, at higher N/P ratios, the number of labeled 
molecules that are present in one polyplex and trapped in close proximity is decreased, 
leading to less self-quenching and thus higher intensity fluorescence signals. Van Rompaey 
et al. had not described this finding for complexation of oligodeoxynucleotides by PEG-
PEI, but as previously reported by Glodde et al. (29), properties of complexes made of the 
same polymer but different types of nucleic acids may vary considerably. Our findings 
indicate that, independent of the polymer, at N/P 20 all polyplexes contained so little 
siRNA that almost no quenching could be observed, although the SYBR® Gold dye 
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binding assays proved that siRNA was entrapped and inaccessible for intercalation. 
Differences between the PEGylated polymers and unmodified PEI 25kDa were opposite to 
what has been described above concerning dye binding: PEI 25 kDa had the lowest 
quenching efficiency, whereas PEI25k-PEG(20k)1 decreased the fluorescence the most. 
Comparison of both, the indirect and the direct approach, exhibited properties of a dynamic 
polyplex – polymer equilibrium that reorganizes according to concentration changes and 
proved that polyplex formation is not a trivial process. Also the direct approach does not  
allow for prediction of condensation at a certain N/P ratio. Additionally, we have to keep in 
mind that by fluorescent labeling, the siRNA duplex is certainly affected in its chemical 
properties and might behave differently concerning complexation, even though 
functionality of the duplex is maintained.  
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Figure 1A: The SYBR® Gold Dye Binding Assay revealed very effective encapsulation 
and protection from intercalation of 2’-OMe DsiRNA. PEI 25 kDa showed the highest 
efficiency, followed by PEI25k-PEG(2k)10 and PEI25k-PEG(20k)1.  1B: The Dye 
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Quenching Assay using fluorescently labeled siRNA on the other hand demonstrated a 
phenomenon earlier described for oligodeoxyribonucleotides (28). Data obtained by this 
method therefore has to be interpreted critically. 
 
Circular Dichroism (CD): 
CD is traditionally used to investigate the tertiary structure of nucleic acids. Changes in the 
spectra can be caused by conformational changes, such as different base stacking which can 
be observed at the long-wavelength band (30), and changes at 210 nm which are attributed 
to backbone conformational transitions (31). Therefore, this method can also be utilized to 
investigate variations in the duplex structure caused by electrostatic interaction with 
polycations. In our study we observed different effects that varied for the three polymers 
investigated. In general, all spectra recorded had strong resemblance with the A-form of 
free double stranded RNA characterized by a C3'-endo conformation (32), which has also 
been confirmed for 2’-OMe RNA duplexes (33). One of the effects observed was that PEI 
25 kDa, even at low N/P ratios (N/P 1 and 3), caused a slightly decreased Cotton effect 
(molar ellipticity) at 264 nm compared to that of free siRNA (Figure 2A). Upon increasing 
the amount of polymer used for complexation (N/P 5-10), the Cotton effect at 264 nm was 
further decreased, but all spectra for N/P 10, 15, 20, 30, and 40 (N/P 30 and 40 not shown) 
were very similar, exhibiting a decreased degree of polarization at 264 nm, a very flat curve 
between 240 and 225 nm and a less negative and slightly red shifted peak at 210 nm. 
PEI25k-PEG(20k)1, on the other hand, showed a very strongly decreased Cotton effect at 
~265 nm at N/P 1 which was increased at N/P 3, 5, and 7 (Figure 2B). Complexation at N/P 
7 caused only a small decrease of polarization at 264 nm but an extremely flat curve 
between 240 and 225 nm and the strongest effects at 210 nm, where the slight minimum 
was red shifted. Upon increasing the N/P ratio, this effect was reversed. Curves at N/P 10, 
15, and 20 were very similar, as observed with PEI 25k. This again could be a sign of a 
reorganization process depending on polymer concentration, as observed in the dye 
quenching assay, with the strongest effects on backbone conformation (210 nm) observed at 
N/P 7. As shown in Figure 2 C, PEI25k-PEG(2k)10 caused a decreased Cotton effect at 264 
nm at all N/P ratios, and curves were similar from N/P 1 up to N/P 20 being comparable to 
the curves observed with PEI 25k. These findings indicated that all of our polymers did 
interact with siRNA leading to changes in backbone conformation and base stacking. The 
disappearance of the negative peak at 210 nm has, on the other hand, previously been 
attributed to high concentrations of PEG, due to an overlapping, positive CD band at shorter 
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wavelengths (34). But if PEG was the reason, the phenomenon would be accompanied by 
an up to 12.5 fold increase of the maximum at 264 nm shifted to 270 nm. Since this was not 
observed, but the negative peak also disappeared upon complexation with PEG-free PEI 25 
kDa, we hypothesize that it was caused by complexation dependent changes in the 
backbone conformation. In contrast to spermine, a tetravalent polycation which was 
reported to stabilize the A-form of dsRNA by increasing the intensity of the positive band at 
264 nm in a concentration range between N/P 1 and 10 (35), all of our polycations 
destabilized the base stacking of the siRNA. While the same report also described an 
increase of intensity of the negative band at 210 nm, Steely et al. explained that a decrease 
of intensity at 210 nm is related to condensation of dsRNA (36). In our study, we showed 
that while concentration dependent effects were different for each polymer, siRNA 
nucleobase stacking and backbone conformation were influenced upon complexation with 
each polymer at every single N/P ratio corroborating the results from the SYBR® Gold 
assay.  
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Figure 2: Circular dichroism (CD) spectroscopy emphasized differences in the 
condensation behavior of the various polymers. While PEI 25 kDa (A) showed increasing 
condensation with increasing polymer concentration, PEI25k-PEG(20k)1 (B) caused a 
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minimum of condensation at N/P 7, and PEI25k-PEG(2k)10 (C) had almost the same effect 
on siRNA at every N/P tested. 
 
Stability Assay in Presence of Mucin and Lung Surfactants: 
Stability of nanocarriers in biological fluids is a major limitation for systemic application 
and was found to be insufficient for PEI or PEG-PEI polyplexes (22). Due to decreased 
nuclease activity in the lung, even naked siRNA yielded successful knock down of gene 
expression (14, 37), but formulations of siRNA were expected to overcome several barriers 
present in the lung allowing reduction of the applied dose by increasing the active 
concentration in the cytosol, thus limiting adverse side effects. Before contact with the 
airway cell membranes occurs, however, nanocarriers need to penetrate the mucus layer, 
the surfactant layer, and the periciliary fluid layer covering the airway cells (38), all of 
which pose considerable biomechanical hurdles in pulmonary siRNA delivery. To 
investigate whether polyplexes could penetrate the airway lineaging fluids as intact 
nanocarriers, we performed SYBR® Gold staining assays in the presence of Alveofact® or 
mucin, respectively, to quantify the release of siRNA from polyplexes. Reduced stability of 
pDNA/PEI complexes compared to pDNA/TAT-PEG-PEI complexes were observed in 
presence of surfactant or BAL fluid 38, yet siRNA complexes showed different stability 
profiles. After an incubation period of 20 minutes, PEI complexes were more stable in the 
presence of surfactant or mucin than PEG-PEI complexes, as shown in Figure 3. Whilst PEI 
complexes released only 2.5 % of their payload in 0.33 mg/ml mucin and 1.0 % in 0.33 
mg/ml surfactant, PEI25k-PEG(20k)1 complexes were less stable and released 34.1 % and 
15.8 % in 0.33 mg/ml mucin and surfactant respectively. The PEI25k-PEG(2k)10 
complexes exhibited intermediate stability with release of 18.9 % and 5.0 % of their 
payload in 0.33 mg/ml mucin and surfactant respectively. The same trend had been shown 
earlier concerning stability in the presence of serum (22). Unmodified PEI formed the 
strongest complexes in terms of electrostatic interactions, while this interaction is decreased 
in PEGylated PEIs, where non-charged PEG chains are present which are hypothesized to 
hinder complex formation. In vivo, on the other hand, these electrostatically formed 
complexes can dissociate when high concentrations of competing polyanions are present. 
Further, it has to be noted that electrolyte complexes which are stable in vitro are not 
necessarily resistant to interaction with other charged components (39), while this is a 
property of sterically shielding complexes (29). 
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Figure 3: Stability of polyplexes in the presence of A: Mucin and B: Lung surfactant was 
the highest for unmodified PEI, followed by PEI25k-PEG(2k)1 and PEI25k-PEG(20k)1. 
This trend corroborates observations made in the presence of serum (22) but does not solely 
determine suitability for pulmonary application.  
 
In vivo Biodistribution and Kinetics after Intratracheal Application:  
As previously described (21, 40), radiolabeling nanocarriers with γ-emitters such as 111In 
enables non-invasive three-dimensional imaging. Dual-isotope SPECT imaging was applied 
to non-invasively prove instillation into the lungs in living animals by co-localization of  
111In-labeled nanocarriers and 99mTc-labeled macro-agglomerated albumin (MAA), which is 
routinely used in the clinics for lung perfusion imaging due to accumulation in airway 
capillaries (41). Since the SYBR® Gold assays had revealed good condensation and the dye 
quenching assay had proven sufficient loading in terms of molecules of siRNA per 
polyplex, an N/P 6 was chosen for in vivo application which had been well tolerated in 
studies where polyplexes were applied intravenously (21, 40). Dual-isotope SPECT, shown 
in Figure 4A, proved non-invasively by co-localization of the 99mTc signal (greyscale) and 
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the 111In signal (color) that the radiolabeled polyplexes were applied to the lungs. 
Interestingly, in some animals, a larger part of the dose was directed to the left lobe, which 
is also shown in Figure 4A, and depends on the position of the tubus during instillation and 
on the anatomy of the murine lung (42). Variations in airway branching patterns in 
mammals are known to contribute to differences in regional deposition in the lungs (43, 
44). Three-dimensional (3D) SPECT images of mice that were only treated with 111In-
labeled polyplexes (but not with MAA) were taken 2, 24, and 48 hours after instillation to 
monitor biodistribution and clearance of the applied polyplexes. As demonstrated in Figure 
4B, which shows a 6-week old balb/c mouse treated with siRNA/111In-DTPA-PEI25k-
PEG(2k)10 polyplexes, radioactive signal could still be observed in the mouth and the upper 
trachea 24 hours post treatment, and excretion via the kidneys was slightly visible. Another 
24 hours later (Figure 4C), radiolabeled material was obviously excreted via the kidneys, 
and liver deposition became slightly visible (See Supporting Information for 3D images). 
But the strongest signal was still observed in the lung; and only in the lower trachea 
radioactive material was still present. Labeled siRNA did not show accumulation in the 
kidneys but higher signals in the bladder and urine, as shown in Figure 5A. For more 
precise quantification, animals were sacrificed 48 hours post treatment, and organs were 
dissected for scintillation counting. Figure 5A only shows organs that demonstrated 
significant uptake. As already discussed for the 3D SPECT images, radioactive substance 
was still measurable in the trachea 48 hours after instillation. Interestingly, the residence 
time in the trachea decreased with PEGylation and was only detectable for polymers, not 
for siRNA. This can be explained by the interaction of the polymer with both mucus and 
cell surfaces, while siRNA was possibly released from the complex and was then most 
probably degraded and cleared from the trachea. As already discussed above, the deposition 
of instilled material depends strongly on the position of the tubus, the murine lung anatomy, 
and aerosolization would yield a more even distribution throughout the whole organ (42). 
Due to handling of radioactive materials, we decided to use instillation, which is a 
commonly used technique as well (2, 23, 37, 45). The disadvantages of liquid instillation 
are clearly local irritations evoked by intubation, the stress that the liquid bolus causes, of 
which an unknown amount may be coughed up or swallowed, and the non-uniform 
distribution due to the position of the application device in the trachea during delivery 
affecting the percentage of material deposited in the different lung lobes (46).  
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Figure 4A: Dual-Isotope SPECT Imaging of mice treated with 111In-labeled PEI25k-
PEG(2k)10/siRNA polyplexes and 99mTc-labeled MAA allowed for control of intratracheal 
application in the living animal. 4B: 3D-SPECT after 24 and 48 (Figure 4C) hours post 
instillation showed slow elimination of radiolabeled polymer via the kidneys and 
circumvention of the first pass effect. 
 
Especially in the group of mice treated with 111In-DTPA-PEI25k /siRNA, a strong 
discrepancy between deposition to the left and right lobes was observed, which was only 
minor in all other groups. Interestingly, unmodified PEI 25 kDa remained in the lung to the 
greatest extent of all compounds labeled (total left + right lobe: 25.7 % ID, compare Figure 
6B), while the two PEGylated polymers showed only about half the dose left after 48 hours. 
This again can be explained by stronger interaction of unmodified PEI with mucus and 
especially cell membranes which might cause sticking of the polymer. Another indication 
which corroborates this assumption is the fact that PEI25k-complexed siRNA did not 
remain in the lung to a greater extent than free siRNA. Apparently, 48 hours after 
Chapter 7 
 
202 
application, all siRNA complexed with PEI 25kDa was released from the polymer that 
possibly, after penetration of mucus, interacted strongly with cells and did not behave any 
differently from free siRNA. PEG-PEI/siRNA complexes, on the other hand, showed lower 
total retention but equivalent percentages of polymer and siRNA left after 48 hours. This let 
us hypothesize that PEG-PEI complexes were more stable after intratracheal application 
than PEI complexes, and this hypothesis will further be discussed below in the context of 
lung kinetics. Additionally to stability in vivo, another point that was crucial in our study 
was the circumvention of the first-pass effect, which is known to be fairly high for cationic 
carriers, due to rapid uptake by the reticulo-endothelial system (RES) (47). Here we showed 
that liver uptake, which was very prominent after i.v. injection of the same polyplexes (22), 
was strongly decreased to about 5 % ID of polymers and negligible amounts of siRNA. 
Interestingly, kidney accumulation of polymers increased with PEGylation, which was the 
other way round after systemic application (22). This surprising effect can be explained, 
though, by the large amount of unmodified PEI which remained in the lung and the lower 
systemic availability and renal excretion. Labeled siRNA, on the other hand did not 
accumulate in the kidneys but was found in the urine. This trend is fully in line with our 
earlier report that showed that (PEG)-PEI/siRNA polyplexes that reach the circulation 
dissociate, with the polymer accumulating in liver and kidneys and the siRNA being 
excreted  into the urine (22). Systemic availability of all labeled compounds was measured 
in blood samples collected over 2 hours post application. While earlier systemic availability 
of pulmonary applied nanoparticles was only attributed to phagocytosis by macrophages in 
the deep lung (48), translocation of inhaled particles is now being studied by several groups 
who have demonstrated transcytosis (49) or transport of systemically available particles into 
the brain via olfactory nerves after pulmonary application (50). One concern we thoroughly 
addressed in order to avoid misleading pharmacokinetic data, is purification of the labeled 
material. With our optimized 2-step purification procedure (21), we are able to ensure that 
no free radiometal ions are present in the complex solution. Free indium or DTPA-indium 
would not accumulate in the liver or kidneys either, so we are rather sure that the 
systemically available radioactivity was not free label. Systemically available free siRNA is 
known to be excreted faster than degraded (1), although it is possible that part of the signal 
in the urine was caused by degradation of nucleic acids. Full length siRNA can be re-
extracted from tissue, blood or urine samples and quantified, e.g. by autoradiography (51), 
which will be subject to a more thorough investigation which is currently underway. 
Although uptake of labeled siRNA into the circulation seemed to be very similar, no matter 
Chapter 7 
 
203 
which polymer was used for complexation (Figure 5B), calculation of the area under the 
curve (AUC) (Figure 5D) revealed following differences: Whilst PEI 25kDa complexed 
siRNA was available to the lowest extent in the first 20 minutes, which corroborates our 
data from the stability assay, the release of siRNA seemed to be delayed, and systemic 
availability surpassed that of free siRNA 1 hour after administration. PEG-PEI complexed 
siRNA, on the other hand, exhibited higher initial blood concentrations, according to their 
stability profiles shown in Figure 3, which did not further increase but even decreased in the 
case of PEI25k-PEG(2k)10 complexed siRNA. The decrease in systemic availability can 
easily be explained by extensive excretion into the urine, as shown in Figure 5A. Polymers 
that were endocytosed or transcytosed from the lung were deposited in the liver and kidneys 
to a greater extent than their payload, as demonstrated in Figure 5A. This also revealed 
shorter circulation and lower AUC values. PEI 25kDa, which was strongly retained in the 
lung, was only to a low extent taken up into circulation. The decrease in blood levels after 1 
hour post application can be attributed to liver and kidney accumulation. PEI25k-
PEG(20k)1 showed increasing systemic availability over 20 minutes post instillation 
followed by a steady state concentration. This polymer, equipped with one long PEG chain, 
is possibly least prone to recognition by liver macrophages or interaction with the cationic 
basal membrane in the kidneys. The systemic concentration of PEI25k-PEG(2k)10 
increased more slowly but was also followed by a steady state concentration after 1 hour 
post application. The lower AUC and the slower increase of blood levels can be explained 
by stronger liver and kidney accumulation shown in Figure 5A and Figures 4B and 4C. 
Overall, AUC values of polymers were significantly lower than those of siRNA (**p< 0.01, 
Figure 5D). No differences were observed amongst the different polymers, but differences 
were more striking concerning siRNA. Due to the strong increase in blood levels of PEI 
25kDa complexed siRNA after 20 minutes post application, AUC of free and PEI 25 kDa 
complexed siRNA were not significantly different. The AUC of PEI25k-PEG(20k)1 
complexed siRNA was not significantly lower, whereas the decreased AUC of the PEI25k-
PEG(2k)10 complexed siRNA was significant (*p< 0.05, Figure 5D), which was certainly 
an effect of excretion and stronger initial stability of the complexes, as also demonstrated in 
Figure 1B.  
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Figure 5A: Biodistribution of radiolabeled polymeric vectors and their payload measured 
in dissected organs 48 hours post instillation revealed that the highest signals were still 
found in the lungs, whereas liver deposition of polymers was about 5 % ID and siRNA was 
rather excreted than accumulated. 5B: Systemic bioavailability of labeled siRNA 
complexed with PEI 25 kDa increased strongly 30 minutes post instillation, while PEG-PEI 
complexed siRNA showed higher blood levels immediately after application and did not 
further increase or even decreased over time. 5C: Radiolabeled polymers were retained 
stronger in the lung (PEI 25 kDa) or accumulated slightly in the kidneys (PEG-PEIs) and 
showed lower blood levels than siRNA. 5D: AUC values of labeled polymers were 
accordingly significantly (**p<0.01) lower than those of labeled siRNA. PEI25k-
PEG(2k)10 complexed siRNA also exhibited a lower AUC value, caused by excretion to 
the urine. 
 
While endpoint scintillation counting of dissected lungs only revealed residual 
concentration after sacrifice of the animals (Figure 5A), SPECT and planar gamma camera 
imaging enabled non-invasive imaging and quantification of the retention of radiolabeled 
material in the same animal over time. Scintillation counting analysis suggested that 
complexation of siRNA with PEI 25kDa did not provide any benefit over application of 
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free siRNA. If considering the kinetics of residual radioactivity in the lung over time, the 
picture looks a bit different: Although in the stability assay PEI complexes seemed to be 
most stable, it certainly has to be acknowledged that stability over time, and especially in 
high ionic strength solutions, might be lower than in the in vitro assay. We already 
discussed increasing blood levels of PEI 25 kDa complexed siRNA after 20 minutes post 
instillation, letting us assume that the polyplexes were stable in the presence of mucus and 
surfactant, but the release of siRNA obviously occurred to a later time point – possibly 
when polyplexes reached the cells and strongly interacted with cell surfaces. The analysis 
of radioactivity signals in the lungs taken by planar gamma camera imaging and analysis of 
ROIs, very well corroborated this assumption (Figure 6A). Whereas the amount of 
radioactively labeled PEI 25 kDa decreased slowly over 48 hours, that of PEI 25 kDa 
complexed siRNA decreased more rapidly than PEG-PEI complexed siRNA. The curves 
for PEG-PEI polymer and the corresponding payload showed very similar behavior. The 
analysis of three time points certainly can not be considered a pharmacokinetic study, but as 
shown in Figure 6B, data acquired in the imaging approach coincides well enough with that 
obtained from dissected organs to make a non-invasive prediction of the retention of labeled 
material in the lung. Most importantly, we were able to prove our assumption that PEG-
PEI/siRNA complexes are more suitable for lung application than PEI/siRNA complexes 
concerning protection of siRNA and residing times in the lung.  
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Figure 6A: Kinetic profiles of radioactively labeled compounds in the lungs over 48 hours 
acquired by planar gamma camera imaging. 6B: Comparison of data obtained by non-
invasive imaging and scintillation counting of residual radioactivity in the lungs 48 hours 
post instillation. 
 
Broncho-Alveolar Lavage:  
Since there are various reports in the literature stating that cationic lipids used for 
pulmonary gene delivery result in immune and cytokine responses in mice (52-55), whereas 
aerosol delivery of PEI/DNA complexes did not induce high levels of cytokines (56), we 
investigated the effect of our siRNA loaded nanocarriers. Interestingly, as shown in Figure 
7, our PEI/siRNA complexes had the lowest proinflammatory effect, whereas PEI25k-
PEG(20k)1 complexes caused a 13-fold increase of CXCL1 (53.2pg/ml±53.3 vs. 4.1 
pg/ml±2.6), 2-fold elevated levels of IL-6 (4.9pg/ml 2.2 vs. 2.3pg/ml±0.8) and a 2.5-fold 
increase of TNF-α (4.5pg/ml±2.5 vs. 2.1pg/ml±0.2)  in the BALF. PEI(25)-PEG(2k)10 
complexes caused a 1.5-fold increase of CXCL1 (21.4pg/ml±13.8 vs. 4.1 pg/ml±2.6), a 3-
fold increase of IL-6 (7.5pg/ml±3.8 vs. 2.3pg/ml±0.8) and a 2.5-fold increase of TNF-
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α levels (5.2pg/ml±5.5  vs. 2.1pg/ml±0.2). In addition to the acute phase cytokines 
response, the release of granulocyte-colony stimulating factor (G-CSF) and the interferon-γ 
inducible protein 10 (CXCL10) was more than ten times elevated for PEI(25)-PEG(2)10 
compared to control (1x PBS treated mice), G-CSF (46.3pg/ml±54.0 vs. 3.1pg/ml±0.7) and   
CXCL10 (16.2pg/ml±16.7  vs. 2.8pg/ml±1.6). The PEGylated nanocarriers were therefore 
considered to have a moderate proinflammatory effect which was more prominent for 
PEI(25)-PEG(2)10. Concerning differential analysis of BAL cells, the two PEG-modified 
PEI nanocarriers caused more than 20 % recruitment of polymorphonuclear neutrophilic 
granulocytes (PMN), which is regarded as a hallmark of lung inflammation especially for 
the 48h response (data not shown). While BAL cells of mice treated with PEI 
25kDa/siRNA polyplexes were exclusively macrophages, in accordance to our cytokine 
profile, where we could not detect elevated levels of acute phase cytokines could.  It has to 
be remarked, though, that BAL was performed 48 hours post instillation, but cytokine 
levels in the BALF were reported to peak at 24 h after PEI/DNA aerosol exposure (56). A 
kinetic analysis as performed in the latter report will be part of our kinetic study concerning 
gene silencing. 
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Figure 7 A-F: Cytokine release in BALF 48h after intratracheal instillation of siRNA 
polyplexes. Data represent mean ± SD (n=8 for treatment with PEI polyplexes, n= 4 for 
controls (free siRNA and 1xPBS); significantly increased cytokine levels compared to 
control (1xPBS) were marked with an asterisk (*p<0.05). 
 
Lung Histology: 
Whilst nanomedicine is an emerging and promising field, possible health risks need to be 
considered as well. Application of nanomaterials to the lung often evokes an allusion to the 
effects of asbestos fibers on lung tissue. Indeed, also carbon black nanoparticles have been 
shown to bear health risks by interfering with cell signaling (57). The airways are a 
relatively robust barrier, being protected by a viscous layer of mucus and equipped with an 
Chapter 7 
 
209 
effective clearance mechanism, but alveoli are presumably more prone to damage. In the 
alveolar region, macrophage phagocytosis is the main mechanism of clearance, but nano-
sized particles are designed not to be recognized by alveolar macrophages, which possibly 
might increase their irritating or toxic effects. In the case of positively charged particles, 
interaction with and toxic effects on cell membranes are well known and studied (58). 
Concerning lung toxicity, it has been shown that the three-dimensional structure and 
flexibility of the macromolecules has a strong impact on accessibility of charges and thus 
on their cytotoxic profiles (59). In order to study the impact of our nanocarriers, which have 
already been characterized for in vitro toxicity (Beyerle et al, in preparation), on lung tissue 
in vivo, we fixed dissected lungs in paraformaldehyde and analyzed paraffin sections after 
H&E staining. As demonstrated in Figure 8, we did not observe indications of inflammation 
in any of the lungs investigated at the light microscopic level. It has to be acknowledged 
though, that chronic effects cannot be precluded based on a single application and 
observation for just 48 hours. 
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Figure 8: Light microscopy dislosed normal lung tissue. The bronchiolar and alveolar 
epithelium appeared normal and the interstitium and alveolar lumina showed no 
inflammation.  
 
In vivo Knock Down: 
In order to confirm that intratracheal siRNA delivery leads to effective intracellular siRNA 
concentration and functional activity, we treated actin-EGFP expressing mice with 
polyplexes containing 50 µg of anti-EGFP siRNA. This dose has been reported to be 
efficient in down regulation of EGFP in the same mouse strain after high pressure tail vein 
(HPTV) injection (60), and is below the dose that has been reported to be effective after 
intratracheal instillation (45). Due to the sustained retention of the polyplexes in the lung, 
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mice were sacrificed 5 days after instillation, and lungs were paraffin embedded after 
fixation in paraformaldehyde. In a preliminary study (data not shown) we compared 
fluorescence of paraffin sections to cryo sections in order to check on any adverse effects of 
paraformaldehyde or paraffin on fluorescence intensity. Neither revealed disadvantages, but 
cells in paraffin sections retained their morphology much better than those in cryo sections 
which encouraged us to embed all lungs for this study in paraffin. CLSM allowed us to 
qualitatively investigate the effects of anti-EGFP siRNA on the expression of EGFP. Figure 
9A shows a bronchiolus of an untreated actin-EGFP mouse, where especially type II 
pneumocytes, but also all surrounding cells exhibit high fluorescence intensity. In the 
siRNA-treated mouse, fluorescence intensity in the bronchial cells seemed to be decreased 
(Figure 9B), and the effect becomes more apparent in the alveolar cells of non-treated 
(Figure 9C) versus treated animals (Figure 9D). Although we are well aware that this 
microscopic indication needs to be quantified in order to test the hypothesis, at this point we 
can safely assume that polyplexes reached the alveoli after instillation and are taken up into 
alveolar tissue where they are released into the cytosol in sufficient concentration for 
functional activity. In a first approach to quantify the knock down of EGFP expression, we 
have treated EGFP-expressing mice with PEG-PEI complexed specific (siEGFP) and non-
specific (siFLuc) siRNA and measured EGFP in total lung homogenates. EGFP expression 
was found to be 42 % knocked down compared to siFLuc-treated animals and thereby 
significantly (*p < 0.05) reduced, and not significantly different from animals that do not 
express EGFP at all but only show autofluorescence of macrophages (p > 0.05).  A 
thorough follow-up study investigating the time-course and dose-dependency of polyplexes 
made of the different polymers and the fractionation of lung homogenates into different 
populations of cells will provide more details. 
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Figure 9: Knock down in actin-EGFP mice. A: Bronchiolus of a control EGFP-mouse 
displaying high fluorescence intensity. 9B: Bronchiolus of a PEI25k-PEG(2k)10/siRNA 
treated EGFP-mouse displaying lower fluorescence intensity. 9C: Alveolar epithelium of a 
control EGFP-mouse displaying high fluorescence intensity. 9D: Alveolar epithelium of a 
PEI25k-PEG(2k)10/siRNA treated EGFP-mouse displaying almost complete loss of 
fluorescence signal.9E: Knock down in actin-EGFP mice compared to non-EGFP-
expressing mice (blank). EGFP-expression in lungs of siEGFP/PEI(25k)-PEG(2k)10 treated 
mice was down regulated by 42 % and is significantly (p<0.05) lower than in mice treated 
with  siFLuc/PEI(25k)-PEG(2k)10. 
7.5 Conclusion 
In conclusion, we have shown that 25/27mer partial 2’-OMe modified DsiRNA can be 
efficiently condensed with PEI and PEG-PEI. From our direct condensation assay we have 
learned that this type of experiment reveals data that has to be critically interpreted. We 
have disclosed that PEI/siRNA polyplexes are more stable than PEG-PEI/siRNA 
polyplexes over 20 minutes in the presence of mucin or surfactant under in vitro conditions. 
By comparison of planar imaging with conventional scintillation counting techniques, we 
showed that for the understanding of the behavior of nanocarriers in vivo, simple endpoint 
measurements are insufficient. While data obtained by both methods coincided well, 3D 
and planar imaging enabled tracking the biodistribution over time. Although PEI/siRNA 
complexes seemed to be most stable in the in vitro stability assays, their in vivo 
performance was poor with PEI being left in the lungs and the siRNA payload released and 
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excreted. Despite of their slightly higher proinflammatory potential, we favored PEG-
PEI/siRNA complexes for investigation of functional gene silencing activity in vivo for 
sustained release reasons and were able to report indications of success with no histological 
abnormality detected. These results are very encouraging for further investigation and 
quantification of in vivo gene silencing in the lung after intratracheal instillation of PEG-
PEI/siRNA complexes.  
7.6 Acknowledgements 
We are grateful to Prof. Renz and Dr. Garn (Department of Clinical Chemistry, Philipps-
Universität Marburg) for the generous use of equipment and facilities, to Viktoria Morokina 
(Department of Pathology, University Hospital Giessen-Marburg) and Klaus Keim 
(Department of Pharmaceutics and Biopharmacy, Philipps Universität Marburg) for 
excellent technical support and to Thomas Carlsson (Department of Experimental 
Neurology, Philipps Universität Marburg) for supplying us with Actin-GFP expressing 
mice. Deutsche Forschungsgemeinschaft (DFG Forschergruppe 627), MEDITRANS, an 
Integrated Project funded by the European Commission under the Sixth Framework 
(NMP4-CT-2006-026668), and the German Lung Foundation (Deutsche Lungenstiftung 
e.V.) are gratefully acknowledged. 
7.7 References 
(1) Dykxhoorn, D. M., Palliser, D., and Lieberman, J. (2006) The silent treatment: 
siRNAs as small molecule drugs. Gene Ther 13, 541-52. 
(2) Garbuzenko, O. B., Saad, M., Betigeri, S., Zhang, M., Vetcher, A. A., Soldatenkov, 
V. A., Reimer, D. C., Pozharov, V. P., and Minko, T. (2009) Intratracheal versus 
intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer 
drug. Pharm Res 26, 382-94. 
(3) Chandy, D., Maguire, G., and Aronow, W. S. (2009) Lung cancer: the importance 
of early intervention. Compr Ther 35, 18-23. 
(4) Centre, W. M. (2008) in Fact Sheet N°310, World Health Organization, Geneva. 
(5) Zhang, W., and Tripp, R. A. (2008) RNA interference inhibits respiratory syncytial 
virus replication and disease pathogenesis without inhibiting priming of the memory 
immune response. J Virol 82, 12221-31. 
Chapter 7 
 
214 
(6) Bitko, V., Musiyenko, A., Shulyayeva, O., and Barik, S. (2005) Inhibition of 
respiratory viruses by nasally administered siRNA. Nat Med 11, 50-5. 
(7) Kwok, T., Helfer, H., Alam, M. I., Heinrich, J., Pavlovic, J., and Moelling, K. 
(2009) Inhibition of influenza A virus replication by short double-stranded 
oligodeoxynucleotides. Arch Virol 154, 109-14. 
(8) Hammond, S. M., Boettcher, S., Caudy, A. A., Kobayashi, R., and Hannon, G. J. 
(2001) Argonaute2, a link between genetic and biochemical analyses of RNAi. 
Science 293, 1146-50. 
(9) Kim, D. H., Behlke, M. A., Rose, S. D., Chang, M. S., Choi, S., and Rossi, J. J. 
(2005) Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat 
Biotechnol 23, 222-6. 
(10) Manoharan, M. (2004) RNA interference and chemically modified small interfering 
RNAs. Curr Opin Chem Biol 8, 570-9. 
(11) Geary, R. S., Watanabe, T. A., Truong, L., Freier, S., Lesnik, E. A., Sioufi, N. B., 
Sasmor, H., Manoharan, M., and Levin, A. A. (2001) Pharmacokinetic properties of 
2'-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. J Pharmacol Exp 
Ther 296, 890-7. 
(12) Judge, A. D., Robbins, M., Tavakoli, I., Levi, J., Hu, L., Fronda, A., Ambegia, E., 
McClintock, K., and MacLachlan, I. (2009) Confirming the RNAi-mediated 
mechanism of action of siRNA-based cancer therapeutics in mice. J Clin Invest 119, 
661-73. 
(13) Sioud, M., Furset, G., and Cekaite, L. (2007) Suppression of immunostimulatory 
siRNA-driven innate immune activation by 2'-modified RNAs. Biochem Biophys 
Res Commun 361, 122-6. 
(14) Zhang, X., Shan, P., Jiang, D., Noble, P. W., Abraham, N. G., Kappas, A., and Lee, 
P. J. (2004) Small interfering RNA targeting heme oxygenase-1 enhances ischemia-
reperfusion-induced lung apoptosis. J Biol Chem 279, 10677-84. 
(15) Massaro, D., and Massaro, G. D. (2004) Critical period for alveologenesis and early 
determinants of adult pulmonary disease. Am J Physiol Lung Cell Mol Physiol 287, 
L715-7. 
(16) Kong, X., Zhang, W., Lockey, R. F., Auais, A., Piedimonte, G., and Mohapatra, S. 
S. (2007) Respiratory syncytial virus infection in Fischer 344 rats is attenuated by 
short interfering RNA against the RSV-NS1 gene. Genet Vaccines Ther 5, 4. 
Chapter 7 
 
215 
(17) Tompkins, S. M., Lo, C. Y., Tumpey, T. M., and Epstein, S. L. (2004) Protection 
against lethal influenza virus challenge by RNA interference in vivo. Proc Natl 
Acad Sci U S A 101, 8682-6. 
(18) Petersen, H., Fechner, P. M., Fischer, D., and Kissel, T. (2002) Synthesis, 
Characterization, and Biocompatibility of Polyethylenimine-graft-poly(ethylene 
glycol) Block Copolymers. Macromolecules 35, 6867-6874. 
(19) Rose, S. D., Kim, D. H., Amarzguioui, M., Heidel, J. D., Collingwood, M. A., 
Davis, M. E., Rossi, J. J., and Behlke, M. A. (2005) Functional polarity is 
introduced by Dicer processing of short substrate RNAs. Nucleic Acids Res 33, 
4140-56. 
(20) Breunig, M., Hozsa, C., Lungwitz, U., Watanabe, K., Umeda, I., Kato, H., and 
Goepferich, A. (2008) Mechanistic investigation of poly(ethylene imine)-based 
siRNA delivery: disulfide bonds boost intracellular release of the cargo. J Control 
Release 130, 57-63. 
(21) Merkel, O. M., Librizzi, D., Pfestroff, A., Schurrat, T., Behe, M., and Kissel, T. 
(2009) In vivo SPECT and real-time gamma camera imaging of biodistribution and 
pharmacokinetics of siRNA delivery using an optimized radiolabeling and 
purification procedure. Bioconjug Chem 20, 174-82. 
(22) Merkel, O. M., Librizzi, D., Pfestroff, A., Schurrat, T., Buyens, K., Sanders, N. N., 
De Smedt, S. C., Behe, M., and Kissel, T. (2009) Stability of siRNA polyplexes 
from poly(ethylenimine) and poly(ethylenimine)-g-poly(ethylene glycol) under in 
vivo conditions: Effects on pharmacokinetics and biodistribution measured by 
Fluorescence Fluctuation Spectroscopy and Single Photon Emission Computed 
Tomography (SPECT) imaging. J Control Release. 
(23) Yu, H., Buff, S. M., Baatz, J. E., and Virella-Lowell, I. (2008) Oral instillation with 
surfactant phospholipid: a reliable alternative to intratracheal injection in mouse 
studies. Lab Anim 42, 294-304. 
(24) Herz, U., Braun, A., Ruckert, R., and Renz, H. (1998) Various immunological 
phenotypes are associated with increased airway responsiveness. Clin Exp Allergy 
28, 625-34. 
(25) Prabhakar, U., Eirikis, E., Reddy, M., Silvestro, E., Spitz, S., Pendley, C., 2nd, 
Davis, H. M., and Miller, B. E. (2004) Validation and comparative analysis of a 
multiplexed assay for the simultaneous quantitative measurement of Th1/Th2 
Chapter 7 
 
216 
cytokines in human serum and human peripheral blood mononuclear cell culture 
supernatants. J Immunol Methods 291, 27-38. 
(26) Mao, S., Neu, M., Germershaus, O., Merkel, O., Sitterberg, J., Bakowsky, U., and 
Kissel, T. (2006) Influence of Polyethylene Glycol Chain Length on the 
Physicochemical and Biological Properties of Poly(ethylene imine)-graft-
Poly(ethylene glycol) Block Copolymer/SiRNA Polyplexes. Bioconjug Chem 17, 
1209-18. 
(27) Germershaus, O., Mao, S., Sitterberg, J., Bakowsky, U., and Kissel, T. (2008) Gene 
delivery using chitosan, trimethyl chitosan or polyethylenglycol-graft-trimethyl 
chitosan block copolymers: establishment of structure-activity relationships in vitro. 
J Control Release 125, 145-54. 
(28) Van Rompaey, E., Engelborghs, Y., Sanders, N., De Smedt, S. C., and Demeester, 
J. (2001) Interactions between oligonucleotides and cationic polymers investigated 
by fluorescence correlation spectroscopy. Pharm Res 18, 928-36. 
(29) Glodde, M., Sirsi, S. R., and Lutz, G. J. (2006) Physiochemical properties of low 
and high molecular weight poly(ethylene glycol)-grafted poly(ethylene imine) 
copolymers and their complexes with oligonucleotides. Biomacromolecules 7, 347-
56. 
(30) Gray, D. (1996) Circular Dichroism of Protein - Nucleic Acid Interactions, in 
Circular Dichroism and the Conformational Analysis of Biomolecules (The 
Language of Science) (Fasman, G., Ed.) pp 469-500, Plenum Press, New York. 
(31) Woody, R. W. (1995) Circular dichroism. Methods Enzymol 246, 34-71. 
(32) Saenger, W. (1984) Principles of Nucleic Acid Structure, Springer-Verlag, Berlin. 
(33) Inoue, H., Hayase, Y., Imura, A., Iwai, S., Miura, K., and Ohtsuka, E. (1987) 
Synthesis and hybridization studies on two complementary nona(2'-O-
methyl)ribonucleotides. Nucleic Acids Res 15, 6131-48. 
(34) Evdokimov, Y. M., Pyatigorskaya, T. L., Polyvtsev, O. F., Akimenko, N. M., 
Kadykov, V. A., Tsvankin, D. Y., and Varshavsky, Y. M. (1976) A comparative X-
ray diffraction and circular dichroism study of DNA compact particles formed in 
water-salt solutions, containing poly(ethylene glycol). Nucleic Acids Res 3, 2353-
66. 
(35) Minyat, E. E., Ivanov, V. I., Kritzyn, A. M., Minchenkova, L. E., and Schyolkina, 
A. K. (1979) Spermine and spermidine-induced B to A transition of DNA in 
solution. J Mol Biol 128, 397-409. 
Chapter 7 
 
217 
(36) Steely, H. T., Jr., Gray, D. M., and Lang, D. (1986) Study of the circular dichroism 
of bacteriophage phi 6 and phi 6 nucleocapsid. Biopolymers 25, 171-88. 
(37) Li, B. J., Tang, Q., Cheng, D., Qin, C., Xie, F. Y., Wei, Q., Xu, J., Liu, Y., Zheng, 
B. J., Woodle, M. C., Zhong, N., and Lu, P. Y. (2005) Using siRNA in prophylactic 
and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat Med 
11, 944-51. 
(38) Rubin, B. K. (2002) Physiology of airway mucus clearance. Respir Care 47, 761-8. 
(39) Burke, R. S., and Pun, S. H. (2008) Extracellular barriers to in Vivo PEI and 
PEGylated PEI polyplex-mediated gene delivery to the liver. Bioconjug Chem 19, 
693-704. 
(40) Merkel, O., Librizzi, D., Pfestroff, A., Schurrat, T., Buyens, K., Sanders, N., De 
Smedt, S. C., Behe, M., and Kissel, T. (2009) Stability of siRNA polyplexes from 
poly(ethylenimine) and poly(ethylenimine)-g-poly(ethylene glycol) under in vivo 
conditions: Effects on pharmacokinetics and biodistribution measured by 
Fluorescence Fluctuation Spectroscopy and Single Photon Emission Computed 
Tomography (SPECT) imaging. Journal of Controlled Release. 
(41) Shih, W. J., Robinson, M. C., Huber, C., and Pulmano, C. (1995) Tc-99m MAA 
lung perfusion scintigraphy performed before and after pulmonary embolectomy for 
saddle-type pulmonary embolism. Clin Nucl Med 20, 128-31. 
(42) Cryan, S. A., Sivadas, N., and Garcia-Contreras, L. (2007) In vivo animal models 
for drug delivery across the lung mucosal barrier. Adv Drug Deliv Rev 59, 1133-51. 
(43) Esch, J. L., Spektor, D. M., and Lippmann, M. (1988) Effect of lung airway 
branching pattern and gas composition on particle deposition. II. Experimental 
studies in human and canine lungs. Exp Lung Res 14, 321-48. 
(44) Spektor, D. M., Hunt, P. R., Rosenthal, F., and Lippmann, M. (1985) Influence of 
airway and airspace sizes on particle deposition in excised donkey lungs. Exp Lung 
Res 9, 363-87. 
(45) Lomas-Neira, J. L., Chung, C. S., Wesche, D. E., Perl, M., and Ayala, A. (2005) In 
vivo gene silencing (with siRNA) of pulmonary expression of MIP-2 versus KC 
results in divergent effects on hemorrhage-induced, neutrophil-mediated septic 
acute lung injury. J Leukoc Biol 77, 846-53. 
(46) Burnell, P. K. P., Kidger, J., Gascoigne, M., and Kotzer, C. (2006) Powder 
deposition in rats assessed in vivo and in silico, in Respiratory Drug Delivery X 
Chapter 7 
 
218 
(Dalby, R. N., Byron, P. R., Peart, J., Suman, J., and Farr, S., Eds.) pp 625–627, 
Davis Healthcare International Publishing, LCC, River Grove, IL. 
(47) Fenske, D. B., MacLachlan, I., and Cullis, P. R. (2001) Long-circulating vectors for 
the systemic delivery of genes. Curr Opin Mol Ther 3, 153-8. 
(48) Nemmar, A., Vanbilloen, H., Hoylaerts, M. F., Hoet, P. H., Verbruggen, A., and 
Nemery, B. (2001) Passage of intratracheally instilled ultrafine particles from the 
lung into the systemic circulation in hamster. Am J Respir Crit Care Med 164, 
1665-8. 
(49) Kato, T., Yashiro, T., Murata, Y., Herbert, D. C., Oshikawa, K., Bando, M., Ohno, 
S., and Sugiyama, Y. (2003) Evidence that exogenous substances can be 
phagocytized by alveolar epithelial cells and transported into blood capillaries. Cell 
Tissue Res 311, 47-51. 
(50) Oberdorster, G., Sharp, Z., Atudorei, V., Elder, A., Gelein, R., Lunts, A., Kreyling, 
W., and Cox, C. (2002) Extrapulmonary translocation of ultrafine carbon particles 
following whole-body inhalation exposure of rats. J Toxicol Environ Health A 65, 
1531-43. 
(51) Malek, A., Merkel, O., Fink, L., Czubayko, F., Kissel, T., and Aigner, A. (2009) In 
vivo pharmacokinetics, tissue distribution and underlying mechanisms of various 
PEI(-PEG)/siRNA complexes. Toxicol Appl Pharmacol 236, 97-108. 
(52) Li, S., Wu, S. P., Whitmore, M., Loeffert, E. J., Wang, L., Watkins, S. C., Pitt, B. 
R., and Huang, L. (1999) Effect of immune response on gene transfer to the lung via 
systemic administration of cationic lipidic vectors. Am J Physiol 276, L796-804. 
(53) Freimark, B. D., Blezinger, H. P., Florack, V. J., Nordstrom, J. L., Long, S. D., 
Deshpande, D. S., Nochumson, S., and Petrak, K. L. (1998) Cationic lipids enhance 
cytokine and cell influx levels in the lung following administration of plasmid: 
cationic lipid complexes. J Immunol 160, 4580-6. 
(54) Freimark, B. D., Blezinger, H. P., Florack, V. J., Nordstrom, J. L., Long, S. D., 
Deshpande, D. S., Nochumson, S., and Petrak, K. L. (1998) Cationic Lipids 
Enhance Cytokine and Cell Influx Levels in the Lung Following Administration of 
Plasmid: Cationic Lipid Complexes. J Immunol 160, 4580-4586. 
(55) Li, S., Wu, S.-P., Whitmore, M., Loeffert, E. J., Wang, L., Watkins, S. C., Pitt, B. 
R., and Huang, L. (1999) Effect of immune response on gene transfer to the lung via 
systemic administration of cationic lipidic vectors. Am J Physiol Lung Cell Mol 
Physiol 276, L796-804. 
Chapter 7 
 
219 
(56) Gautam, A., Densmore, C. L., and Waldrep, J. C. (2001) Pulmonary cytokine 
responses associated with PEI-DNA aerosol gene therapy. Gene Ther 8, 254-7. 
(57) Brown, D. M., Donaldson, K., Borm, P. J., Schins, R. P., Dehnhardt, M., Gilmour, 
P., Jimenez, L. A., and Stone, V. (2004) Calcium and ROS-mediated activation of 
transcription factors and TNF-alpha cytokine gene expression in macrophages 
exposed to ultrafine particles. Am J Physiol Lung Cell Mol Physiol 286, L344-53. 
(58) Hong, S., Leroueil, P. R., Janus, E. K., Peters, J. L., Kober, M. M., Islam, M. T., 
Orr, B. G., Baker, J. R., Jr., and Banaszak Holl, M. M. (2006) Interaction of 
polycationic polymers with supported lipid bilayers and cells: nanoscale hole 
formation and enhanced membrane permeability. Bioconjug Chem 17, 728-34. 
(59) Singh, A. K., Kasinath, B. S., and Lewis, E. J. (1992) Interaction of polycations 
with cell-surface negative charges of epithelial cells. Biochim Biophys Acta 1120, 
337-42. 
(60) Wesche-Soldato, D. E., Chung, C. S., Lomas-Neira, J., Doughty, L. A., Gregory, S. 
H., and Ayala, A. (2005) In vivo delivery of caspase-8 or Fas siRNA improves the 
survival of septic mice. Blood 106, 2295-301. 
  
220 
8 Off-target effects in non-viral siRNA delivery – A study on the 
effect of polymer genomics on in vitro cell culture models 
 
In Preparation for the Journal of Controlled Release 
Chapter 8 
221 
8.1 Abstract 
Since off-target effects in non-viral siRNA delivery are common but not well understood, in 
this study we thoroughly investigated single sources of unexpected events and their 
interplay. 
A variety of stably luciferase expressing cell lines was compared concerning toxic effects 
after transfection with polyplexes of siRNA and polyethylene imine (PEI) or polyethylene 
glycol-grafted PEI (PEG-PEI). Cell viability, LDH release, genetic profiles of molecular 
mechanisms of toxicity and activation of the driving promoter were investigated. 
Eventually, two cell lines which only differed in the driving promoter were established. 
We were able to confirm that PEG-PEI is generally better tolerated than PEI, but also 
showed that in a cell line and concentration dependent manner, PEG-PEIs can activate 
apoptosis pathways. While both polymers caused sigmoidal dose-response curves of cell 
viability in L929 cells (IC50(PEI) = 6 µg/ml, IC50(PEG-PEI) = 11 µg/ml), H1299/Luc cells 
exhibited only sigmoidal dose-response for PEI but strongly increased cell viability 
between 0.002 and 0.25 mg/ml PEG-PEI. Gene expression profiling revealed that these 
cells appeared to undergo apoptosis via thousand-fold activation of TNF receptor-
associated factors.  Additional to the influence of cell type, the role of the promoter driving 
the gene of interest in artificial cell culture models was elucidated, and it was shown that 
NFκB mediated activation of CMV promoter interferes with knockdown experiments. 
Polymeric vectors cannot be considered as inert substances. Their effects in vitro and in 
vivo depend on a number of parameters which have to be investigated before a vector and 
model can be used together. While ruling out off-target effects is highly important in 
screening models, these effects can therapeutically be exploited for synergism.  
8.2 Introduction 
Due to safety issues of viral vectors, non-viral systems for siRNA delivery enjoy great 
popularity. Several cationic lipids, polymers or dendrimers are sold as handy transfection 
reagents. But in the last years, reports about “polymer genomics” (1) or “toxicogenomics” 
(2) are increasing, proving that many drug delivery systems are not inert components. 
Polyethyleneimine (PEI), the most commonly used polymer in gene transfection, 
poloxamers, poly amidoamine (PAMAM) and diaminobutane (DAB) have been reported to 
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cause up- and down-regulation of hundreds of genes in treated cells (2). One has to 
differentiate between the effects the pure transfection reagents cause and those generated by 
lipo-, poly- or dendriplexes.  
Another issue in vitro screening of bioactivity of transfection reagents or siRNA sequences 
is the cell model used. Reporter genes like GFP, luciferase, ß-galactosidase are commonly 
utilized in cell culture models since their expression can easily and relatively inexpensively 
be quantified. In case of siRNA delivery studies, reporter gene assays can only be employed 
if either the plasmid encoding the reporter gene is co-delivered (3-5), or if stably transfected 
cell lines are used (6-8). Both approaches display major drawbacks: “Co-transfection” of 
plasmid and siRNA requires plasmid and siRNA to be complexed with the same 
transfection reagent, since it can not be maintained that there will not be interchange 
between the two sorts of nucleic acids complexed by different transfection reagents. And as 
reported earlier, transfection reagents that work well for plasmid delivery are not 
necessarily good for siRNA transfection and vice versa (6, 9, 10). By transfecting cells with 
a certain transfection reagent, uniform protein expression can not be ensured. Therefore, co-
transfection bears a second source of uncertainty concerning the results of protein 
downregulation. Hence, stably transfected cells that “pseudo-endogenously” express 
reporter genes are widely used. After stable transfection, cells are selected by treatment 
with antibiotics against which the successfully transfected cells are resistant. Single clones 
are picked and propagated, and the expression of the gene of interest in a certain population 
is widely uniform (11). The catch of this system is that a rather artificial cell system is 
generated in which the reporter gene expression is driven by a certain promoter. If this 
promoter is down- or up-regulated, the expression of the target gene is affected as well. 
Due to several observations of effects of polymeric vectors (1, 2) and influences on the 
driving promoter (12), in this study we investigated both phenomena separately as well as 
the interconnection between both of them in order to interpret off-target effects in non-viral 
siRNA delivery and to optimize further polymer and cell culture design. 
8.3 Materials and Methods 
Materials: 
Branched polyethylene imine with a molecular weight of 25 kDa (PEI 25 kDa, Polymin™, 
25 kDa) was a gift from BASF (Ludwigshafen, Germany). The block copolymers 
poly(ethylene glycol)-poly(ethylene imine) PEI(25k)-PEG(30k)1, PEI(25k)-PEG(20k)1, 
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and PEI(25k)-PEG(550)30 were synthesized as described earlier (13). Two different siRNA 
duplexes, siLuc (Anti-Luciferase specific sequence) and siCONTROL (non-specific control 
sequence IX), were bought from Dharmacon (Lafayette, CO, USA). The luciferase 
encoding plasmid pTRE2hyg-Luc and the cell lines CHO/Luc and HeLa/TetOff were 
purchased from Clontech (Sait-Germain-en-Laye, France). Luciferase Assay Reagent 
(LAR) and Cell Culture Lysis Reagent (CCLR) were bought from Promega (Mannheim, 
Germany), LipofectamineTM2000 from Invitrogen (Karlsruhe, Germany), E. coli K12 
DH5α (laboratory stock), the restriction enzymes BamHI and NotI from Fermentas (St. 
Leon-Rot, Germany), Qiagen Plasmid Giga Kit and RNeasy Mini columns from Qiagen 
(Hilden, Germany), and the PCR-Array RT2-ProfilerTM, the cDNA synthesis assay kit First 
Strand Kit (C-02), and the mastermix Super Array PCR master mix were bought from 
SuperArray Bioscience Corporation (Frederick, MD, USA).    
 
Cell Culture: 
L929 murine fibroblasts were purchased from LG Promochem, (Wesel, Germany) and 
maintained in DMEM low glucose (PAA Laboratories, Cölbe, Germany), supplemented 
with 10% fetal calf serum (Cytogen, Sinn, Germany), in humidified atmosphere with 5% 
CO2 at 37°C. 
NCI-H1299 cells were purchased from LG Promochem (Wesel, Germany), and transfected 
with a StimulightTM Reporter Vector pHTS-CRE (Biomyx, San Diego, USA) containing 
the luciferase reporter gene and a hygromycine resistance gene formulated with 
Lipofectamine and PLUS reagent (Invitrogen, Karlsruhe, Germany) as recommended by 
the manufacturer. Stably transfected cells were selected in cell culture medium containing 
200µg/ml hygromycin B (Invitrogen, Karlsruhe, Germany) in a previously described 
procedure (14). Briefly, clones were propagated and characterized concerning luciferase 
expression and proliferation rate, and only one of the clones was picked for the further 
propagation. Cells were maintained in RPMI 1640 (PAA Laboratories, Cölbe, Germany), 
supplemented with 10 mM HEPES, 1.0 mM sodium pyruvate, and 10 % fetal bovine serum 
(Cytogen, Sinn, Germany), in humidified atmosphere with 8 % CO2 at 37°C. 
HeLa/TetOff and CHO/Luc cells were purchased from Clontech (Saint-Germain-en-Laye, 
France) and maintained in DMEM high glucose (PAA Laboratories, Cölbe, Germany), 
supplemented with 10 % fetal bovine serum (Cytogen, Sinn, Germany), in humidified 
atmosphere with 5 % CO2 at 37°C. 
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Transfection Experiments: 
Transfections were performed as previously described (14). Briefly, cells were seeded in 96 
well plates (Thermo Fisher Scientific (Nunc GmbH & Co. KG), Langenselbold, Germany) 
with a density of 8,000 cells per well. Transfection efficiencies of the polymers were 
compared to PEI 25kDa and Lipofectamine2000 (Invitrogen, Karlsruhe, Germany) (LF) as 
a positive control by treating the cells with polyplexes of 10 pmol siLuc or non-specific 
control siCONTROL and polymers at N/P 10 in a total volume of 200 µl (50nM). In mock 
transfections, cells were treated with polymer or lipid only. Medium was changed 4 hours 
post transfection and cells were incubated for another 44 hours before they were washed 
with PBS buffer, lysed with CCLR (Promega, Mannheim, Germany) and assayed for 
luciferase expression with a 10 mM luciferin containing solution (Promega, Mannheim, 
Germany) on a BMG LUMIstar OPTIMA luminometer plate reader (BMG Labtech, 
Offenburg, Germany). Results are given as mean values of a replicate of four ± SD.  
 
 
MTT-Assays: 
Cytotoxicity of the polymers was investigated by MTT assay as reported earlier (15). 24 
hours before they were treated with polymer solutions of increasing concentrations in the 
range of 0.0005 to 0.4 mg/ml, murine L929 fibroblasts or human non-small cell lung cancer 
cells H1299/Luc were seeded on 96-well plates at a density of 8000 cells per well. Another 
24 hrs later, medium was changed; MTT solution was added into fresh serum-free medium 
and incubated with the cells for 4 hrs. Remaining mitochondrial enzyme activity compared 
to untreated cells was determined photometrically after cell lysis in 200 µl DMSO by 
measuring absorbance of enzymatically formed formazane at 580 nm with 690 nm 
background corrections. Results are gives as mean values of a replicate of four ± SD.  
 
LDH-Assays: 
Membrane toxicity of the polymers was investigated by LDH assay (CytoTox-OneTM, 
Promega, Mannheim, Germany) according to the manufacturer’s protocol. H1299/Luc cells 
were seeded in puruvate-free medium on white FluoroNunc™ 96 well plates (Nunc, 
Thermo Fisher Scientific, Langenselbold, Germany) at a density of 8000 cells per well 24 
hours before they were treated with polymer solutions of increasing concentrations in the 
range of 0.004 to 0.2 mg/ml. Another 24 hrs later, 100 µl of a mixture of substrate mix and 
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assay buffer were added into the polymer containing medium and incubated with the cells 
and used medium for 10 minutes at 22 °C before 50 µl of stop solution were added. LDH 
release of leaky cells compared to no-cell control (0 %) and Triton-X 100 lysed (100 %) 
cells was determined fluorometrically by measuring emission of the NADH caused 
oxidation product of resazurine, namely resofurin, at 560 nm excitation and 590 nm 
emission wavelengths. Results are gives as mean values of a replicate of four ± SD.  
 
PCR-Array: 
In a PCR-based multiarray, 84 apoptosis-related genes were investigated concerning up- or 
downregulation compared to control cells after treatment with polymer solutions. 
H1299/Luc cells were seeded with 500,000 cells per well in 6-well-plates 24 hours prior to 
treatment with two different concentrations (2 µg/ml and 20 µg/ml) of either PEI 25kDa or 
PEI25k-PEG(30k)1. RNA was isolated 6 or 24 hours after treatment. Control cells were 
untreated, and RNA was isolated at the same time points as from treated cells. RNA quality 
was checked with an Agilent BioAnalyzer 2100, and RNA from replicates of three was 
pooled for cDNA synthesis which was performed according to the manufacturer’s protocol. 
After mixing with the specific Super Array PCR master mix, aliquots of 25 µl were pipetted 
into the wells of the primer-containing plate and a qRT-PCR was run on an ABI 7500 RT 
PCR System. A gene map is to be found in the Supporting Informations. 
 
Establishment of two stably luciferase expressing cell lines: 
In order to establish two different cell lines HeLa/Luc in which the luciferase expression 
would be driven either by the CMV promoter or an endogenous promoter, HeLa/TetOff 
cells were stably transfected with different restriction products. First of all, chemically 
competent E. coli DH5α were transformed by heat shock with the Luciferase Reporter 
Vector pTRE2hyg-Luc (Clontech, Saint-Germain-en-Laye, France) containing the 
luciferase reporter gene and a hygromycine resistance gene, and an ampicillin resistance 
gene. Bacteria were cultured on ampicillin containing LB plates over night at 37 °C before 
3 colonies were picked. Selected colonies were used to inoculate 500 ml cultures of LB 
medium. After 24 hours of incubation, cultures were centrifuged and plasmid was prepared 
with a Qiagen Plasmid Giga Kit (Qiagen, Hilden, Germany) before it was linearized with 
either BamH1 or NotI according to the manufacturer’s protocol. For a 95 % confluent 10 
cm Petri dish of HeLa/TetOff cells, 20 µg linearized plasmid were mixed with with 
Lipofectamine and PLUS reagent (Invitrogen, Karlsruhe, Germany) as recommended by 
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the manufacturer and added to cells in serum- and antibiotics-free medium. Four hours 
later, medium was changed and cells were treated with hygromycin-containing medium for 
two weeks before single clones were selected and propagated as described above. After the 
selection process, cells were maintained in DMEM high glucose (PAA Laboratories, Cölbe, 
Germany), supplemented with 10 % fetal bovine serum (Cytogen, Sinn, Germany), in 
humidified atmosphere with 5 % CO2 at 37°C. 
 
Titration of Concentration-Dependent Off-Target-Effects: 
After establishment of the two cell lines in which the luciferase expression is either driven 
by a CMV promoter or not, the effect of polymer addition at different concentrations was 
compared. Cells were seeded 24 hours prior to treatment. Medium was changed and 
polymer dilutions analogous to the concentrations used for transfections at certain N/P 
ratios were added. Medium was again changed 4 hours after mock transfection, and cells 
were incubated for another 44 hours before luciferase expression was assessed as described 
above. 
8.4 Results and Discussion 
Observation of Off-Target Effects in Transfection Experiments: 
A couple of years ago, it was reported that by grafting poly (ethylene glycol) (PEG) on to 
PEI, shortly PEGylating PEI, biocompatibility could be increased (13). But in the first 
transfection experiments with the stably transfected cell line H1299/Luc, morphologic 
changes to the cells transfected with PEG-PEI/siRNA complexes were observed which had 
never been described before (Figure 1A and 1B). The transfected cells were swollen and 
their growth was strongly impaired which had caused low cell density in the wells of 
transfected cells. The reproducibility of this effect was given every time the experiment was 
repeated (n > 10), and the same morphologic effects as after transfection were also caused 
with free polymer solutions at 2 µg/ml final solution (Figure 1C), but not at a final 
concentration of 20 µg/ml. Interstingly, cells transfected with PEI25kDa/siRNA complexes 
or free PEI 25kDa did not reveal these strong morphologic effects (data not shown). Since 
exactly the PEG-PEIs used for the latter experiments (16, 17) as well as other PEG-PEI 
conjugates (18, 19) have been described to be less toxic than PEI 25 kDa in various cell 
lines and in vivo, it seemed to be interesting to find out why the H1299/Luc cells were so 
susceptible to PEG-PEI in this particular concentration-dependent manner.  
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Figure 1: Effects of polymer treatment on cell morphology. 1A: H1299/Luc untreated 
control cells, 1D: H1299/Luc cells 24 hours after transfection with 10 pmol siRNA (50 nM) 
complexed with PEI(25k)-PEG(30k)1 at an N/P ratio of 10 exhibit the same morphologic 
changes as cells treated with 2 µg/ml free polymer. 1C: H1299/Luc cells treated with 2 
µg/ml PEI(25k)-PEG(30k)1 reveal strong changes in morphology towards swollen 
vacuolized cells. 1D: Treatment with higher concentrations of PEG-PEI (20 µg/ml) did not 
cause such effects.  
Various mechanisms of toxicity related with non-viral delivery systems for nucleic acids 
(20) and caused by siRNA itself have been described (21-23). Recently, a report by 
Robbins et al. revealed that some of the siRNA-based success was caused by activation of 
Toll-like receptors and not by RNAi (21). The Toll-like receptors 7 and 8, which are present 
in endosomes (24), can be activated upon endocytosis of complexed siRNA and cause 
release of inflammatory cytokines. Polymers, which are used as non-viral vectors, are 
known to be intrinsically toxic as well. While membrane activity, that leads to nano-hole 
formation, is reported for several cationic polymers and dendrimers such as poly-L-lysine 
(PLL), polyethylenimine (PEI), diethylaminoethyl-dextran (DEAE-DEX) and sphere-like 
poly(amidoamine) (PAMAM) (25), some of these polycations can also exhibit immune-
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stimulatory effects (1). Additionally, charge dependent activation of the complement 
system has been reported for PLL, PAMAM, PEI and dioctadecylamidoglycylspermine 
(DOGS) (26).  
In order to systematically find out the exact reason for the interesting behavior of the 
H1299/Luc cells used in the transfection assays, we investigated the following points: 
1) Is the effect caused by siRNA, the polymer, or the polyplex? 
2) How is cell viability decreased by the different polymers? 
3) Is the effect observed cell line-specific? 
4) Is membrane toxicity involved? 
5) Are caspases or death receptor activated? 
To answer these questions, a number of experiments were performed:  
 
Cell Viability: 
Since the effects observed did not increase but disappeared with increasing concentration of 
PEI25k-PEG(30k)1 and were not observed after transfection with PEI 25k, it was suspected 
that they were either caused by polymer or polyplex. To test this and effects on cell 
viability, cells were treated with a broad range of concentrations of the two polymers and 
investigated for remaining viability in MTT-assays as described above. In order to compare 
the data with previously collected and published results (16), MTT assays were performed 
in both H1299/Luc cells and L929 fibroblasts, which are routinely used for the 
determination of IC50 values, according to the US Pharmacopoeia. This also allowed for 
investigation of cell line-specificity of the observed toxic effects. While PEI 25kDa showed 
a clear concentration-dependent sigmoidal dose-response in both cell lines (Figure 2A and 
2B), PEG-PEI data could only be well fitted for results from L929 cells (Figure 2B) (R2 = 
0.71 in H1299/Luc cells, Figure 2A). In H1299/Luc cells, a relative minimum in cell 
viability was observed at 0.004 mg/ml polymer, which is slightly lower than the 
concentration at which the transfections were performed (dashed vertical line, Figure 2A). 
IC50 values were higher for PEG-PEI than for PEI in both cell lines, although the value for 
PEG-PEI in H1299/Luc cells cannot be trusted, as it is derived from the non-linear fit. Still, 
it has to be admitted that low concentrations of PEG-PEI are better tolerated in H1299/Luc 
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cells than low concentrations of PEI. The more interesting part of the curve, however, is the 
concentration range between 0.002 and 0.25 mg/ml.  
With this assay we were able to determine that 1) the effects are caused by the polymer, 2) 
cell viability is affected in an unexpected way by PEG-PEI treatment, and 3) the effects are 
only observed in H1299/Luc cells, but not in L929 cells.  
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Figure 2: Cell viability of A: H1299/Luc and B: L929 cells treated with various 
concentrations of PEI 25k and PEI(25k)-PEG(30k)1. While L929 cells show sigmoidal 
dose-response, H1299/Luc cells exhibit a minimum at 0.004 mg/ml PEG-PEI. C: Heat map 
of the gene expression profile of H1299/Luc cells treated with 2µg/ml or 20 µg/ml PEI 
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25kDa or PEI25k-PEG30k after 6 or 24 hours. The color scale above the expression profile 
shows that positive fold change is expressed by red color, while negative fold change is 
shown in green. 
Membrane Toxicity: 
As polycations like PEI are known to create or expand defects in the lipid bilayers of cells 
(25, 27), it could be assumed that the low cell viability at 0.004 mg/ml PEG-PEI in 
H1299/Luc cells was caused by membrane interaction. In that case, lactate dehydrogenase 
(LDH) would be released from the cytosol into cell culture medium. LDH assays were 
performed as described above but revealed a rather more favorable profile for PEG-PEI 
than for PEI over a broad concentration range and confirmed, what has been reported earlier 
(13, 16, 28) for specific concentrations. No minima or peculiar deviations from the 
sigmoidal dose-response were observed. Simple membrane toxicity was therefore ruled out 
as main cause of the interesting behavior of H1299/Luc cells if treated with PEG-PEI. 
Since in this assay we were able to prove that PEG-PEI even causes lower LDH release 
than PEI, issue number 4), namely membrane toxicity, could be ruled out as a relevant 
factor. 
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Figure 3: LDH release of H1299/Luc cells treated with various concentrations of PEI 25k 
and PEI(25k)-PEG(30k)1. Both polymers cause a sigmoidal dose-response while PEI 25 
kDa has a stronger effect than PEG-PEI. 
Chapter 8 
 
232 
Regulation of Gene Expression: 
PEI is known to cause apoptosis by interaction with mitochondrial membranes which leads 
to loss of mitochondrial membrane potential, a decrease in ATP, and decreased cell 
viability, as well as activation of caspases and cytochrome c release (29). As reduced cell 
viability was observed, but not linked to membrane toxicity, we further investigated the 
genetic profiles of apoptosis-related pathways in PEG-PEI and PEI treated cells in a PCR-
based array.  The PCR array allowed for investigation of up- and down-regulation of 84 
genes that are related to apoptosis, but also anti-apoptotic genes, TNF ligand and receptor 
genes, caspases, the Bcl-family, death domain, death effector domain family and p53 as 
well as DNA damage response genes, such as many others.  
From the heat map, it is obvious that 6 hours after treatment, only a few genes were up-
regulated, whereas after 24 hours, a number of genes were up- and a comparably number of 
genes were down-regulated. This can be understood as a response to early effects that 
activated further pathways. While genes in between a family of genes were not only up- or 
only down-regulated, just a few patterns were perceptible. Genes of the caspase recruitment 
domain (CARD) family, for example BIRC2, BIRC3, CARD6, and CARD8 were rather 
up-regulated. Genes that also belong to the inhibitor of apoptosis (IAP) family, like BIRC2, 
BIRC3, BIRC4, BIRC6, and BIRC8 were down-regulated 6 hours after treatment, but 
strongly up-regulated 18 hours later (for description of genes, see Supplementary 
Information). Genes of the B-cell lymphoma 2 (Bcl-2) family which can either be pro- or 
antiapoptotic, depending on the protein they homo- or heterodimerize with (30), were 
partially up- and partially down-regulated. The same was true for genes related with p53 
and DNA damage response, while it has to be mentioned that the cell line is homozygous 
partially p53-depleted. The caspases were rather up-regulated, especially at the later 
timepoint, whereas interestingly caspase 2 and caspase 8 were down-regulated at either 
timepoint. This is an indication that rather mitochondrial death was involved in the effects 
observed, but no or little death receptor-mediated apoptosis. This question, on the other 
hand, cannot be answered with on the mRNA level but caspase activity must be measured. 
While we were not able to observe strong differences between the two different polymers or 
the two different concentrations, respectively, we focused on striking red spots in the left 
half of the heat map demonstrating the 6-hour values. It is not surprising that polycations 
can activate and abrogate hundreds of genes, but the effects that were observed with 2 µg 
PEG-PEI could be retrieved in the heat map: One red spot at 2 µg/ml PEG-PEI can be 
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found for Bcl-B/Boo (BCL2L10), one for CINCIN1 (CARD6, a caspase recruitment 
domain protein), one for ICE(rel)III (caspase 5), and one for CD27L (CD70). The strongly 
increased expression of BCL2L10, which is able to block the mitochondria death pathway 
but not TNF-α induced apoptosis (31), might be a result of activation of this pathway. 
Other strongly increased values that are less striking in the heat map but functionally 
interesting were found for CD153/CD30L (TNFSF8), IAP-1/CD40 (TRAF3) and 
LT/TNFB (LTA). It has been reported that TNFSF8 (CD30) stimulation can cause 
apoptosis of anaplastic large cell lymphoma cells (32), with TRAFs downstream of CD30 
involved in apoptosis induction (33) by NFκB activation. The pathway must be understood 
as crosstalk with TRADD (Hs.89862) after activation by FADD (CASH/CASP8AP1), two 
genes that were also activated in our assay and related to death receptor mediated apoptosis. 
Since CD30 activation was also reported to enhance production of lymphotoxin α 
(LT/TNFB) (34), which was up-regulated with PEG-PEI as well, there are a number of 
indications that CD30 activation triggered a lot of the effects observed, that must be seen in 
context of p53-depletion in H1299 cells. 
When combined into a therapeutic delivery system, activation of molecular mechanisms by 
biologic response modifiers can be exploited for synergistic effects, as described for 
pluronic block copolymers (35), which have been shown to effectively sensitize multi-drug 
resistant cancer cells (36, 37).  
These results, of course, raised further questions, especially concerning the suitability of 
other cell lines as screening model for non-viral vectors. If our hypothesis proved true, p53-
sufficient cells would not react in the same way p53-deficient cells do. 
 
Influence of Cell Line: 
Since we confirmed that PEG-PEIs are generally less toxic than PEI 25 kDa and found that 
the highly interesting effects caused in H1299/Luc cells were cell line specific, we 
investigated knockdown efficiency and biocompatibility of PEG-PEI/siRNA complexes in 
a the cell line CHO/Luc. In this cell line, we did not observe any microscopically visible 
morphologic effects, but when the cells were lysed and assayed for luciferase expression, or 
rather knockdown efficiency, again, puzzling results were obtained: While Lipofectamine 
had mediated specific knockdown without unspecific effects of siCONTROL lipoplexes or 
free Lipofectamine, PEI25k did neither cause specific not unspecific events. Cells 
transfected with the A-B-block copolymers PEI(25k)-PEG(30k)1 and PEI(25k)-PEG(20k)1, 
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which contain one PEI and one PEG domain, on the other hand, exhibited highly increased 
luciferase expression. It has to be emphasized that cells that underwent “mock transfection” 
and were therefore treated with polymer only, showed lower up-regulation of pseudo-
endogenous luciferase expression, as reported earlier (12). As already described by Akhtar 
et al., polymers and polyplexes have to be considered totally different systems when it 
comes to toxicogenomics (2). While polymer dilutions are molecular solutions, self-
assembled polyplexes have particulate properties. Another striking observation we were 
able to make in this assay was the fact that highly PEGylated polymers, that have earlier 
been described to be less active than derivatives with lower grafting degree (28), did not 
increase the luciferase expression in CHO/Luc cells. Knockdown of the target gene 
expression was not observed either. Keeping in mind that the luciferase expression in those 
cells is driven by a CMV promoter, the effects caused by A-B-block polyplexes can be 
understood as results of activation of the CMV promoter. If NF-κB is released by 
phosphorylation and degradation of inactivated IκBα (38), it can bind to the CMV promoter 
and activate it, since the transcription factor binding site of NF-κB is unique for the CMV 
promoter (39). While this effect is desirable in pDNA transfections, as it leads to higher 
transgene expressions, it strongly complicates data interpretation in siRNA transfection 
experiments. 
This experiment clearly proved that p53-sufficient cells are not susceptible to PEG-PEI. But 
as a new kind of off-target effects was observed on the other hand, the hypothesis of 
promoter activation had to be challenged as well 
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Figure 4: Transfection in CHO/Luc, Activation of CMV-promoter after treatment with AB-
diblock-like copolymer complexed siRNA, stronger effects than with free polymer. 
Influence of Promoter: 
After cell line specific affects on signal transduction pathways and most probably activation 
of the driving promoter were observed, two cells lines that only differed in the driving 
promoter were established for direct comparison. Since the restriction enzyme BamHI cuts 
the plasmid pTRE2hyg-Luc between the CMV promoter and the luciferase gene, the 
luciferase expression in those cells that were transfected with the BamHI-linearized vector 
(HeLa/Luc BamHI) was no longer driven by the CMV promoter and therefore independent 
of excretion of TNFα (12). The restriction enzyme NotI, on the other hands, cuts the vector 
after the sequence that encodes the luciferase gene. Therefore, luciferase expression in cells 
transfected with NotI-linearized vector (HeLa/Luc NotI) was still depending on activation 
of the CMV promoter.  
 
Figure 5: Establishment of two stably luciferase expressing cell lines, Amplification of 
plasmid pTRE2hygLuc, Linearization with 2 different restriction enzymes 
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After selection of single clones (clone A6 of Hela/Luc NotI cells and clone B1 of HeLa/Luc 
BamHI cells) that expressed the luciferase gene well and also grew without complications, 
master and working cell banks were created. Cells were seeded in 96-well plates as 
described above and subjected to mock transfections for proof of principle. HeLa/NotI cells 
exhibited higher basal luciferase expression, of course, since the gene encoding the 
sequence for luciferase was right downstream to the CMV promoter. In HeLa/BamHI cells, 
luciferase expression was independent of the CMV promoter, and therefore in general 
lower than in HeLa/NotI cells (Figure 6A). When treated with polymer solutions of 
PEI(25k)-PEG(20k) of increasing concentrations, HeLa/NotI cells expressed significantly 
higher levels of luciferase than untreated cells (**p < 0.01, ***p < 0.001). Luciferase 
expression in HeLa/BamHI cells, on the other hand, was not significantly affected by PEG-
PEI treatment (Figure 6A). It was therefore concluded to finally have established a cell line 
which would be not adversely affected by PEG-PEI in siRNA transfection experiments. To 
prove the assumption, HeLa/Luc BamHI cells were transfected with polyplexes of PEI 25 
kDa or PEI(25k)-PEG(20k) and lipoplexes of Lipofectamine as positive control. Mock 
transfections were performed as well, and this setup finally revealed data similar to our 
previously reported results (40). While Lipofectamine caused specific and significant (***p 
< 0.001) knockdown accompanied by little toxicity of free cationic lipid, PEI 25 kDa was 
not able to mediate significant down regulation of luciferase expression. PEI(25k)-
PEG(20k), on the other hand, caused specific and significant (**p < 0.01) knockdown of 45 
% without apparent toxicity or promoter activation.  
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Figure 6A: Influence of promoter: Luciferase expression in HeLa/Luc NotI, driven by 
CMV-promoter, is significantly increased by treatment with PEI(25k)-PEG(20k)1 (**p < 
0.01 at N/P 5-15, and ***p < 0.001 at N/P 20) compared to untreated cells, whereas no 
significant differences are observed in HeLa/Luc BamHI. 6B: Specific and significant 
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knockdown of luciferase expression without significant off-target effects can be achieved in 
HeLa/Luc BamHI cells. 
8.5 Conclusion 
Off-target effects in in vitro and in vivo siRNA delivery are common and often not well 
understood. As we systematically built up in this study, various parameters may have an 
influence on unwanted effects and were therefore investigated. First of all, certain siRNA 
duplexes can induce the innate immune system, which can be avoided with validated 
sequences. Second, the delivery vehicle, or the formulation can have severe influence in a 
number of pathways that may alter signal transduction. Third, effects can be cell line 
specific, and especially stably transfected cells are genetically altered organisms, that 
have to be handled with care. Fourth, if reporter genes are utilized, the driving promoter is 
crucially important, or rather its transcription factor binding sites. We observed that every 
single parameter can induce further reactions which may differ from cell line to cell line. 
While activation of TNF-related pathways that finally leads to activation of NFκB can 
cause apoptosis in p53-deficient cells, it leads to up-regulation of CMV-promoter driven 
genes in other cell lines. Additionally, the diblock-like PEGylated PEI that is designed to 
be less toxic can stimulate other pathways than PEI and lead to more striking off-target 
effects in a cell line and promoter dependent manner. In a cell culture screening model, all 
of these determining factors have to be kept in mind and essential control experiments 
have to be performed in order to obtain valid data. While in cell culture models off-target 
effects are troublesome, the investigation of their mechanisms may even lead to 
synergistic therapeutic effects. 
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SI Table 1: Gene Map of 84 apoptosis-related genes investigated in a PCR array. For 
clarity, gene bank numbers, symbols, descriptions, and gene names are given. 
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9.1 Summary 
In this thesis, new and multifunctional non-viral vectors for delivery of nucleic acids were 
synthesized and characterized concerning biophysicochemical parameters. The first part of 
this work deals with in vitro studies of gene delivery which was accomplished by synthesis 
of PEI-based targeted vectors and a new class of triazine-based dendritic vectors. In the 
second part, in vitro and in vivo delivery of siRNA with PEI-based polymers is addressed 
by different routes of application and non-invasive imaging. 
Chapter 1 introduces into the field of nanomedicine which advanced drug delivery systems 
can be numbered among. The questions which this work was based on, such as specificity 
of non-viral vectors, use of dendrimers as gene delivery vectors, pharmacokinetic issues of 
in vivo administered siRNA, in vivo stability of polyelectrolyte complexes, suitability of 
application routes, in vivo RNAi, and nanotoxicology are elucidated.  
Chapter 2 describes the synthesis of 5 different PEI-based integrin ανβ3-targeting 
conjugates by attaching a novel small molecule in two different coupling routes. Increasing 
the multimodality of these conjugates by fluorescent and radioactive labeling allowed for 
further characterization concerning their ability to condense pDNA into nano-sized 
complexes, concerning their surface charge, biocompatibility, transfection efficiency, and 
finally specificity. Highly specific and efficient transgene expression was observed in 
integrin-overexpressing MeWo cells, where the most efficient conjugate lead to 26-fold 
higher luciferase expression than the PEG-PEI the conjugate was based on. Interestingly, 
the conjugates with lower coupling degree of the targeting moiety were more efficient in 
vitro, which can be explained by the adverse effect strong blocking of integrin receptors can 
have. 
In Chapter 3, a novel family of dendrimers for gene delivery is presented. The synthesis of 
8 new modifications in the periphery of generation 2 rigid piperazine-connected triazine 
dendrimers is described as well as the periphery-induced impact on biophysicochemical 
parameters of self-assembled “dendriplexes” from pDNA and dendrimer. Eventually, 
transfection efficiencies of the differently substituted triazine dendrimers was assessed 
leading to the result that a certain amount of primary amines or guanidinium groups among 
the end groups is most important to maintain good transfection efficiency, while alkylation 
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also enhanced transgene expression. Since the toxicity of all triazine dendrimers, except for 
the alkylated dendrimer, was at least an order of magnitude lower than that of PEI, triazine 
dendrimers were considered promising vectors.  
Chapter 4 is the direct continuation of Chapter 3, involving further synthetic progress 
concerning the structure of triazine dendrimers. Design criteria for this two-dimensional 
study were to investigate both the influence of generation and of core structure on in vitro 
parameters. Therefore, generation 1, 2 and 3 of the rigid triazine-piperazine structures were 
compared with each other.  But also more flexible generation 2 cores involving piperazine- 
and ethylene glycol-connection between the triazines in a “bow-tie” structure, and mostly 
ethylene glycol chains in a flexible structure were synthesized and compared with the rigid 
core dendrimers. While toxicity increased with generation and increasing numbers of 
peripheral primary amines, the change of core flexibility had the most striking and 
promising effect: At comparably low toxicity, the highly flexible generation 2 dendrimer 
achieved higher transfection efficiencies than both PEI and SuperFect®, which is a 
commercially available generation 4 fractured PAMAM dendrimer.  
Chapter 5, already belonging to the second part of this thesis, deals with siRNA delivery in 
vivo. It describes the problem that non-invasive detection of pharmacokinetic parameters of 
in vivo siRNA administration is most desirable but has not extensively been described in 
the literature. Nuclear imaging techniques are suitable for longitudinal measurements in the 
same animal, while the main issue is probe design. This chapter therefore describes a fast 
and efficient method to radiolabel and purify siRNA, and also shows results of in vivo 
application and SPECT imaging. Invasively and non-invasively acquired pharmacokinetic 
parameters and distributional data are compared for free siRNA and PEI-complexed siRNA 
which showed well known accumulation in the liver. 
In Chapter 6, the method optimized in the chapter before was applied to radiolabel siRNA 
for an extensive comparative study on in vivo stability, pharmacokinetics and 
biodistribution of differently PEGylated PEI/siRNA complexes. In order to investigate 
stability of these complexes and to distinguish between possibly different distribution 
profiles of vector and load, each component was separately labeled and pharmacokinetic 
and distributional profiles were assessed for each vector and load invasively and by SPECT 
imaging. Additionally, Fluorescence Fluctuation Spectroscopy was applied to quantify 
stability under in vivo conditions. In this chapter, a great contingent of the toolbox of 
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multifunctionality was made use of: PEI, known to pH-sensitively buffer endosomal 
acidification, grafted with PEG to shield the positive charges of siRNA/PEI complexes in 
vivo was further functionalized with a chelating moiety for nuclear imaging. Fluorescently 
or radioactively labeled siRNA was complexed to allow for investigation of in vivo stability 
and biopharmaceutical parameters. This multidisciplinary approach yielded in the 
awareness, that the modified siRNA which was used in vivo apparently bound to serum 
albumins and, possibly as partially degraded albumin complex, circulated longer than any 
other component. It was also observed, that PEG-PEI/siRNA complexes were less stable 
than PEI/siRNA complexes, which all seemed to disassemble in the liver, although at the 
concentration applied, the complexes seemed to be stable in circulation. 
Due to the rather poor pharmacokinetic profiles of intravenously administered (PEG-
)PEI/siRNA polyplexes, Chapter 7 investigates suitability of the same complexes for 
intratracheal application. Therefore, in stability of the complexes, in vivo residence time in 
the lung, biocompatibility and knock down efficiency in transgenic mice was tested. While 
PEI/siRNA complexes seemed to be more stable in vitro, even in presence of mucin or lung 
surfactant, the in vivo conditions were the opposite. PEI-complexed siRNA did not 
experience any benefit compared with free siRNA concerning lung residence time or 
washout. PEG-PEI/siRNA complexes, on the other hand seemed to be stable after 
intratracheal application and to exhibit sustained release of siRNA which allowed for 
significant down-regulation of EGFP in the lung five days after treatment of Actin-EGFP-
expressing mice. Biocompatibiliy was tested, and only six of 22 chemo- and cytokines were 
found to be increased in the BALF.  
Chapter 8 deals with an unpopular but very important issue in non-viral siRNA delivery, 
namely off-target effects. After unaccountable toxic effects of PEG-PEI were observed in a 
stably luciferase-expressing cell line, which was supposed to serve as a screening model, 
the reasons for these effects were systematically investigated. Reproducibility of the effects 
was maintained, and cell viability was strongly impaired at a certain concentration of PEG-
PEI. Membrane toxicity was investigated but found not to be the cause. An array 
experiment for investigation of gene up- and down-regulation allowed presuming that not 
mitochondrial death but activation of CD30 regulated certain pro-apoptotic pathways 
involving NFκB in this p53-deficient cell line. In other cell lines, NFκB did not cause 
severe cell death but activation of CMV-promoter driven luciferase expression. Only the 
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establishment of a luciferase expressing cell line where the reproter gene was independent 
of a CMV-promoter allowed for specific RNAi without major off-target effects. 
9.2 Perspectives 
In continuation of the projects described, a number of further developments are possible. 
The targeted vectors described in Chapter 2 are certainly worth investigating in vivo. 
Integrin targeting has been described for tumor therapy and diagnostics. Since we have 
been able to radiolabel the conjugates with a gamma emitter, they could be used for nuclear 
imaging as well as for gene delivery into a tumor. Additionally, suitability as delivery 
vehicles for siRNA should be tested. 
Since triazine dendrimers seem to be well tolerated in vivo, these vectors could be applied 
as in vivo gene delivery systems, but could of course also be tested for siRNA delivery. 
Further generations or attachment of different peripheral groups can be synthetically 
achieved, as well as modification with imaging or targeting moieties. 
The method described in Chapter 5 for radiolabeling siRNA will certainly be further 
employed in the future for the investigation of biopharmaceutical parameters of siRNA 
delivery systems.  
Since polyplexes of pre-PEGylated PEI with siRNA did not show superiority over PEI 
complexes in Chapter 6, post-PEGylation, which has successfully enhanced circulation 
times of DNA complexes, needs to be investigated. 
In vivo bioactivity and knock down of EGFP in the lung of Actin-EGFP expressing mice in 
Chapter 7 is the most impressive result of this work, but it has to be further characterized 
concerning time-course and dose response. Additionally, it has to be investigated which 
cells in the lung are preferentially transfected. 
Little is known about the differences of pathways that are activated or inactivated in 
different cells transfected with polycations. The study on off-target effects in Chapter 8 is 
evocative that not all effects measured are RNAi and that screening systems have to be 
carefully characterized before valid data can be acquired. 
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9.3 Zusammenfassung 
In der vorliegenden Arbeit wurden neue und multifunktionelle nicht-virale Vektoren für 
den Transport von Nukleinsäuren synthetisiert und charakterisiert bezüglich ihrer 
biophysikochemischen Eigenschaften.  Der erste Teil der Arbeit handelt von in vitro 
Untersuchungen zum Gentransfer, welcher mit PEI-basierten zielgerichteten Vektoren und 
einer neuen Substanzgruppe von Gentransfer-Vektoren basiert auf Triazin-Dendrimeren 
erreicht wurde. Im zweiten Teil wird in vitro und in vivo Transfer von siRNA mit PEI-
basierten Polymeren in unterschiedlichen Applikationsrouten und mit radioaktiver 
Bildgebung untersucht. 
Kapitel 1 leitet ein ins Feld sogenannter “Nanomedizin”, wozu hochentwickelte 
Arzneiformen  gezählt werden können. Die Fragen, auf denen diese Arbeit beruhte, wie 
Spezifität nicht-viraler Vektoren, die Verwendung von Dendrimeren als Genvektoren, 
pharmakokinetische Fragestellungen in vivo applizierter siRNA, Stabilität von 
Polyelektrolytkomplexen unter in vivo Bedingungen, Eignung verschiedener 
Applikationsrouten, in vivo RNAi und Nanotoxikologie werden erläutert. 
Kapitel 2 beschreibt die Synthese 5 verschiedener ανβ3-Integrin gerichteter Konjugate 
durch die Kopplung eines neuartigen kleinen Moleküls in zwei verschiedenen 
Kopplungsstrategien. Die Steigerung der Multimodalität dieser Konjugate durch 
Fluoreszenz- und Radioaktiv-Markierung erlaubten die weitere Charakterisierung ihrer 
Fähigkeit, pDNA in nanoskalige Komplexe zu kondensieren, die Charakterisierung ihrer 
Oberflächenladung, Bioverträglichkeit, Transfektionseffizienz und schließlich Spezifität. 
Hoch spezifische Expression des Transgens wurde in Integrin-überexprimierenden MeWo-
Zellen beobachtet, wo das effizienteste Konjugat zu einer 26-fach höheren Luciferase-
Expression führte als das PEG-PEI, auf dem das Konjugat basiert. Interessanterweise waren 
die Konjugate mit niedrigerem Kopplungsgrad in vitro effizienter, was durch die 
nachteiligen Effekte, die starke Integrin-Blockade haben kann, erklärt werden kann.  
In Kapitel 3 wird eine neue Familie von Dendrimeren zum Gentransfer präsentiert. Die 
Synthese von 8 neuen Modifikationen in der Peripherie von starren Generation 2 Piperazin-
verknüpften Triazin-Dendrimerem wird beschrieben, sowie der Peripherie-bedingte 
Einfluss auf biophysikochemische Eigenschaften selbst-angeordneter „Dendriplexe“ aus 
pDNA und Dendrimer. Schließlich wurde die Transfektionseffizienz der unterschiedlich 
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substituierten Dendrimere untersucht, was zum Ergebnis führte, dass eine gewisse Menge 
primärer Amine oder Guanidinium-Gruppen als Endgruppen am wichtigsten für gute 
Transfektionseffizienz ist, während Alkylierung auch die Transfektionseffizienz erhöhte. 
Da die Toxizität der Triazin-Dendrimere, abgesehen vom alkylierten Dendrimer, 
mindestens eine Zehnerpotenz niedriger als die von PEI was, wurden die Triazin-
Dendrimere als chancenreiche Transfektions-Vektoren erachtet. 
Kapitel 4 ist die direkte Fortsetzung Kapitel 3 und beinhaltet weiteren Fortschritt in der 
Synthese bezüglich der Struktur von Triazin-Dendrimeren. Entwicklungskriterien dieser 
zweidimensionalen Studie waren, den Einfluss der Generation und der Kernstruktur auf in 
vitro Eigenschaften zu untersuchen.  
Deshalb wurden die Generationen 1, 2 und 3 der starren Triazin-Dendrimere miteinander 
verglichen. Aber auch flexiblere Kernstrukturen der Generation 2, die Piperazin- und 
Ethylenglykol-Verknüpfung zwischen den Triazinen einer „Fliegen-Struktur“ oder  
hauptsächlich Ethylenglykol-Verknüpfungen in einer flexiblen Struktur beinhalteten, 
wurden synthetisiert und mit den starren Dendrimeren vergleichen. Während die Toxiziät 
der Dendrimere mit der Generation und der zunehmenden Anzahl primärer Amine in der 
Peripherie anstieg, hatte die Änderung der Kern-Flexibilität den auffälligsten und 
aussichtsvollsten Effekt: Bei vergleichsweise niedriger Toxizität erreichte das flexibelste 
Dendrimer der Generation 2 höhere Transfektionseffizienzen als PEI und SuperFect®, was 
ein käuflich erwerbliches abgebautes PAMAM-Dendrimer der Generation 4 ist .  
Kapitel 5, was bereits zum zweiten Teil dieser Arbeit gehört, beschäftigt sich mit in vivo 
Transfer von siRNA. Es beschreibt das Problem, dass nicht-invasive Beobachtung 
pharmakokinetischer Parameter höchst erstrebenswert ist, für siRNA aber in der Literatur 
nicht ausführlich beschrieben wurde. Radioaktive Bildgebungstechniken sind gut geeignet 
für längslaufende Messungen im selben Tier, während das größte Problem die Entwicklung 
von Sonden ist. Dieses Kapitel beschreibt deshalb ein schnelles und effizientes Verfahren 
zum Radiomarkieren und Aufreinigen von siRNA und zeigt Resultate von in vivo 
Anwendung und SPECT-Bildgebung. Invasiv und nicht-invasiv erhobene 
pharmakokinetische Parameter und Verteilungsdaten freier und PEI-komplexierter siRNA 
werden vergleichen, was bereits bekannte Akkumulation PEI-komplexierter siRNA in der 
Leber zeigte. 
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In Kapitel 6 wurde die Methode, die im vorhergegangenen Kapitel optimiert wurde, 
verwendet, um siRNA für eine ausgiebige Vergleichsstudie zur in vivo Stabilität, 
Pharmakokinetik und Bioverteilung unterschiedlich PEGylierter PEI/siRNA Komplexe. 
Um die Stabilität dieser Komplexe zu untersuchen und um zwischen etwaig 
unterschiedlicher Verteilungsprofile von Vektor und Ladung unterscheiden zu können, 
wurde jede Komponente einzeln markiert, und pharmakokinetische und Verteilungsprofile 
wurden für jeden Vektoren und dessen Beladung invasiv und nicht-invasiv mittels SPECT 
erfasst. Zusätzlich wurde Fluoreszenz-Fluktuations Spektroskopie angewendet, um die 
Stabilität unter in vivo Bedingungen zu quantifizieren. In diesem Kapitel wurde ein großer 
Anteil der Multifunktionalitäts-Werkzeugkiste gebraucht: PEI, was bekanntlich die 
endosomale Azidifizierung puffert, gepfropft mir PEG, um die positive Ladung von 
siRNA/PEI-Komplexen in vivo abzuschirmen, wurde weiterhin mit einem Chelator für 
radioaktive Bildgebung funktionalisiert. Fluoreszenz- oder radioaktiv-markierte siRNA 
wurde für die Untersuchung biopharmazeutischer Parameter und der Stabilität in vivo 
komplexiert. Diese multidisziplinäre Herangehensweise brachte die Erkenntnis hervor, dass 
die modifizierte siRNA, die in vivo verwendet worden war, anscheinend an Serumalbumin 
band und, möglicherweise teilweise abgebaut, als Albumin-Komplex länger zirkulierte als 
alle anderen Komponenten. Es wurde auch beobachtet, dass PEG-PEI/siRNA-Komplexe 
weniger stabil waren als PEI/siRNA-Komplexe, welche alle in der Leber zu zerfallen 
schienen obwohl sie bei der applizierten Konzentration in der Zirkulation stabil zu sein 
schienen. 
Aufgrund der eher dürftigen pharmakokinetischen Profile intravenös verabreichter (PEG-
)PEI/siRNA-Polyplexe untersucht Kapitel 7 die Eignung der gleichen Komplexe für die 
intratracheale Anwendung. Dafür wurde in vitro Stabilität der Komplexe, in vivo 
Verweildauer in der Lunge, Biokompatibilität und Herunterregulierung in transgenen 
Mäusen getestet. Während PEI/siRNA-Komplexe in vitro, sogar in Anwesenheit von 
Mucin und Lungensurfactant, stabiler zu sein schienen, waren die in vivo Gegebenheiten 
entgegengesetzt. PEI-komplexierte siRNA erfuhr keinerlei Vorteil gegenüber freier siRNA 
bezüglich Verweildauer in der Lunge oder Ausscheidung. PEG-PEI/siRNA-Komplexe 
hingegen schienen nach intratrachealer Applikation stabil zu sein und fortwährende 
Freisetzung von siRNA aufzuweisen, was signifikante Reduktion von EGFP-Expression in 
der Lunge fünf Tage nach Behandlung Actin-EGFP exprimierender Mäuse ermöglichte. 
Bioverträglichkeit wurde untersucht, und es wurde nur für 6 von 22 Chemo- und Zytokinen 
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erhöhte Werte in der BALF gefunden. 
Kapitel 8 behandelt ein wenig beliebtes aber sehr wichtiges Thema im Bereich nicht-viralen 
Transfers von siRNA, und zwar unerwünschte Effekte. Nachdem unerklärliche toxische 
Effekte in einer stabil Luciferase-exprimierenden Zelllinie beobachtet worden waren, 
welche gedacht war, als Selektions-Modell zu dienen, wurden die Gründe dieser Effekte 
systematisch untersucht. Reproduzierbarkeit war gegeben, und Zell-Lebendigkeit war stark 
eingeschränkt bei einer gewissen Konzentration von PEG-PEI. Membrantoxizität wurde 
untersucht aber nicht als Ursache festgestellt. Ein Matrix-Versuch zur Bestimmung der 
Hoch- und Runterregulierung von Genen ermöglichte anzunehmen, dass nicht 
Mitochondrientod sondern Aktivierung von CD30 bestimmte pro-apoptotische Signalwege 
in der p53-defizienten Zelllinie regulierte, die NFκB-Aktivierung einschlossen. In anderen 
Zelllinien verursachte NFκB zwar keinen Zelltod aber Aktivierung des CMV-Promotors, 
der die Luciferase-Expression reguliert. Nur die Etablierung einer Luciferase-
exprimierenden Zelllinie, in der die Luciferase-Expression CMV-unabhängig ist, 
ermöglichte spezifische RNAi ohne größere Nebeneffekte. 
9.4 Ausblick 
Als Weiterführung der beschriebenen Projekte ist eine Menge von Weiterentwicklungen 
denkbar. Die zielgerichteten Vektoren in Kapitel 2 sind es sicherlich wert, in vivo 
untersucht zu werden. Integrin-Targeting ist bereits zur Tumor-Therapie und –Diagnostik 
beschrieben worden. Da es bereits möglich war, die Konjugate mit Gammastrahlern zu 
markieren, könnten sie für radioaktive Bildgebung, aber ebenso für Gentransfer in einen 
Tumor verwendet werden. Zusätzlich sollte die Eignung als siRNA-Vektoren getestet 
werden.  
Da Triazin-Dendrimere in vivo gut vertragen werden, könnten diese Vektoren als in vivo 
Gentransfer-Vektoren angewendet werden, aber könnten natürlich ebenso für den Transfer 
von siRNA ausprobiert werden. Weitere Generationen oder Anhängen anderer Endgruppen 
kann synthetisch erreicht werden, ebenso wie Modifikationen mit Bildgebungs- oder 
Targeting-Liganden. 
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Die Methode, die zur radioaktiven Markierung von siRNA in Kapitel 5 beschrieben wurde, 
wird sicherlich in Zukunft weiter Anwendung finden, um biopharmazeutische Parameter 
von siRNA-Vektoren zu untersuchen.  
Da Polyplexe aus pre-PEGyliertem PEI und siRNA in Kapitel 6 keine Verbesserung 
gegenüber PEI zeigten, muss post-PEGylierung untersucht werden, was bereits erfolgreich 
die Zirkulationsdauer von DNA-Komplexen erhöht hat.  
Biologische in vivo Aktivität und Reduktion von EGFP-Expression in der Lunge von 
Actin-EGFP exprimierenden Mäusen in Kapitel 7 ist das eindrücklichste Ergebnis dieser 
Arbeit, aber muss weiter bezüglich zeitlichen Verlaufs und Dosis-Optimierung 
charakterisiert werden. Zusätzlich muss untersucht werden, welche Lungenzellen bevorzugt 
transfiziert werden. 
Es ist wenig darüber bekannt über die Unterschiede von Signalwegen, die in 
unterschiedlichen Zellen, nach polykationischer Transfektion aktiviert oder inaktiviert 
werden. Die Studie zu Nebeneffekten in Kapitel 8 erinnert daran, dass nicht alle 
gemessenen Effekte RNAi sind, und dass Selektions-Systeme sorgfältig charakterisiert 
werden müssen, bevor valide Daten erhoben werden können. 
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10.1 Abbreviations 
2’OMe  2’O-Methoxy- 
AFM  Atomic Force Microscopy 
ANOVA Analysis of Variance 
AUC  Area under the Curve 
BAL  Bronchio-Alveolar Lavage  
BALF  Bronchio-Alveolar Lavage Fluid 
CD  Circular Dichroism 
CLSM  Confocal Laser Scanning Microscopy 
CT  Computed Tomography 
DLS  Dynamic Light Scattering 
DDS  Drug Delivery System 
DTPA  Diethylenetriaminepentaacetic Acid 
dsRNA Double-Stranded RNA 
EGFP  Enhanced Green Fluorescent Protein 
EPR  Enhanced Permeability and Retention 
FACS   Fluorescence Assisted Cell Sorting 
FFS  Fluorescence Fluctuation Spectroscopy 
FITC  Fluorescein-Isothiocyanate 
HEPES  2-[4-(2-Hydroxyethyl)-1-piperazinyl]ethanesulfonic Acid 
HIV  Human Immunodeficiency Virus 
IC50  Half-Inhibitory Concentration 
LDA  Laser Doppler Anemometry 
LMW  Low Molecular Weight 
MCT  Monochlorotriazine 
MRI  Magnetic Resonance Imaging 
MTT  3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Bromide 
N/P   Nitrogen to Phosphate Ratio 
PBS   Phosphate Buffered Saline 
PCR  Polymerase Chain Reaction 
pDNA  Plasmid DNA 
PAMAM Polyamidoamine 
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PEG   Polyethylenglycol 
PEI   Polyethylenimine 
PET  Positron Emission Tomography 
PDI  Polydispersity Index 
PLL  Poly-L-Lysine 
PM  Particulate Matter 
QD  Quantum Dot 
RES   Reticuloendothelial System 
RGD   Arginine-Glycine-Aspartic Acid 
RGD-M RGD-Mimetic 
RISC  RNA Induced Silencing Complex 
RNAi  RNA Interferance 
ROI  Region of Interest 
siRNA  Short Interfering RNA 
SPDP   N-succinimidyl 3-(2-pyridyldithio)propionate 
SPECT Single Photon Emission Computed Tomography 
TLR  Toll-Like Receptor 
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